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Ca2+ is an important second messenger which modulates a variety of signalling pathways in 
both excitable and non-excitable cells. In the CNS, Ca2+ plays an important role in neurons 
both physiologically and pathologically. Ca2+ influx following synaptic activity, is important 
in development, plasticity, redox balance, as well as in neuroprotection, largely through 
activation of pro-survival pathways downstream of synaptic NMDAR activation, including 
upregulation of antioxidant defences. However, excessive Ca2+ influx in neurons leads to 
neuronal damage and excitotoxicity, in which mitochondrial Ca2+ uptake through the 
mitochondrial Ca2+ uniporter (Mcu) resulting in mitochondrial dysfunction is a key player. 
Excitotoxicity occurs due to glutamate efflux from astrocytes following stroke, traumatic brain 
injury and in chronic neurodegenerative diseases, leading to excessive neuronal NMDAR 
activation and triggering of its downstream pro-death pathways. This thesis focuses on 
understanding the pro-survival and pro-death effects of signalling pathways activated by Ca2+ 
in neurons, as well as the potential effect of neuronal synaptic activity on influencing 
neuroprotective gene transcription in astrocytes. 
I investigated the role of AMPK, a master regulator of metabolism, in NMDA excitotoxicity 
in cortical neurons as a potential downstream effector of Mcu-dependent excitotoxic death; 
and found the deletion of AMPKα1/2 to be neuroprotective against NMDA-mediated 
excitotoxicity, however I found AMPK activation to be independent of Mcu. I also 
investigated the expression pattern of Mcu and other mitochondrial calcium regulatory genes 
(MCRGs), and found MCRGs to be differentially expressed in different neural cells (primary 
neurons vs astrocytes), and neuronal subtypes (CA1 vs CA3 region of the hippocampus), 
suggesting differing dependence on the various MCRGs in mitochondrial Ca2+ handling in 
these cell types. A better functional understanding of these genes will allow for investigation 
of their importance in mitochondrial Ca2+ handling, including their potential role in 
excitotoxicity. 
I next investigated the neuroprotective effects of synaptic activity induced Ca2+ influx, 
focusing on antioxidant target genes of Nrf2, a transcription factor and major regulator of 
antioxidant genes. I found that unlike astrocytes, neurons express very low levels of Nrf2. 
However, synaptic activity increased the expression of several Nrf2 target genes in neurons, 
independently of astrocytes and Nrf2. Additionally, I found no effect of synaptic activity on 
increasing Nrf2 protein levels, despite previous reports in literature of Nrf2 pathway activation 
following synaptic activity. Finally, using RNA-seq I identified a list of genes strongly 
upregulated by a known Nrf2 activator in astrocytes, and found no evidence that neuronal 
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activity triggers expression of these genes independently of neurons, providing further 
evidence that neuronal activity does not activate the Nrf2 pathway in astrocytes. This suggests 
that synaptic activity via pathways activated by Ca2+ signalling provides neurons with cell-
autonomous antioxidant defences, independently of Nrf2; thus providing a distinct pathway 
for antioxidant defences in neurons from the Nrf2 pathway, which is activated in astrocytes 
providing neurons with non-cell autonomous antioxidant support. 
These results give us further insight into the mechanisms that underlie synaptic and non-
synaptic Ca2+ signalling pathways mediating neuronal survival and death, which could help in 






Stroke, traumatic brain injury and neurodegenerative diseases, such as Alzheimer’s disease, 
involve the death of neurons, a type of brain cell. Neurons can take up excessive amounts of 
calcium due to their over activation in these diseases, leading to their death. This is partly due 
to too much calcium entering mitochondria, which are responsible for providing cells with 
energy, disrupting their function and leading to the death of neurons. I looked at the machinery 
responsible for the calcium content of mitochondria, which control the amount of calcium 
going in and out of mitochondria, in different brain cells. I also looked at the possible role of 
AMPK, a molecule responsible for promoting energy production in cells, in conveying cell 
death messages from mitochondria which are overloaded with calcium. Additionally, I looked 
at whether antioxidants produced after increasing normal brain activity were made by neurons 
or astrocytes, which are supporting brain cells. I found that mitochondrial calcium machinery 
varied in neurons and astrocytes, as well as in different types of neurons. I found that AMPK 
was important in the cell death of neurons after too much calcium uptake, but was not 
connected to cell death due to excessive calcium uptake by mitochondria. I found that although 
astrocytes are able to make antioxidants themselves with the help of Nrf2, the master regulator 
of antioxidants in the brain, antioxidants are also made by neurons themselves after increasing 
normal brain activity, although these are not made with the help of Nrf2. Thus, antioxidants 
are made in both neurons and astrocytes to prevent neuronal death, but by different 
mechanisms.  
The results show the importance of these molecules in causing or preventing cell death 
following calcium uptake by neurons. AMPK encourages cell death following too much 
calcium uptake by neurons, whilst normal brain activity increases antioxidant production in 
neurons, providing them with protection against oxidative stress. Thus, stopping the effects of 
excessive calcium uptake into neurons by blocking AMPK activity or manipulating 
mitochondrial calcium machinery to reduce mitochondrial calcium uptake, as well as 
enhancing antioxidants production by increasing normal brain activity, would make good 
therapeutic targets for dugs which promote the survival of neurons in different brain diseases 
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Most neurons in the CNS are post-mitotic and cannot regenerate, thus it is essential for neurons 
to be highly adaptive to their environment to ensure their survival throughout the lifetime of 
the organism. Neurons have high metabolic activity and rely heavily on oxidative 
phosphorylation as their source of ATP, for which correct functioning of mitochondria is 
essential (Fernandez-Fernandez et al. 2012; Harris et al. 2012; Kann & Kovács 2007). Despite 
their high metabolic activity, neurons have low endogenous antioxidant defences making them 
vulnerable to oxidative stress (Fernandez-Fernandez et al. 2012). 
Ca2+ is an important second messenger in the CNS, and neurons are dynamically regulated by 
increases in intracellular Ca2+ levels following their activation, which is important in 
development, plasticity, redox balance and neuroprotection (Hardingham 2009; Hardingham 
& Bading 2003; Tashiro et al. 2006; Paoletti et al. 2013). Neuronal activity places an increased 
demand on neuronal metabolism to produce ATP to restore ionic gradients through the 
activation of ATPases (Kann & Kovács 2007). Increased metabolism leads to increased ROS 
production, which needs to be eliminated to avoid mitochondrial dysfunction and cell death; 
thus it makes biological sense for neuronal activity-mediated Ca2+ uptake, largely mediated by 
NMDA receptors, to be essential in adapting neurons to their changing environment and 
protecting them from various intrinsic and extrinsic insults via the upregulation of 
neuroprotective pathways, including strengthening of endogenous antioxidant defences 
(Hardingham & Bading 2010; Papadia et al. 2008; Baxter et al. 2015). Astrocytes also play a 
role in neuroprotection, largely through their superior antioxidant defences compared to 
neurons, helping to reduce oxidative stress (Fernandez-Fernandez et al. 2012; Shih et al. 2003). 
Although physiological Ca2+ uptake is essential for neuronal survival, excessive amounts of 
Ca2+ uptake leads to neuronal damage and excitotoxicity (Hardingham 2009). Excitotoxicity 
occurs in response to excessive neuronal NMDAR activation leading to excessive Ca2+ uptake 
by neurons following glutamate efflux from astrocytes (Hardingham & Bading 2010). Ca2+ 
handling by mitochondria in neurons plays an essential role in both neuronal survival and 
death (Kann & Kovács 2007; Qiu et al. 2013).  
Both oxidative stress and excitotoxicity have been implicated in acute and chronic 
neurodegenerative disorders (Parsons & Raymond 2014; Gan & Johnson 2014). Thus, 
understanding how neurons are dynamically regulated by Ca2+, and which pathways and 
molecules are responsible for mediating cell death and survival is essential for development 
of novel therapeutic treatments. 
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This thesis aims to uncover the potential role of astrocytes in increased antioxidant gene 
transcription following neuronal activity, as well as to investigate a possible pathway 
downstream of mitochondrial dysfunction mediated cell death following excitotoxicity, and to 
uncover the neural specificity of genes involved in mitochondrial Ca2+ handling. 
This introduction provides a summary of the current knowledge about oxidative stress and 
antioxidant pathways, including the role of transcription factor Nrf2 in upregulating 
antioxidant gene transcription, as well as the pro-survival and pro-death effect of NMDAR-
mediated Ca2+ uptake in neurons, and the importance and function of the genes involved in 







1.1. Oxidative stress and antioxidant pathways 
1.1.1. Oxidative stress and reactive oxygen species 
Reactive oxygen species (ROS) are oxygen radicals containing unpaired electrons such as 
superoxide (O2-), or non-radical oxygen species such as hydrogen peroxide (H2O2), which can 
oxidise molecules in the cell (Halliwell 2006). Reactive nitrogen species (RNS) are ROS 
containing nitrogen, such as nitric oxide (NO).  
Neurons have a high metabolism and thus consume large amounts of oxygen for ATP 
production to supply energy through aerobic respiration. Most oxygen is reduced to water by 
the mitochondrial cytochrome oxidase, but some oxygen can form ROS, such as superoxide, 
as the by-product of the mitochondrial electron transport chain (ETC) complexes I and III, or 
NADPH oxidase in the cytoplasm (Halliwell 2006; Kann & Kovács 2007). ROS have several 
biological functions in neurons, such as for cell signalling and fighting inflammation, but 
excess ROS need to be detoxified by antioxidant mechanisms in the cell (Halliwell 2006). If 
this does not occur, or the amount of ROS overwhelms the antioxidant capacity of the cell, 
oxidative stress occurs leading to ROS-mediated posttranslational modifications of various 
molecules, such as DNA, proteins and lipids, leading to cellular damage and eventually cell 
death (Popa-Wagner et al. 2013; Halliwell 2006). Thus, dynamic regulation of antioxidant 
defences to maintain redox balance is essential for neuronal survival.  
The “free radical theory of ageing” states that oxidative damage caused by ROS in cells can 
accumulate over time contributing to the aging process, increasing neuronal susceptibility to 
insults and disease in the process (Patenaude et al. 2005). Indeed, excessive amounts of ROS 
and oxidative stress have been implicated in several different neurological disorders, not just 
acute conditions such as stroke, but also chronic neurodegenerative (ND) disorders, such as 
Alzheimer’s disease (AD), Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS), 
which usually appear later in life and exhibit signs of oxidative stress-induced damage 
(Halliwell 2006; Patenaude et al. 2005). Furthermore, oxidative stress can cause cell damage 
and promote excitotoxicity. The importance of oxidative stress in ageing and various diseases 
makes antioxidant pathways attractive candidates for therapeutic targeting.  
Preventing oxidative stress and subsequent cell death is crucial in neurons, due to their post-
mitotic nature and thus the lack of neurogenesis in most brain regions following development, 





1.1.2. Antioxidant pathways in neural cells 
Neurons have high metabolic activity, especially during physiological neuronal activity, but 
have low antioxidant defences leaving them vulnerable to oxidative stress (Fernandez-
Fernandez et al. 2012; Harris et al. 2012; Kann & Kovács 2007). Neurons have low levels of 
catalase, which reduces H2O2 to H2O and O2 (Bell et al. 2015; Fernandez-Fernandez et al. 2012; 
Shih et al. 2003), and much lower levels of glutathione than astrocytes (Dringen et al. 1999). 
In addition to their own antioxidant defences, neurons receive non cell-autonomous 
antioxidant support from neighbouring astrocytes through the Nrf2 pathway, which is further 
discussed in the next section.  
Superoxide dismutases (SODs) are responsible for the elimination of superoxide by forming 
H2O2 and O2 from two O2- (Findlay et al. 2005; Patenaude et al. 2005). H2O2 can be further 
converted to the hydroxyl radical (OH·) through the Fenton reaction (Aoyama et al. 2008). 
Furthermore, excess superoxide can react with NO to form peroxynitrite (ONOO-), which is 
also toxic for cells (Halliwell 2006).  
H2O2 and other ROS can be eliminated by a number of other antioxidants in neurons and 
astrocytes, such as by the thioredoxin-peroxiredoxin system, glutathione catalysed by 
glutathione peroxidase and ascorbate, which are some of the major antioxidant systems in the 
brain described further below, along with SODs.  
1.1.2.1. Superoxide dismutases 
SODs are ubiquitously expressed enzymes with metals in their active site which can dismutate 
superoxide into O2 and H2O2 (Sheng et al. 2014). 
There are three different types of human SOD: SOD1 is a CuZnSOD mainly found in the 
cytosol with some SOD1 in the mitochondrial intermembrane space, whilst SOD2 is a MnSOD 
localised to the mitochondrial matrix, and SOD3 is found extracellularly and is also bound to 
Cu and Zn (Aoyama & Nakaki 2015; Fernandez-Fernandez et al. 2012; Sheng et al. 2014). 
SOD1 is a homodimer, whilst SOD2 and 3 have a tetrameric structure (Sheng et al. 2014; Kaur 
et al. 2016). 
The importance of SOD2 is demonstrated by its KO leading to perinatal death in mice (Li et 
al. 1995). SOD2 is thought to be a tumour suppressor, and indeed its epigenetic silencing has 
been observed in some forms of cancer (Archer 2016). 
SOD1 KO on the other hand is not lethal, but does lead to increased susceptibility of motor 
neurons to cell death following injury (Reaume et al. 1996), and has been shown to slightly 
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decrease the lifespan of mice due to increased chances of developing some diseases (Edrey & 
Salmon 2014; Sheng et al. 2014). 
SODs are especially important in neurons, where superoxide is one of the major ROS 
produced. Dismutation of superoxide by SOD is essential in preventing peroxynitrite 
formation by superoxide and NO, which causes oxidative damage to cells. Moreover, 
peroxynitrite can nitrate SOD2, inhibiting its function (Yamakura et al. 1998). Nitrated SOD2 
levels are increased in some patients with neurodegenerative diseases, such as amyotrophic 
lateral sclerosis (ALS) (Aoyama et al. 2000; Yamakura et al. 1998). 
Various mutations in SOD1 have been identified which cause familial forms of ALS, a lethal 
neurodegenerative disease involving motor neuron degeneration (Rosen et al. 1993; Sheng et 
al. 2014; Kaur et al. 2016). The mechanism by which SOD1 mutation causes ALS has been 
debated. A mouse model overexpressing a human SOD1 mutant (SOD1G93A) showed 
impairment in anterograde axonal transport of mitochondria, leading to a reduction of 
mitochondria in axons, thought to be a consequence of increased levels of ROS (De vos et al. 
2007). Furthermore, SOD1 mutations are also linked to increases in mitochondrial dysfunction 
(Kaur et al. 2016). Moreover, SOD1 mRNA is thought to be stabilised in neurons, a function 
which seems to be lost due to SOD1 mutations linked to ALS, decreasing the half-life of the 
protein (Ge et al. 2006). Most SOD1 mutations are thought to make the protein more unstable, 
promoting SOD1 aggregates which can be found in intracellular inclusions (Kaur et al. 2016). 
Additionally, mutant SOD1 has been thought to be able to act in a prion-like manner, triggering 
the misfolding of mutant and WT SOD1 (Bunton-Stasyshyn et al. 2014). Although, inclusions 
with WT SOD1 have also been found in sporadic ALS cases, suggesting that SOD1 may be 
generally involved in all types of ALS (Bunton-Stasyshyn et al. 2014). Moreover, Graffmo et 
al. showed that overexpression of human WT SOD1 in mice, similar to levels of expression 
in SOD1G93A mice, led to an ALS-like phenotype including cell death and development of 
SOD1 aggregates (Graffmo et al. 2013). 
SOD1 mutations have also been found to affect glia, such as astrocytes and microglia, which 
are activated following neuronal damage and release toxic factors (and potentially mutant 
SOD1), increasing inflammation and further damaging neurons (Boillée et al. 2006; Bunton-
Stasyshyn et al. 2014). 
1.1.2.2. The thioredoxin-peroxiredoxin pathway 
The thioredoxin-peroxiredoxin (Trx-Prx) system reduces peroxides using NADPH in neurons 
and astrocytes, and is thus an important antioxidant defence system in neural cells.  
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There are six different types of peroxiredoxins, which are grouped into typical or atypical 2-
Cys, or 1-Cys Prxs (Findlay et al. 2005; Halliwell 2006). The most common types of Prxs in 
the CNS are the typical 2-Cys Prxs which consist of Prxs I-IV, with Prx III being 
mitochondrial, and contain both a catalytic and resolving cysteine (Papadia et al. 2008). Some 
Prxs have cell-type specific expression patterns, for example Prx I is astrocytic, whilst Prx II 
is neuronal (Patenaude et al. 2005). 
Prxs reduce H2O2 to H2O using their cysteine thiol group (-SH), which gets oxidised to -SOH 
(Figure 1.1; Halliwell 2006). In 2-Cys Prxs the -SOH group reacts with the resolving cysteine 
on another Prx and they form a disulphide bridge releasing H2O in the process, which can be 
reduced back to Prx-SH by Trx, an antioxidant enzyme which can reduce disulphide bonds 
such as those between cysteines of Prxs, resulting in the oxidation of its catalytic cysteines 
(Patenaude et al. 2005). Both cytoplasmic Trx1 and mitochondrial Trx2 are expressed in the 
brain, both in neurons and astrocytes (Patenaude et al. 2005). The oxidised form of Trx is 
reduced using NADPH as an electron donor, catalysed by Trx reductase (Bell & Hardingham 
2011a; Patenaude et al. 2005). Trx can be inhibited by thioredoxin inhibitor protein (Txnip), 
which is induced following NMDAR blockade (Papadia et al. 2008). Trx has various other 
biological functions, such as inhibiting apoptosis through inhibition of apoptosis signal-
regulating kinase I (ASK1) (Patenaude et al. 2005). 
Prx can be oxidised further to form Prx-SO2H or -SO3H following insults such as oxidative 
stress, H2O2 exposure, middle cerebral artery occlusion (MCAO) mimicking stroke, bath 
application of glutamate or NMDAR blockade (Papadia et al. 2008; Léveillé et al. 2009; Bell 
& Hardingham 2011a). Hyperoxidised Prxs cannot be reduced using the resolving cysteine of 
Prx, but instead are reduced back to Prx-SH catalysed by sulfiredoxin 1 (Srxn1) or sestrin 2 
(Sesn2) in an ATP-dependent process, preventing Prx inactivation and its eventual degradation 
(Soriano et al. 2009; Findlay et al. 2005; Bell & Hardingham 2011a). Although the role of 
Sesn2 in this process has been debated (Bell & Hardingham 2011a). However, the 
overexpression of Srxn1 and Sesn2 in primary neuronal culture is protective against H2O2-
mediated cell death (Papadia et al. 2008). In addition to reducing cytosolic Prxs, Srxn1 can 
translocate to the mitochondria upon oxidative stress and reduce hyperoxidised Prx III, thus 
preventing mitochondrial depolarisation (Noh et al. 2009; Léveillé et al. 2009). 
Since the Trx-Prx system is active in both neurons and astrocytes, it is likely to play an 
important antioxidant role in neurodegenerative disorders and stroke, which involve oxidative 
damage. Prxs have been shown to be neuroprotective following H2O2 and excitotoxic insults 
to neurons (Bell & Hardingham 2011a). Additionally, Trx1 has been shown to be 
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neuroprotective in models of stroke (Patenaude et al. 2005). Mitochondrial Prx III has also 
been demonstrated to provide protection following an ischaemic or excitotoxic insult, 
suggesting a role for it in the clearance of accumulated ROS (Bell & Hardingham 2011a). The 
Trx-Prx system may be especially important in neurons, due to their low expression of other 
H2O2 detoxifying antioxidants such as GSH and catalase. Neuronal Prx II decreases with age, 
whilst Txnip is upregulated, causing greater inhibition of Trx, and there is an increase in 
hyperoxidised Prxs which may increase neuronal susceptibility to oxidative stress in disease 
(Patenaude et al. 2005; Papadia et al. 2008). In line with this, Prx II has been shown to be 
important in preventing mitochondrial dysfunction in aged mice (Bell & Hardingham 2011a). 
Additionally, Prxs undergo inactivating modifications in AD as well as PD, whilst Prx OE was 
shown to be protective against MPTP-induced PD-like symptoms (Bell & Hardingham 2011a). 
 
1.1.2.3. Glutathione 
Glutathione (GSH) is a tripeptide thiol, and is one of the major antioxidants in the brain. GSH 
reacts non-enzymatically with free radicals to eliminate them, is a co-factor for the reduction 
of peroxides, and can conjugate with proteins to protect them from oxidative damage by 
hyperoxidising their thiol groups termed glutathionylation (Bridges et al. 2012; Findlay et al. 
2005; Aoyama et al. 2008). Srxn1 has been suggested to catalyse the deglutathionylation of 
proteins (Findlay et al. 2005).  
Figure 1.1. The Trx-Prx system. Diagram showing the reduction of H2O2 to H2O by 2 Cys Prxs, the 
reduction of oxidised Prxs by Trx, and the reduction of hyperoxidised Prxs by Srxn1.  Prx – 





Glutathione peroxidase catalyses the reduction of H2O2 to H2O using GSH as a co-factor, 
oxidising it to GSH disulphide (GSSG), which is reduced back to GSH catalysed by 
glutathione reductase using NADPH (Figure 1.2; Halliwell 2006; Dringen et al. 2015). GSH 
can be conjugated to xenobiotics using GSH S-transferase (GST), the product of which is then 
exported to the extracellular space, to help detoxify xenobiotics in the cell (Dringen et al. 
2015). Furthermore, GSH can modulate NMDAR function, and possibly functions as a 
neurotransmitter itself (Janáky et al. 1999). GSH is present at millimolar concentrations 
intracellularly and the GSH:GSSG ratio can be used as a redox sensor (Findlay et al. 2005). 
Whilst most GSH is found in the cytoplasm, some GSH is located in mitochondria and other 
cell compartments (Vargas & Johnson 2009; Dringen et al. 2015).  
GSH is synthesised from cysteine which binds to glutamate, catalysed by glutamate cysteine 
ligase (Gcl) (made of a modulatory (Gclm) and catalytic subunit (Gclc)), γGluCys is then 
attached to glycine catalysed by GSH synthase (GS) to form GSH; with all reaction steps 
requiring ATP (Figure 1.2; Aoyama et al. 2008; Vargas & Johnson 2009). Once synthesised, 
GSH inhibits Gcl activity to stop further γGluCys synthesis (Aoyama et al. 2008). 
GSH levels are higher in astrocytes than neurons, thus astrocytes release GSH to provide 
neurons with the necessary precursors for GSH synthesis, and help detoxify the extracellular 
space of ROS (Figure 1.2; Halliwell 2006; Vargas & Johnson 2009). Indeed, culturing rat 
primary cortical neurons with astrocytes increases neurons’ GSH content, whilst culturing 
them with astrocytes lacking GSH has no effect on neuronal GSH content, leaving neurons 
susceptible to damage of the ETC by NO (Gegg et al. 2005). Astrocytes release GSH through 
the multidrug resistance-associated protein 1 (MRP1) into the extracellular space, where it is 
broken down to Cys-Gly by gamma-glutamate-transpeptidase (gGT) and cysteine and glycine 
by aminopeptidase-N, thus supplying neurons with a source of cysteine, which is rate-limiting 
for GSH synthesis (Dringen et al. 1999; Shih et al. 2003; Bridges et al. 2012). Astrocytes also 
convert glutamate to glutamine which is transported to neurons for converting back to 
glutamate for GSH synthesis (Robert et al. 2014). Cysteine is often taken up by astrocytes in 
its oxidised dimer form, cystine, through system Xc- (xCT), a cystine/glutamate antiporter 
(Bridges et al. 2012). Cystine can be taken up by developing cortical neurons through xCT, 
but cysteine is taken up by more mature neurons instead through other transporters such as the 
excitatory amino acid transporter 3 (EAAT3, aka EAAC1) (Bridges et al. 2012; Robert et al. 
2014; Aoyama & Nakaki 2015). Excessive activation of xCT can cause glutamate overspill 
extracellularly activating extrasynaptic NMDARs leading to excitotoxicity, and thus xCT has 
been implicated in several neurological conditions such as epilepsy and neurodegenerative 
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diseases (Massie et al. 2015; Thorn et al. 2015; Lewerenz et al. 2014). Interestingly, both xCT 
and EAAT3 can be upregulated by the Nrf2 pathway (Lewerenz et al. 2014; Escartin et al. 
2011). 
Since GSH is essential for maintaining cellular redox balance as well as eliminating 
xenobiotics, it is not surprising that GSH and genes involved in its use, synthesis and recycling 
have been implicated in a number of neurological disorders involving oxidative stress. GSH 
is thought to decrease with age, a decline which is more pronounced in neurodegenerative 
diseases such as AD and PD (Aoyama et al. 2008). Thus, pharmacologically increasing GSH, 




Figure 1.2. Glutathione synthesis, use and recycling in neurons and astrocytes. GSH is synthesised 
in astrocytes and is exported to the extracellular space through MRP1. Here, it is broken down to 
γGlu and CysGly, which is further broken down into Cys and Gly by AP-N. Neurons can take up GSH 
precursors Cys and Gly, as well as Gln (which is subsequently converted to Glu) to synthesise their 
own GSH. This is crucial since neurons have lower levels of GSH and Cys, which is the rate-limiting 
factor in GSH synthesis. Once synthesised, GSH can be used as a co-factor for Gpx to reduce H2O2 
in neurons, decreasing oxidative stress. AP-N – aminopeptidase N, EAAT3 – excitatory amino acid 
transporter 3, Cys – cysteine, C-C – cystine, Glu – glutamate, Gln – glutamine, Gly – glycine, GPx – 
glutathione peroxidase, GR – glutathione reductase, Gcl – glutamyl cysteine ligase, GS – 
glutathione synthase, GSH – glutathione, GSSG – glutathione disulphide, GluS – glutamine 
synthase, GluA – glutaminase, GlnT – glutamine transporter, gGT – gamma-glutamyltransferase, 





The brain contains high levels of the antioxidant ascorbate, with higher levels in neurons than 
astrocytes, where it exerts its neuroprotective effects through its ability to detoxify ROS acting 
as an electron donor (Halliwell 2006). Ascorbate is the anionic form of ascorbic acid (vitamin 
C) acquired through diet, arriving to the brain via cerebrospinal fluid (CSF) (Rice 2000). 
Ascorbate is taken up into neurons through the Na+-dependent vitamin C transporter 2 
(SVCT2) (Qiu et al. 2007). During elimination of ROS, ascorbate is oxidised to 
dehydroascorbate, which can be transported into astrocytes via glutamate transporters 
(GLUTs), which is also thought to be a possible route of entry for dehydroascorbate through 
the blood-brain barrier (Figueroa-Méndez & Rivas-Arancibia 2015). The efflux mechanism of 
ascorbate has been debated, but is thought to possibly occur through the activation of volume 
sensitive anion channels (VSACs) (Figueroa-Méndez & Rivas-Arancibia 2015). 
Dehydroascorbate and other oxidised forms of ascorbate can be reduced back to ascorbate by 
thiol-containing molecules such as GSH and Trx inside neurons and astrocytes, as well as by 
ascorbyl-free radical reductase (Rice 2000; Figueroa-Méndez & Rivas-Arancibia 2015).  
Additionally, ascorbate can act as an enzyme co-factor, for example in the synthesis of 
noradrenaline and dopamine, and as a neuromodulator, inhibiting the binding of glutamate to 
NMDA receptors (Majewska et al. 1990; Rice 2000). Ascorbate has also been found to be 
important in neuronal maturation and myelination of axons (Rice 2000; Figueroa-Méndez & 
Rivas-Arancibia 2015; Qiu et al. 2007). 
Ascorbate is important in neuronal survival following excitotoxicity, which is not surprising 
given its antioxidant effects, such as eliminating superoxide produced during an excitotoxic 
insult, and its ability to modulate NMDAR activity (Rice 2000; Figueroa-Méndez & Rivas-
Arancibia 2015). Primary hippocampal culture from SVCT2 KO mice at DIV14 caused an 
increase in cell death in response to excitotoxic doses of NMDA, as well as high doses of H2O2 
(Qiu et al. 2007). The importance of ascorbate was also demonstrated in human dopaminergic 
neurons against oxidative stress during glutamate excitotoxicity by Ballaz et al., showing 
increased cell survival against glutamate addition in the presence of ascorbate compared to its 






1.2.1. The Nrf2 pathway and its regulation 
Nuclear factor erythroid 2 like 2 (Nrf2) is a transcription factor belonging to the Cap ‘n’ Collar 
basic leucine zipper family, which controls the transcription of several antioxidant and phase 
II detoxification genes in response to oxidative stress, providing antioxidant defence in various 
organs, from the kidney to the liver and the brain (Lee et al. 2005).  
Nrf2 is basally bound to the cysteines of Kelch-like ECH-associated protein 1 (Keap1) in the 
cytoplasm through one of its 6 Neh domains, Neh3 at its N-terminus, and is ubiquitylated and 
targeted for 26S proteasomal degradation, with a half-life of 20 minutes; thus basal levels of 
Nrf2 activity are low (Loboda et al. 2016; Nguyen et al. 2004; McMahon et al. 2003). Nrf2 is 
well conserved throughout the animal kingdom, and its homologues are found in zebrafish, 
nematodes and Drosophila, amongst other organisms (Loboda et al. 2016). Oxidative stress, 
small molecule activators of Nrf2 or microRNAs alter the cysteine residues on Keap1 binding 
to Nrf2, thus dissociating Nrf2 from Keap1 and promoting its translocation to the nucleus 
using its nuclear localisation signal, where together with the help of small Maf proteins binding 
to its Neh1 domain, it binds to the antioxidant response element (ARE), initiating the 
transcription of phase II detoxification and antioxidant genes which contain the ARE in their 
promoter region (Figure 1.3; Loboda et al. 2016; Itoh et al. 1997; Jain et al. 2005).  
Some protein kinases, such as PKC are known to phosphorylate Nrf2, initiating its dissociation 
from Keap1 (Vargas & Johnson 2009; Nguyen et al. 2004). Anchoring of Nrf2 in the cytosol 
by Keap1 is necessary, since too much Nrf2 activation can lead to reductive stress; supported 
by Keap1 KO being lethal (Wakabayashi et al. 2003). Whilst, glycogen synthase kinase 3β 
(GSK3β) has been shown to be able to phosphorylate Nrf2 and target it for degradation, 
independently of Keap-1 (Rada et al. 2011). 
Nrf2 controls a battery of antioxidant genes which contain ARE in their promoter regions, 
such as catalase, genes involved in glutathione use, synthesis and recycling, such as Gclc, as 
well as components of the Trx-Prx system, such as Srxn1 (Singh et al. 2009; Soriano et al. 
2009). Nrf2 also activates haem-oxygenase 1 (Hmox1) which breaks down haem into carbon 
monoxide, iron and biliverdin, which is later converted to bilirubin by biliverdin reductase 
(Vargas & Johnson 2009; Loboda et al. 2016). The products of haem cleavage not only protect 
against oxidative stress, but also possess anti-inflammatory and anti-apoptotic properties 
(Loboda et al. 2016). Hmox1 increases iron levels which can be damaging to cells, but it also 
increases ferritin synthesis which eliminates iron to stop its involvement in the Fenton reaction 
(Loboda et al. 2016). Moreover, Hmox1 KO is known to be embryonically lethal (Loboda et 
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al. 2016). SOD1 is also an Nrf2 target gene (Lacher et al. 2015). Nrf2 also activates a battery 
of other genes, such as genes involved in glucose metabolism (Lacher et al. 2015).  
Nrf2 has also been suggested to autoregulate its own transcription, since AREs can be found 
in its promoter region (Kensler et al. 2007). Although AREs are also thought to be found in 
the promoter region of Keap1, suggesting that Nrf2 may also negatively regulate itself (Jiang 
et al. 2016). 
Nrf2 activators such as tert-butylhydroquinone (tBHQ), a phenolic antioxidant, and 
sulforaphane (SLF) do not affect Nrf2 mRNA levels, instead they stabilise Nrf2 by its 
phosphorylation or target Keap1’s cysteines to promote Nrf2 release, prolonging its half-life 
and allowing its nuclear translocation and binding to the ARE (Nguyen et al. 2004; Li et al. 
2005; Kraft et al. 2004; Shih et al. 2005; Kensler et al. 2013; McMahon et al. 2003). A 
proteasomal inhibitor, MG-132, is often used experimentally to cause Nrf2 accumulation 







Figure 1.3. The Nrf2-ARE pathway. Nrf2 is basally bound to Keap1, but when it gets activated by 
oxidative stress, small molecule activators or other activators of Nrf2, it translocates to the nucleus 
and binds to the ARE to initiate transcription of antioxidant genes. The consensus sequence for the 
ARE is: 5’-puGTGACnnnGC-3’, where pu is a purine and n is any nucleotide (Rushmore et al. 1991). 
ARE – antioxidant response element, Keap 1 – kelch-like ECH-associated protein, Maf – small Maf 
proteins, Nrf2 – nuclear factor erythroid 2 like 2 
15 
 
1.2.2. Nrf2 function in the brain and its potential as a therapeutic target in 
neurological diseases 
1.2.2.1. The expression of Nrf2 in neural cells 
Activation of the Nrf2 pathway is well documented in astrocytes (Vargas & Johnson 2009). In 
neurons on the other hand there have been conflicting accounts, with reports of the Nrf2 
pathway being active primarily in astrocytes over neurons in mixed cultures by some (Kraft et 
al. 2004; Bell, Al-Mubarak, et al. 2011; Shih et al. 2003; Jimenez-Blasco et al. 2015), and the 
Nrf2 pathway being active in neurons themselves by others (Satoh et al. 2006; Yin et al. 2010; 
Zhang et al. 2009a). Many of the studies claiming that Nrf2 is activated in neurons carried out 
their experiments in mixed neuronal cultures containing astrocytes. The results in Ch.5 of this 
thesis demonstrate that Nrf2 is present at very low levels in neurons, and that Nrf2 levels 
observed in mixed culture are primarily due to the presence of astrocytes. Furthermore, our 
group demonstrated that low levels of Nrf2 in neurons are due to epigenetic repression of Nrf2 
early in development, silencing the Nrf2 pathway in neurons (Bell et al. 2015).  
Nrf2 has also been shown to be expressed in other neural cells. For instance, Nrf2 activators 
SLF and D3T have been shown to induce the transcription of various Nrf2 target genes in 
microglia (Konwinski et al. 2004). Furthermore, Nrf2 activation by a number of its activators 
has been shown to be protective in microglia (Jiang et al. 2016). 
1.2.2.2. The role of Nrf2 in diseases involving oxidative stress 
Since Nrf2 is activated by oxidative stress and regulates the transcription of antioxidant genes, 
it’s involvement in neurological diseases in which oxidative stress plays a role, such as stroke 
and neurodegenerative diseases, is not surprising.  
Nrf2 pathway activity is known to decrease during ageing, with lower levels of Nrf2 and its 
target genes, which may be due to the increase of Keap1 levels with age, leaving neurons 
vulnerable to oxidative stress (Loboda et al. 2016). Naked mole rats, which are known to live 
long, have higher levels of Nrf2 target genes and lower Keap1 levels compared to other rodents 
species, showing the importance of Nrf2 in longevity (Lewis et al. 2015). Although, Nrf2 
target genes as well as Nrf2 have been found to be overexpressed in several neurological 
disorders, but this may be a compensatory mechanism following increased oxidative stress in 
these disorders.  
Nrf2 activation in astrocytes provides neuroprotection, both in vitro and in vivo, mainly 
through the upregulation of GSH in astrocytes, providing the necessary precursors for neurons 
to synthesise their own GSH (Shih et al. 2003). 
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1.2.2.3. Nrf2 activation in neurodegenerative diseases is neuroprotective 
Misfolded proteins and inclusions formed by them are characteristic pathological features in 
many chronic neurodegenerative diseases, such as α-synuclein forming intracellular Lewy 
bodies in Parkinson’s disease (PD), tau forming intracellular neurofibrillary tangles and 
amyloid-β peptide (Aβ) aggregating into extracellular senile plaques in Alzheimer’s disease 
(AD), mutant huntingtin causing intracellular inclusions in Huntington’s disease (HD) or 
mutated SOD1 or TDP-43 forming inclusions in amyotrophic lateral sclerosis (ALS) (Gan & 
Johnson 2014). Mitochondrial dysfunction and oxidative stress are also characteristic signs in 
these diseases. Oxidative damage to many of these proteins is thought to promote their 
eventual misfolding and aggregation into protein inclusions, the formation of which induces 
further oxidative stress and toxicity in neurons. Thus, it is not surprising that Nrf2 pathway 
activation has been found to have a neuroprotective effect in several chronic 
neurodegenerative conditions. 
Nrf2 overexpression (OE) has been found to have neuroprotective effects in animal models of 
ND diseases, such as AD, ALS and PD. For instance, Nrf2 OE was shown to correct the 
movement impairment caused by α-synuclein expression in dopaminergic neurons of 
Drosophila (Barone et al. 2011). Whilst viral injection of human Nrf2 into the hippocampus 
of an AD mouse model was shown to increase insoluble Aβ levels compared to soluble Aβ, 
which is thought to be the more toxic form, and to decrease memory impairment (Kanninen et 
al. 2009). Crossing of an Nrf2 KO mouse with this mouse model was found to exacerbate 
neuroinflammation and accumulate intracellular Aβ, possibly due to loss of autophagy 
regulation by Nrf2 (Joshi et al. 2015). In addition, transfection of Nrf2 into striatal neurons 
reduced cell death induced by mutant huntingtin protein, showing that Nrf2 OE is also 
beneficial in Huntington’s disease (HD) (Tsvetkov et al. 2013). Furthermore, Nrf2 OE was 
also protective in a mouse model of Alexander disease, another type of ND disease (LaPash 
Daniels et al. 2012).  
Mitochondrial dysfunction is also prevalent in ND diseases, and inhibition of the 
mitochondrial ETC has been shown to lead to excessive ROS production and oxidative stress. 
Interestingly, Nrf2 activation in astrocytes provides neuroprotection against ETC complex I 
and complex II inhibitors (Lee et al. 2003; Calkins et al. 2005). Furthermore, Nrf2 KO primary 
cortical neurons were shown to be more vulnerable to the toxicity caused by complex II 
inhibitors (Calkins et al. 2005). 
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Nrf2 OE in astrocytes has neuroprotective effects in various ND disorders, which has been 
demonstrated using a mouse line (Nrf2-GFAP mice), in which Nrf2 is bound to the GFAP 
promoter, thus selectively overexpressing Nrf2 in astrocytes (Vargas et al. 2008).  
Co-culturing Nrf2-GFAP astrocytes with motor neurons expressing a human SOD1 mutant 
(SOD1G93A) was shown to decrease neuronal death in vitro, due to secretion of GSH by 
astrocytes (Vargas et al. 2008). Additionally, crossing the Nrf2-GFAP to an ALS mouse 
model, expressing neurotoxic human SOD1G93A, lead to an increased lifespan of these mice 
(Vargas et al. 2008).  
Gan et al. demonstrated that Nrf2 OE in astrocytes is neuroprotective against the toxic effects 
of mutated α-synuclein, by crossing the Nrf2-GFAP mouse with a mouse line with a human 
α-synuclein mutation (SynA53T) (Gan et al. 2012). Nrf2 OE in astrocytes decreased oxidative 
stress, reduced the formation of SynA53T and phosphorylated SynA53T aggregates in the CNS in 
vivo, thought to be due to Nrf2 activation reversing the impairment of macroautophagy in the 
mouse model, thus promoting clearance of SynA53T, and increased the survival of motor 
neurons in the spinal cord, prolonging the life of these mice (Gan et al. 2012). 
Additionally, the Nrf2-GFAP mouse was shown to block toxicity caused by MPTP, used to 
induce PD-like symptoms, in mice with and without Nrf2, suggesting that Nrf2 OE is only 
required in astrocytes for neuroprotection (Chen et al. 2009). 
Thus, the neuroprotective effects of Nrf2 OE against protein misfolding are thought to be 
largely due to attenuation of oxidative stress in neurons themselves, by increased production 
and secretion of GSH, providing neurons with precursors for GSH synthesis; as well as Nrf2 
modulating autophagy through its control of p62 (Fujita et al. 2011; Gan et al. 2012; Vargas 
et al. 2008; Shih et al. 2003). These results suggest that Nrf2 OE, specifically in astrocytes, 
could be a viable therapeutic treatment in several neurodegenerative diseases. 
Interestingly, Nrf2 activator CDDO and its analogues have been shown to provide 
neuroprotection in a number of ND diseases. CDDOTFEA and CDDOEA were shown to provide 
neuroprotection in mouse models of ALS and HD, by upregulating the Nrf2 pathway, 
combating oxidative stress and increasing the lifespan of mice (Stack et al. 2010; Neymotin et 
al. 2011). Furthermore, CDDOMA reduced amyloid plaque formation and oxidative stress in a 
mouse model of AD (Dumont et al. 2009), and was neuroprotective against MPTP-induced 
neuronal death (Yang et al. 2009). 
Another Nrf2 activator, dimethyl fumarate (DMF), which modifies the cysteines of Keap1 to 
promote Nrf2 activity, has been approved for the treatment of multiple sclerosis (MS) 
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(Brennan et al. 2015; Linker et al. 2011). It may be possible that DMF or other activators of 
Nrf2 may be a possible therapeutic for a number of other ND diseases.  
1.2.2.4. Nrf2 activation in stroke and traumatic brain injury is neuroprotective 
Oxidative stress is also an important contributor to the neuronal damage caused by stroke.  
Both mild oxidative stress (H2O2) and oxygen glucose deprivation (OGD) activate Nrf2 and 
its target genes, preconditioning neurons against later ischemic insults (Bell, Al-Mubarak, et 
al. 2011; Bell, Fowler, et al. 2011). Although there have also been reports of an Nrf2-
independent mechanism for mild H2O2 mediated neuroprotection (Haskew-Layton et al. 
2010). Nevertheless, application of Nrf2 activator plumbagin to cortical neurons in vitro was 
shown to reduce cell death following OGD (Son et al. 2010). 
Injection of Nrf2 activators SLF and tBHQ into rodents had neuroprotective effects against 
middle cerebral artery occlusion (MCAO), used to mimic ischaemic stroke, in various 
experiments (Jiang et al. 2016). For instance, Shih et al. demonstrated that pre-treatment of 
rats with tBHQ for 3 days attenuated damage caused by MCAO even one month after the 
insult, whilst in Nrf2 KO mice the infarct volume in the cortex was increased following 
permanent focal ischaemia compared to wild-type mice (Shih et al. 2005).  
Moreover, a tat-peptide was recently shown to activate the Nrf2 pathway, by dissociating Nrf2 
from Keap1, and to provide neuroprotection against global cerebral ischaemia in the CA1 
region of the hippocampus in rats (Tu et al. 2015). 
Nrf2 activator SLF decreased neuronal death and oxidative stress due to TBI in rodents, in an 
Nrf2 dependent manner (Hong et al. 2010). Additionally, hypoxic preconditioning was shown 
to upregulate Nrf2 and its target gene Hmox1, providing protection against TBI in a rat model 
(Shu et al. 2016). 
These results suggest that Nrf2 OE or activation prior to stroke or TBI may also be 
neuroprotective, although due to the acute nature of the diseases the therapeutic capacity of 








1.3. The NMDA receptor 
N-methyl D-aspartate receptors (NMDARs) are ionotropic glutamate receptors found in the 
central nervous system. Other glutamate receptors include ionotropic AMPA (α-amino-3-
hydroxy-5-methyl-isoxazole propionate) and kainate receptors, and metabotropic glutamate 
receptors.  
Binding of glutamate with glycine as a co-agonist leads to the opening of the NMDAR channel 
pore, but NMDARs are not only ligand, but also voltage gated, thus membrane depolarisation 
is required to remove the Mg+ block from the channel pore to allow Ca2+ influx into neurons 
(Regan et al. 2015; Wyllie et al. 2013; Papadia & Hardingham 2007).   
NMDARs are mostly located post-synaptically on neurons as well as extrasynaptically, but 
can also be located peri- or pre-synaptically (Paoletti et al. 2013). NMDARs can also be found 
on glia, including astrocytes, as well as in other tissue, where they carry out several different 
functions, for which the reader is referred to a recent review (Hogan-Cann & Anderson 2016). 
Here, the effects of post-synaptic NMDAR activation in neurons will be discussed. 
1.3.1. NMDAR structure and expression in the brain 
NMDARs are heterotetramers made up of two Glun1 and two Glun2 subunits, with 4 
transmembrane domains (TMDs), an extracellular N terminus and an intracellular C terminus 
to which many intracellular proteins bind via the PDZ domain (Wyllie et al. 2013; Kim & 
Sheng 2004). GluN1 subunits contain the glycine binding site, whilst GluN2 subunits contain 
the binding site for glutamate and NMDA (Regan et al. 2015). GluN1 is encoded by Grin1 
which has 8 different splicing variants, Glun1-1a-d and Glun1-2a-d (Regan et al. 2015). GluN2 
subunits have 4 subtypes: GluN2A, B, C and D, encoded by Grin2A-D; of which 2A and 2B 
are the most expressed in the forebrain, whilst C and D are largely expressed in other areas of 
the brain such as the cerebellum (Paoletti et al. 2013; Regan et al. 2015). GluN2 subunit 
composition changes throughout development, with a developmental switch from GluN2B to 
GluN2A shortly after birth (Paoletti et al. 2013). GluN2 subtype expression determines the 
biophysical properties of NMDARs, such as its sensitivity to Mg+ and its Ca2+ permeability, 
as well as the proteins coupling to its C termini (Wyllie et al. 2013; Paoletti et al. 2013).  
Additionally, two GluN3 subunits, Glun3A and B also exist, which contain a glycine binding 
site and can be incorporated into NMDARs, either with both GluN1 and 2 subunits present in 
a triheteromeric receptor, or supposedly with GluN1 only forming excitatory glycine receptors 
(Pachernegg et al. 2012; Paoletti et al. 2013). GluN3 subunits were initially thought to be 
dominant-negative regulators of NMDAR activity, and have since been suggested to be 
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involved in synaptic plasticity and development amongst others functions (Pachernegg et al. 
2012). 
Moreover, NMDARs have recently been suggested to also be able to function in a non-
ionotropic fashion, through conformational changes following agonist binding (Gray et al. 
2016).  
1.3.2. NMDAR function 
NMDARs play a large role in synaptic plasticity, and mediating the slow-phase of excitatory 
post-synaptic potentials, and are thus implicated in learning and memory and help in 
facilitating long-term potentiation along with metabotropic glutamate receptors; and are also 
important in mediating cell survival and death (Hardingham 2009; Hardingham & Bading 
2003; Tashiro et al. 2006; Paoletti et al. 2013). 
Activation of NMDARs causes Ca2+ influx into post-synaptic neurons activating various 
downstream signalling cascades, the outcome of which can have protective or destructive 
effects, depending on several different factors, such as the intensity and duration of Ca2+ influx, 
as well as the site of entry (Hardingham 2009; Hardingham & Bading 2010). Blockade of 
NMDARs leads to cell death, as does excessive activation of NMDARs which causes 
excitotoxicity, whilst physiological activation of NMDARs has neuroprotective effects 
(Hardingham 2009; Hardingham & Bading 2010; Ikonomidou 1999). Excitotoxicity has been 
implicated in several different neurological disorders, such as chronic neurodegenerative 
diseases, stroke and TBI (Parsons & Raymond 2014; Lipton 2006). NMDAR dysfunction and 
mutations have also been implicated in some neurodevelopmental disorders, such as 
schizophrenia (Burnashev & Szepetowski 2015; Cohen et al. 2015). 
The location of Ca2+ signalling within neurons is also important, with cytoplasmic, nuclear 
and mitochondrial Ca2+ activating different signalling cascades (Hardingham 2009; 
Hardingham & Bading 2010). The subunit composition of NMDARs can also influence 
downstream cascades activated, due to the differential binding of proteins to the C-terminal 
domains of the NMDAR subunits (Wyllie et al. 2013; Paoletti et al. 2013).  
The site of Ca2+ entry is an important contributing factor to the outcome of NMDAR-mediated 
Ca2+ influx. NMDARs are located both synaptically and extrasynaptically on neurons. 
Synaptic NMDARs get activated following normal physiological synaptic activity, whilst 
extrasynaptic receptors are activated following chronic activation resulting in glutamate 
spillover, such as during pathological conditions or bath application of glutamate (Hardingham 
2009; Hardingham & Bading 2010). Spontaneous neuronal activity causes action potential 
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(AP) firing, activating synaptic, but not extrasynaptic NMDARs. Thus, synaptic activity is 
thought to be linked with beneficial effects of NMDAR activity, promoting neuronal survival, 
whilst extrasynaptic NMDARs are thought to have destructive effects, promoting excitotoxic 
cell death (Hardingham 2009; Hardingham & Bading 2010; Bell & Hardingham 2011b).  
Below the major pro-survival and pro-death pathways activated by NMDAR activity in 
neurons will be discussed.  
1.3.3. Neuroprotective signalling mediated by the NMDAR and the role of neuronal 
activity 
1.3.3.1. Neuronal activity and the NMDAR 
Lack of spontaneous neuronal activity in the CNS during development leads to apoptotic 
neuronal death, such as after prolonged blockade of activity with tetrodotoxin (ttx), a sodium 
channel blocker, or after eliminating neuronal input (Mennerick & Zorumski 2001).  
Thus, neuronal activity leading to AP firing is essential for neuronal health and survival in 
developing as well as mature neurons, and is known to protect neurons against subsequent 
oxidative, excitotoxic and apoptotic insults (Bell & Hardingham 2011b). Physiological 
neuronal activity is largely mediated by synaptic NMDARs through the activation of 
downstream cascades following Ca2+ influx, causing upregulation of anti-apoptotic genes and 
antioxidant systems and the inhibition of pro-apoptotic gene transcription, discussed in more 
detail below. Although other routes of cytosolic Ca2+ increase following neuronal activity exist 
and are known to promote neuronal survival, such as activation of L-type voltage gated Ca2+ 
channels, which can be mimicked in vitro by applying high K+ extracellularly to depolarise 
neurons, and release of Ca2+ from intracellular stores (Mennerick & Zorumski 2001).  
Consumption of alcohol during pregnancy can lead to apoptotic neuronal death and 
development of fetal alcohol syndrome in humans, largely due to the inhibitory effects of 
ethanol on NMDARs, demonstrating the harmful effects of NMDAR blockade in vivo during 
development (Olney et al. 2000; Wirkner et al. 1999). NMDAR inhibitors other than ethanol, 
such as MK-801, have been utilised in rodents to show the importance of NMDAR in apoptotic 
cell death during development (Olney et al. 2002). Injection of MK-801 to block NMDAR 
activity caused cell death by apoptosis in the cortex of P6 mice (Papadia et al. 2008). 
Ikonomidou demonstrated that even a few hours of NMDAR blockade with MK-801 triggers 
apoptosis during development in rats (Ikonomidou 1999). Blockade of NMDARs is also 
detrimental for mature neurons especially during injury, demonstrated by the failure of 
NMDAR antagonists as a treatment for stroke and TBI in clinical trials (Ikonomidou et al. 
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2000; Ikonomidou & Turski 2002). Synaptic activity through NMDARs is also essential for 
the survival of newly formed neurons in the adult mouse dentate gyrus (Tashiro et al. 2006).  
Synaptic NMDAR activation has been mimicked in vitro by the addition of GABAA receptor 
antagonist bicuculline and K+ channel antagonist 4-aminopyridine (Bic/4-AP) leading to an 
increase in synaptic activity, action potential firing and activation of synaptic NMDARs, to 
study the effects of synaptic NMDAR activation (Papadia et al. 2008). Bic/4-AP activity also 
induces Ca2+ influx through voltage-gated Ca2+ channels and Ca2+ release from internal stores, 
but is thought to mainly act through synaptic NMDARs (Papadia et al. 2008).  
Preconditioning neurons in vitro with Bic/4-AP stimulation provides neurons with long-term 
protection against oxidative and excitotoxic insults (Bell & Hardingham 2011b; Papadia et al. 
2008; Qiu et al. 2013). Preconditioning hippocampal neurons with subtoxic doses of NMDA 
also has neuroprotective effects against subsequent apoptotic and excitotoxic insults, 
activating both synaptic and extrasynaptic NMDARs, although synaptic receptors dominate 
the outcome due to induction of AP firing (Soriano et al. 2006). Thus, the neuroprotective 
effects of NMDARs are mostly due to synaptic NMDAR activity, but mild activation of 
extrasynaptic receptors along with strong synaptic activation still promotes neuroprotective 
signalling. 
Environmental enrichment (EE) in rodents, such as increasing novel objects within their 
housing, leads to neuronal activity in vivo, and has been shown to have neuroprotective effects 
against excitotoxicity and spontaneous apoptotic cell death (Young et al. 1999). EE is thought 
to induce glutamatergic signalling in rats, thus NMDARs are likely to play a role (Nichols et 
al. 2007). EE also improves learning and memory and has been shown to delay disease onset 
in mouse models of HD and decrease oxidative stress in a model of AD (Spires & Hannan 
2005; Herring et al. 2010). Additionally a cognitively active lifestyle has been shown to reduce 
the risk of developing AD in humans (Spires & Hannan 2005). Increased neuronal activity 
throughout the lifetime of an organism will likely result in less oxidative damage due to 
increased ROS elimination, thus decreasing susceptibility to age-related diseases. Memantine, 
a weak NMDAR antagonist, is thought to block extrasynaptic NMDAR activity, but not 
synaptic NMDAR activity, and has been licenced for treatment of AD (Xia et al. 2010; Lipton 
2006). The success of memantine as opposed to other NMDAR antagonists lies in its selective 
allowance of physiological synaptic NMDAR activity including the upregulation of 
antioxidant defences in neurons (Papadia et al. 2008). This further implicates synaptic 
NMDAR activity as an important mediator of the neuroprotective effects of neuronal activity.  
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The protection provided by neuronal activity is largely due to downstream effects of synaptic 
NMDAR activation, inducing the transcription of anti-apoptotic genes, suppressing pro-
apoptotic gene transcription and increasing the neurons own antioxidant defences, which are 
discussed below.  
1.3.3.2. Neuroprotective pathways mediated by the NMDAR 
1.3.3.2.1. Synaptic NMDAR activation leads to the expression of anti-apoptotic genes 
Synaptic NMDAR activity is known to activate the transcription factor CREB (cAMP 
response element-binding protein), which binds to the cAMP response element (CRE) in the 
promoter region of several anti-apoptotic genes inducing their transcription (Figure 1.4; 
Hardingham et al. 2001b). CREB is phosphorylated and activated by nuclear 
calcium/calmodulin dependent protein kinase IV (CaMKIV) and the Ras-Erk1/2 pathway 
(Hardingham et al. 2001b; Hardingham et al. 2001a; Papadia et al. 2005). Nuclear Ca2+ 
resulting from release of Ca2+ from intracellular stores activates CREB which binds to its co-
activator CBP (CREB binding protein) and induces transcription of many pro-survival genes, 
via CaMKIV in the absence of CaM (Hardingham et al. 2001b; Zhang et al. 2009b). Activation 
of CREB by synaptic activity is responsible for inducing the long-lasting phase of synaptic 
NMDAR activation mediated neuroprotection (Papadia et al. 2005). CREB activation also 
takes place following application of low doses of NMDA in vitro, which induce AP firing, 
favouring synaptic NMDAR activation (Soriano et al. 2006).  
Brain derived neurotrophic factor (Bdnf), a CREB target gene, is upregulated following 
synaptic NMDAR activation, dependent on neuronal firing, and is known to be important in 
neuronal survival (Soriano et al. 2006). Bdnf was shown to have a large role in the 
neuroprotective effects of NMDA preconditioning against a subsequent excitotoxic insult in 
hippocampal neurons (Jiang et al. 2005). Moreover, Bdnf has been shown to be upregulated 
following EE (Young et al. 1999). 
CREB has also been found to induce the transcription of Npas4 following neuronal activity, 
inhibiting the transcription of Mcu, preventing mitochondrial Ca2+ overload and the resulting 
mitochondrial dysfunction and excitotoxic cell death (Qiu et al. 2013). Npas4 belongs to the 
neuroprotective activity-regulated inhibitor of death (AID) family of genes, which can be 
upregulated by nuclear Ca2+ signalling following neuronal activity and many of which are 
involved in preventing mitochondrial dysfunction (Zhang et al. 2009b).  
Another AID gene, Btg2, was found to be induced by synaptic activity in hippocampal 
neurons, providing neuroprotection against mitochondrial permeability transition induced by 
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NMDA excitotoxicity, which involves the opening of the mitochondrial permeability 
transition pore (mPTP), mitochondrial depolarisation and the release of cytochrome c from 
mitochondria which induces apoptosis (Lau & Bading 2009; Zhang et al. 2007). CREB-target 
gene Bcl6 has also been implicated in providing neuroprotection against apoptosis (Zhang et 
al. 2007). 
NMDAR-mediated Ca2+ influx also activates other transcription factors, such as nuclear factor 
of activator T cells (NFAT) and nuclear factor I subtype A (NFI-A), which play important 
roles in NMDAR-mediated neuroprotection (Vashishta et al. 2009; Zheng et al. 2010).  
1.3.3.2.2. Synaptic NMDAR activity suppresses several pro-apoptotic pathways 
Synaptic NMDAR activation has been shown to inhibit the expression of pro-apoptotic BH3-
only gene Puma (p53 upregulated modulator of apoptosis) in cortical neurons (Léveillé et al. 
2010; Baxter et al. 2015). Puma through its interactions with pro-apoptotic genes Bax and Bak 
activates the release of cytochrome c from mitochondria, which together with apoptosis 
protease activating factor (Apaf1) forms the apoptosome, triggering apoptosis via the 
activation of procaspase 9 and its downstream target caspase 3 (Léveillé et al. 2010). 
Interestingly, synaptic activity was found to supress the transcription of Apaf1, procaspase 9 
and caspase 3, inhibiting neuronal apoptosis in cortical neurons (Léveillé et al. 2010). 
Activation of transcription factor p53 and its target genes, including Puma, were found to be 
inhibited following neuronal activity in hippocampal neurons, preventing mitochondrial 
permeability transition and resulting apoptosis due to oxidative stress or following an 
excitotoxic insults (Lau & Bading 2009). Activation of Puma in cortical neurons has also been 
reported to occur independently of tumor suppressor p53 activation following some insults 
(Fricker et al. 2010). 
Activation of the PI3K-Akt pathway by synaptic NMDAR activation leads to phosphorylation 
and nuclear export of FOXOs (FOXO1 and 3 in neurons), a family of transcription factors 
which promote transcription of pro-apoptotic genes, such as FasL and Bim (Figure 1.4; 
Hardingham & Bading 2010). Since FOXO1 is a FOXO target gene, inhibition of FOXO 
activity causes a reduction in FOXO1 transcription, leading to prolonged neuroprotection by 
FOXO target gene suppression, even after activation of PI3K has ceased (Al-Mubarak et al. 
2009). Neuronal activity also inhibits glycogen synthase kinase 3β (GSK3β) and Bcl2 family 
member Bad, via activation of the PI3K-Akt or Ras-Erk1/2 pathways (Hardingham 2006b). 
Thus, synaptic NMDAR activity provides neuroprotection against apoptotic insults by 
suppressing pro-death pathways. 
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1.3.3.2.3. Synaptic NMDAR activity enhances neuronal antioxidant defences 
Neuronal activity places an increased metabolic demand on neurons, upregulating oxidative 
phosphorylation to produce ATP and thereby ROS production, enhancing the requirement for 
antioxidant defences to prevent oxidative stress. Indeed, synaptic NMDAR activity has been 
linked to the upregulation of intrinsic antioxidant defences (Figure 1.4).  
Activation of synaptic NMDARs by Bic/4-AP upregulates Srxn1 and Sesn2 mRNA in cortical 
rat neurons, which catalyse the reduction of hyperoxidised Prxs following a H2O2 insult 
(Papadia et al. 2008). Activation of Srxn1 is through transcription factor activator protein 1 
(AP-1), whilst Sesn2 is upregulated by C/EBPβ, both of which are CREB target genes, and 
the induction of which is dependent on neuronal firing (Papadia et al. 2008). 
Additionally, synaptic activity triggers phosphorylation and nuclear export of the FOXO 
family of transcription factors through PI3K activation, inhibiting the transcriptional 
upregulation of its target gene thioredoxin interacting protein (Txnip), thereby increasing Trx 
activity in neurons (Papadia et al. 2008). Thus, synaptic activity upregulates the activity of the 
Trx-Prx system, increasing endogenous neuronal antioxidant defences helping to prevent ROS 
accumulation and development of oxidative stress, and providing long lasting neuroprotection 
against oxidative insults, such as H2O2 (Papadia et al. 2008). These antioxidant pathways may 
also play a role in reducing cytochrome c, which is thought to prevent neuronal apoptotic death 
(Brown & Borutaite 2008). Interestingly, memantine has been shown to preferentially allow 
synaptic NMDAR activation, and was found not to upregulate Txnip or promote nuclear 
translocation of FOXOs (Papadia et al. 2008).  
Applying subtoxic amounts of NMDA is known to preferentially activate synaptic NMDARs 
due to induction of AP firing (Soriano et al. 2006). When bath applying subtoxic doses of 
glutamate in the presence of ttx to block firing activity, activating both synaptic and 
extrasynaptic receptors, the neuroprotective antioxidant effects of NMDARs were abolished, 
suggesting that activation of synaptic, but not extrasynaptic NMDARs provides protection 
against subsequent oxidative insults (Papadia et al. 2008). Even very brief synaptic NMDAR 
activity (5 min) was enough to provide the cell with increased antioxidant defences, and was 
not specific to NMDAR subunit composition (Papadia et al. 2008). 
More recently, neuronal activity through activation of synaptic NMDARs was found to induce 
the transcription of genes involved in the GSH system. Neuronal activity increases GSH 
activity in primary rat cortical neurons through upregulation of GSH peroxidase and GSH 
reductase activity and induces Gclc transcription and translation increasing use of Gcl in an 
NMDAR-dependent manner, independently of the presence of astrocytes (Baxter et al. 2015). 
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Preconditioning of primary rat cortical neurons with Bic/4-AP stimulation was protective 
against Puma-dependent apoptosis following H2O2 application, in a GSH dependent and 
astrocyte independent manner (Baxter et al. 2015). In contrast, blockade of NMDAR activity 
using MK-801, lead to a decrease in Gclc and thus GSH activity in vivo (Baxter et al. 2015). 
Thus, neuroprotection provided by neuronal activity seems to be intrinsic to neurons and 
independent of astrocytes. Transcription of xCT, a glutamate/cystine exchanger, has also been 
shown to be induced following neuronal activity, by activating transcription factor 4 (ATF-4) 
downstream of the PI3K-Akt pathways inhibition of GSK-3β leading to phosphorylation of 
eukaryotic initiation factor 2α (eIF2α), which may contribute to the neuroprotective effects of 
synaptic NMDAR activity (Lewerenz et al. 2014).  
Thus, neuronal activity can activate endogenous antioxidant defences in neurons, involved in 
boosting the activity of both GSH and the Trx-Prx system. This upregulation of intrinsic 
neuronal antioxidant systems is required to help detoxify ROS following increases in 
metabolism, as well as to provide long-lasting protection against future oxidative, apoptotic 
and excitotoxic insults.  
 
Figure 1.4. Pro-survival effects of NMDAR signalling. Figure modified from (Hardingham 2009). 
Physiological NMDAR activity leads to the upregulation of anti-apoptotic genes and the suppression 
of pro-apoptotic genes, leading to anti-apoptotic effects, and leads to enhanced endogenous 
antioxidant defences, which provides protection against various insults. 
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Recently Habas et al. showed activation of Nrf2 and upregulation of Nrf2 target genes 
following neuronal activity, suggesting that neuronal activity signals through the tripartite 
synapse to astrocytes activating the Nrf2 pathway (Habas et al. 2013). As demonstrated above, 
several antioxidant genes are upregulated by neuronal activity itself, some of which are Nrf2 
target genes, such as Srxn1. Thus, in chapter 5 I address whether the induction of Nrf2 target 
genes by neuronal activity is dependent on Nrf2 or astrocytes.  
1.3.4. Pro-death signalling from the NMDAR 
1.3.4.1. The role of NMDARs in excitotoxicity 
The toxic effects of glutamate on neurons was first observed around 50 years ago. Olney 
demonstrated that administration of glutamate caused neuronal death in the mouse brain, 
including the hippocampus and hypothalamus (Olney 1969; Olney & Ho 1970). Since this 
type of cell death resulted from the excessive activation of excitatory glutamate receptors and 
the downstream consequences of Ca2+ influx, the resulting cell death was termed excitotoxicity 
(Aarts & Tymianski 2003). Although glutamate application activates several routes of Ca2+ 
entry, NMDARs were found to be the predominant mediators of excitotoxicity (Choi 1988). 
Excitotoxicity has since been observed in many animal models, as well as in human pluripotent 
stem cell-derived neurons (Gupta et al. 2013b). Furthermore, excitotoxicity has been 
implicated as a major mechanism of cell death in several acute and chronic disorders, such as 
stroke and ND diseases, such as HD and AD, as well as in TBI (Hardingham & Bading 2010; 
Foster et al. 2016; Zhang et al. 2016; Prentice et al. 2015).  
Excitotoxic cell death occurs through the activation of various signalling pathways by 
increased cytosolic Ca2+ in neurons, the activation of which can depend on various factors such 
as the cell type, developmental stage, NMDAR subunit composition, the site of Ca2+ entry as 
well as stimulus intensity and duration (Hardingham & Bading 2010; Wyllie et al. 2013; 
Hardingham 2006a). Excitotoxicity can be induced by bath application of high concentrations 
of NMDA or glutamate, or by recreating ischaemic conditions, such as with oxygen-glucose 
deprivation (OGD) in vitro or by middle cerebral artery occlusion (MCAO) in vivo. Ischaemic 
conditions lead to the reversal of glutamate transporters and the overactivation of neuronal 
glutamatergic receptors (Hardingham & Bading 2010).  
Some of the signalling cascades activated during excitotoxicity are thought to be mediated 
preferentially by extrasynaptic receptors (Hardingham & Bading 2010; Hardingham 2006a; 
Hardingham et al. 2002; Parsons & Raymond 2014). Bath application of toxic doses of NMDA 
to hippocampal neurons in vitro leads to preferential activation of extrasynaptic NMDARs, 
due to suppression of AP firing, leading to neurodestructive effects (Soriano et al. 2006). 
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Nevertheless, the involvement of synaptic NMDARs in mediating pro-death signalling during 
excitotoxicity cannot be ruled out, due to technical difficulties in activating extrasynaptic 
receptors. NMDAR channel blocker MK-801 is often used to preferentially block synaptic 
NMDARs, but it has recently been shown that in contrast to previous findings, MK-801 can 
be washed out, bringing into question the validity of these experiments (McKay et al. 2013). 
Although synaptic NMDARs mediate neuronal survival following subtoxic doses of NMDA, 
toxic doses of NMDA are thought to activate both synaptic and extrasynaptic NMDARs, thus 
synaptic NMDARs may also contribute to cell-death signalling during bath activation of 
NMDARs (Zhou et al. 2015a). 
The severity of excitotoxic death can also be influenced by the subtype of NMDAR activated 
at some stimulus intensities, due to the differential interactions of the C termini of GluN2 
subunits with intracellular proteins, which activate different intracellular cascades mediating 
excitotoxicity. The preferential activation of excitotoxicity by GluN2B due to its C terminal 
domain coupling to PSD-95 and nNOS was demonstrated using mouse models in which the 
GluN2A C terminal was switched with that of GluN2B and vice versa (Martel et al. 2012). 
PSD-95 and nNOS have previously been proven to be important effectors of NMDAR-
mediated excitotoxicity (Cui et al. 2007). The coupling of PSD-95 to the NMDAR is thought 
to underlie the importance of the preferential toxicity of Ca2+ entry through NMDARs as 
opposed to other receptors/channels, agreeing with the “source specificity hypothesis” which 
states that not just the amount, but the route of Ca2+ entry is important in the consequences of 
Ca2+ influx into neurons (Aarts & Tymianski 2003).  
Due to the deleterious effects of NMDAR blockade, and the pro-survival effects of 
physiological NMDAR activation, the blockade of NMDARs therapeutically is not a viable 
option. Thus, it is important to understand the pro-death pathways mediated by NMDARs to 
find potential therapeutic targets downstream of NMDAR activation.  
1.3.4.2. Pro-death signalling pathways activated by excitotoxicity 
Extrasynaptic NMDAR-mediated Ca2+ influx following an excitotoxic insult activates 
calpains, a family of cysteine proteases, which cleave NCX3, the Na+/Ca2+ exchanger in the 
plasma membrane which is the main route of Ca2+ efflux from neurons, leading to delayed 
Ca2+ deregulation and eventual cell death (Figure 1.5; Bano et al. 2005). Calpains also cleave 
striatal enriched tyrosine phosphatase (STEP), ceasing its inhibition of p38 mitogen activated 
(MAP) kinase, which induces cell death independently of caspase activation following 
excitotoxic insults as well as ischaemia (Xu et al. 2009). Furthermore, calpain activation leads 
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to mGlur1α cleavage, which ceases its activation of Akt, thus decreasing the anti-apoptotic 
defences of neurons leading to cell death (Xu et al. 2007). 
Inhibition of pro-survival signalling by pathological NMDAR activation through the 
inactivation of CREB via inhibition of the Ras-ERK1/2 pathway or activation of Jacob, has 
been suggested to preferentially occur through extrasynaptic NMDAR activation (Hardingham 
& Bading 2010). This blocks the transcription of several anti-apoptotic and pro-survival genes 
induced by CREB. Inhibition of the Ras-ERK1/2 pathway also eliminates inhibition of GSK3β 
and Bad, promoting cell death (Hardingham 2009). 
Activation of extrasynaptic NMDARs is also known to promote the nuclear import of FOXOs, 
leading to transcriptional upregulation of pro-apoptotic genes (Hardingham & Bading 2010). 
In addition, excitotoxicity increases hyperoxidised Prxs in neurons (Léveillé et al. 2009), most 
likely due to ceasing of Srxn1 and Sesn2 transcription. Thus, excitotoxicity decreases some of 
neurons intrinsic antioxidant defences. 
Bath application of toxic NMDA doses leads to activation of extrasynaptic NMDARs, causing 
prolonged increases in Ca2+, leading to mitochondrial Ca2+ uptake through the mitochondrial 
calcium uniporter (Mcu) and loss of the mitochondrial membrane potential, causing 
mitochondrial dysfunction and cell death (Soriano et al. 2006). Mcu KD in primary cortical 
cultures decreased mitochondrial Ca2+ uptake and depolarisation following NMDA 
application, preventing excitotoxic cell death; whilst Mcu OE rendered neurons more prone to 
excitotoxic cell death (Qiu et al. 2013). This demonstrates that mitochondrial Ca2+ uptake via 
Mcu is an essential mediator of excitotoxicity.  
Excessive NMDAR signalling by glutamate activates neuronal nitric oxide synthase (nNOS), 
which along with mitochondrial Ca2+ uptake is an important mediator of mitochondrial 
dysfunction and excitotoxic cell death, by producing NO and activating p38-induced cell 
death, and is preferentially coupled to the GluN2B through PSD-95 (Keelan et al. 1999; 
Soriano et al. 2008b; Martel et al. 2012; Cao et al. 2005). Indeed, inhibition of nNOS was 
found to stop the loss of mitochondrial membrane potential and subsequent depletion of ATP 
in rat cortical neurons (Almeida et al. 1999). Excessive glutamate activation of NMDARs also 
activates phospholipase A2 (PLA2) which enhances ROS production leading to excitotoxic cell 
death (Bonventre 1997).  
Along with p38, c-Jun N-terminal kinase (JNK) also helps to mediate excitotoxic cell death, 
but independently of the subtype of NMDAR (Martel et al. 2009). JNK is activated following 
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pathological NMDAR signalling, by ROS formed, and is therefore a possible downstream 
effector of Mcu-mediated Ca2+ uptake (Soriano et al. 2008b). 
NO produced by nNOS and superoxide produced due to an excitotoxic insult can form 
peroxynitrite, which can damage DNA by causing single-strand breaks, activating nuclear 
enzyme poly (ADP-ribose) polymerase 1 (PARP-1) (Duan et al. 2007). Peroxynitrite also 
activates TRPM7, which increases Ca2+ influx, leading to further cellular dysfunction and 
death (Aarts & Tymianski 2003; Hardingham 2009). During excitotoxicity, PAR polymers 
formed by PARP-1 leave the nucleus and bind to the apoptosis inducing factor (AIF) to 
promote its release from mitochondria, to mediate PARP-1 dependent cell death in the nucleus 
(Wang et al. 2011; Wang et al. 2009). PARP-1 has been shown to be activated by 
excitotoxicity, but only when mediated by NMDARs, implicating NO produced by nNOS to 
contribute to its activation due to its co-localisation with NMDARs (Mandir et al. 2000). 
PARP-1 was also suggested to be downstream of mitochondrial superoxide production (Duan 
et al. 2007), thus it may function as a downstream mediator of Mcu-mediated mitochondrial 
Figure 1.5. Pro-death effects of NMDAR signalling. Figure modified from (Hardingham 2009). 
Excessive NMDAR activation leads to inhibition of pro-survival genes, calpain activation, oxidative 
stress, mitochondrial dysfunction and eventually cell death. 
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Ca2+ uptake. Although superoxide produced by NADPH oxidase (NOX) following excessive 
Ca2+ influx may also contribute to peroxynitrite formation (Brennan et al. 2009). The 
involvement of PARP-1 in excitotoxicity is further supported by PARP-1 inhibitors decreasing 
necrosis following OGD in cortical cultures (Moroni et al. 2001).   
Another possible downstream mediator of cell death following Mcu-mediated mitochondrial 
Ca2+ uptake is 5’AMP-activated protein kinase (AMPK), discussed in more detail below. 
1.3.4.3. The potential role of AMPK in excitotoxicity 
1.3.4.3.1. AMPK structure and function 
AMPK is a serine threonine kinase which is the major cellular energy sensor, maintaining 
energy homeostasis in a number of different tissues through its activation of ATP producing 
pathways, such as glycolysis and mitochondrial biogenesis, and inhibition of ATP consuming 
pathways, such as protein synthesis (Carling 2004; Carling et al. 2008; Hardie 2007). AMPK 
is essential for energy homeostasis on the whole-body level, for instance in the hypothalamus 
AMPK is inhibited by leptin, and activated by ghrelin and low glucose concentrations, helping 
to regulate food intake (Minokoshi et al. 2004; Hardie 2007). Possibly through AMPK 
activation by its upstream kinase, Ca2+/calmodulin dependent kinase kinase β (CaMKKβ), the 
pharmacological inhibition or KD of which reduces food intake (Anderson et al. 2008). 
AMPK consists of a catalytic α and regulatory β and γ subunits making a triheteromeric 
protein. There are two types of AMPK α and β subunits, α1 and 2, and β1 and 2 and three 
types of γ subunits, γ1, 2 and 3 (Carling 2004; Hardie 2007). The expression pattern of AMPK 
subunits differs amongst tissues (Carling 2004). The most expressed subunits of AMPK in the 
embryonic and adult rat brain were found to be α1 and 2, β1 and 2 and γ1, although expression 
levels of α2 and β2 change throughout development (Turnley et al. 1999; Culmsee et al. 2001). 
Interestingly, although AMPK was found to be expressed throughout the brain, the expression 
of AMPK subunits in the cortex was predominantly neuronal, with α2 having higher 
expression than α1 (Turnley et al. 1999).  
AMPK gets activated by a number of upstream kinases, which allow AMPK to exert its effect 
through phosphorylation of its downstream effectors. AMP binds to AMPK on Bateman 
domains on its γ subunit and allosterically activates the protein promoting the phosphorylation 
of Thr172 in the activation loop of its α subunit by LKB1 (Figure 1.6; Carling et al. 2008; 
Hardie 2007). The binding of AMP to the γ subunit has also been suggested to inhibit the 
dephosphorylation of AMPK by protein phosphatase 2Cα (Sanders et al. 2007; Fogarty et al. 
2010). Alternatively, AMPK can form a complex with and be phosphorylated by CaMKKβ 
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following elevations in intracellular Ca2+ (Figure 1.6; Woods et al. 2005; Hawley et al. 1996; 
Carling et al. 2008; Green et al. 2011). Another kinase, transforming growth factorβ-activated 
kinase 1 (TAK-1) has been suggested to phosphorylate AMPK in yeast, but whether it is 
present in the mammalian CNS and what its roles are have not been extensively studied 
(Momcilovic et al. 2006). Some cells do not express all of these kinases, such as HeLa cells 
which lack LKB1 and require CaMKKβ for AMPK activation; but it is likely that in many cell 
types both kinases are activated in parallel (Hawley et al. 2005).  
Due to AMPK controlling cell metabolism, it can be assumed that it will play a role in 
metabolic diseases and could be targeted therapeutically. Indeed, many anti-diabetic drugs for 
the treatment of Type II diabetes have been found to activate AMPK, such as rosiglitazone 
and metformin (Fryer et al. 2002). Resveratrol has been shown to promote the phosphorylation 
of AMPK by LKB1 in neurons, which increases mitochondrial biogenesis (Dasgupta & 
Milbrandt 2007). AICAR is often used to activate AMPK experimentally, due to its product 
formed in cells, ZMP, mimicking the actions of AMP. Furthermore, AMPK modulates the late 
phase of LTP, by inhibiting mTOR and plays a role in epilepsy (Potter et al. 2010). Moreover, 
AMPK has been suggested to be involved in cancer formation due to its ability to regulate the 
cell cycle and metabolic pathways in cells, and its upstream kinase LKB1 is mutated in a type 
of cancer, suggesting that AMPK may be important to suppress this type of cancer; thus 
AMPK could be targeted in the treatment of certain cancers (Luo et al. 2010). AMPK has been 
shown to be activated by various insults in neurons, such as hypoxia, ischaemia and glucose 
deprivation, and is implicated in stroke and chronic neurodegenerative diseases (Mairet-Coello 
et al. 2013; Thornton et al. 2011; Cai et al. 2012; Manwani & McCullough 2013; McCullough 
et al. 2005; Ju et al. 2012). 
1.3.4.3.2. The role of AMPK in excitotoxicity 
Activation of AMPK is thought to have a dual role in neurons during excitotoxicity, mediating 
both pro-death and pro-survival effects.  
Brief activation of AMPK has been shown to have pro-survival effects. AMPK was activated 
independently of CaMKKβ following a brief glutamate exposure of cerebellar granule neurons 
(CGNs), promoting the translocation of glucose transporter 3 (GLUT3) to the cell membrane, 
increasing glucose uptake, thus upregulating neuronal metabolism leading to elevated levels 
of ATP and hyperpolarisation of the mitochondrial membrane potential (Figure 1.6; Weisova 
et al. 2009). The expression of GLUT3 provided neurons with tolerance against excitotoxicity, 
demonstrated by GLUT3 KD increasing neuronal death (Weisova et al. 2009). Activation of 
AMPK has also been found to mediate the protective effect of preconditioning with FCCP, 
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which causes mild mitochondrial uncoupling, in CGNs against subsequent glutamate-induced 
excitotoxicity, also by upregulating GLUT3 expression (Weisová et al. 2012). 
Pharmacological activation of AMPK with low concentrations of AICAR was shown to be 
neuroprotective against metabolic, oxidative and excitotoxic insults in rat hippocampal 
neurons, when applied 1 hour before the insult (Culmsee et al. 2001). Preconditioning with 
AICAR also transiently activated AMPK in mouse cortical neurons, providing protection 
against a subsequent excitotoxic insult; thought to be mediated by the transcriptional 
upregulation of a Bcl-2 family anti-apoptotic gene, Mcl-1, by AMPK (Anilkumar et al. 2013). 
In contrast, prolonged activation of AMPK with higher AICAR concentrations was found to 
promote cell death following ischaemia, while inhibition of AMPK with compound C had 
neuroprotective effects (McCullough et al. 2005). Interestingly, phosphorylation of AMPK 
following ischaemia was found to be abolished in nNOS KO mice, suggesting that AMPK 
activation may be downstream of nNOS (McCullough et al. 2005). nNOS produces NO which 
together with superoxide forms peroxynitrite, which has been shown to activate AMPK in 
bovine aortic endothelial cells (Zou et al. 2003).  
AMPK has also been shown to phosphorylate and activate mammalian FOXO3, resulting in 
the increase of various genes including Txnip in mouse embryonic fibroblasts (Greer et al. 
2007). FOXOs are known to upregulate pro-apoptotic genes such as Bcl2 homology domain 
3 (BH3)-only gene Bim in neurons, thus the activation of FOXO3 by AMPK may be a possible 
mechanism by which AMPK induces neuronal death. Indeed, Concannon et al. observed that 
upregulation of Bim following an excitotoxic insult by glutamate in CGNs or NMDA in 
cortical neurons, leads to caspase-independent apoptotic cell death through delayed Ca2+ 
deregulation and release of the apoptosis inducing factor (AIF) from mitochondria 
(Concannon et al. 2010). Bim activation was found to be dependent on AMPK activation 
following a transient decrease in mitochondrial membrane potential and loss of ATP levels 
due to an excitotoxic insult (Concannon et al. 2010). The transcriptional induction of Bim by 
AMPK was shown to take place via its activation of FOXO3 in CGNs in a proposed two-step 
process: firstly AMPK inhibits Akt in the cytoplasm promoting dephosphorylation and nuclear 
translocation of FOXO3, and secondly it phosphorylates FOXO3 in the nucleus to induce gene 
transcription, which only takes place upon prolonged AMPK activation (>100 min) (Figure 
1.6; Davila et al. 2012). AMPK has also been shown to activate other BH3-only family 
members in different tissues, such as Bmf in INS-1 cells (Kilbride et al. 2010). PARP-1 
activation leads to AIF dissociation from mitochondria, thus it is tempting to speculate that 
AMPK activation may also induce PARP-1 mediated cell death (Wang et al. 2011). Indeed, a 
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link between AMPK and PARP-1 has been described in human endothelial cells (Gongol et 
al. 2013). 
Thus, transient AMPK activation is thought to have neuroprotective effects, whilst prolonged 
activation of AMPK is thought to be neurodestructive following an excitotoxic insult through 
Bim-induced apoptosis. Although other factors, such as the neuronal subtype, the intensity of 
AMPK activation, the type of insult, the AMPK subunits expressed as well as the localisation 
of AMPK within the cell may contribute to the outcome of AMPK activation. 
Since Concannon et al. demonstrated AMPK activation after a drop in ATP levels following 
decreased mitochondrial membrane potential, and our group has found Mcu-mediated 
mitochondrial Ca2+ uptake to lead to excitotoxic cell death, I hypothesised that AMPK may be 
activated downstream of Mcu, a possibility which is explored in chapter 3 of this thesis. 
Both LKB1 and CaMKKβ have been demonstrated to promote AMPK activation in the CNS.  
The binding of AMP to AMPK increased the phosphorylation of AMPKα at Thr172 by LKB1, 
whilst AMP binding only had a small effect on α2 and had no effect on α1 phosphorylation by 
CaMKKβ (Woods et al. 2005). Ca2+/calmodulin on the other hand increased that activation of 
AMPK by CaMKKβ, raising the possibility that AMPK could be activated directly by Ca2+ 
influx following NMDAR activation independently of rises in AMP. Indeed, AMPK was 
found to be activated following high K+-induced depolarisation in rat cortical slices, which 
was abolished by CaMKKβ blocker STO-609; demonstrating that AMPK can be activated by 
Ca2+ without decreased ATP levels (Hawley et al. 2005). CaMKKβ is expressed in rat brain 
and has been shown to be able to activate AMPK in vitro (Woods et al. 2005). Interestingly, 
AMPK has been shown to be activated independently of CaMKKβ following glutamate 
exposure in CGNs (Weisova et al. 2009). 
Toxic Aβ oligomers were shown to activate AMPK through CaMKKβ in neurons, 
demonstrating the possible involvement of AMPK in AD (Mairet-Coello et al. 2013). 
Interestingly, Mairet-Coello et al. showed that AMPK activation in cortical neurons was 
abolished with CaMKK inhibitor STO-609, suggesting CaMKKβ as the main upstream kinase 
in cortical neurons. Exposure of hippocampal neurons to kainic acid has also been suggested 
to induce cell death via the CaMKKβ-AMPK pathway (Lee et al. 2009). Toxic Aβ oligomers 
were shown to act via the NMDAR and lead to a loss of dendritic spines in neurons in vitro 
and in vivo in a mouse model of AD, due to the hyperphosphorylation of Tau by AMPK 
(Mairet-Coello et al. 2013; Thornton et al. 2011). Intriguingly, memantine was shown to 
inhibit AMPK activation (Thornton et al. 2011), suggesting that AMPK may be preferentially 
activated by pathological NMDAR activation. AMPK was found to be activated via CaMKKβ 
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following an ischaemic insult both in hippocampal slice culture in vitro and in mice in vivo 
and to promote neuronal death, which was dependent on the presence of nNOS (McCullough 
et al. 2005). AMPK activation following metabolic insults or ischaemia has also been 
suggested to lead to neuroprotective effects in the brain by increasing the activity of 
metabotropic GABAB receptors through phosphorylation of its R2 subunit, promoting post-
synaptic inwardly rectifying K+ channels activation and inhibiting pre-synaptic Ca2+ channels, 




Figure 1.6. The AMPK signalling cascade in neurons. Following the activation of NMDARs, Ca2+ 
enters neurons activating the AMPK kinase CaMKKβ, and the drop in the ATP:AMP ratio (due to 
the increased activity of ATPases and/or decreased energy production by mitochondria) promotes 
AMPK phosphorylation by LKB1. AMPK is phosphorylated on T172 by these upstream kinases, and 
the activity of PP2Cα is inhibited due to the binding of AMP to AMPK. pAMPK can then activate 
neuroprotective pathways (green arrows), such as the translocation of GLUT3 to the cell 
membrane, which increases energy production and leads to neuronal survival. However, 
prolonged AMPK activation can lead to cell death (red arrows), such as following the 
phosphorylation of FOXO3 in the nucleus, which induces Bim transcription leading to apoptosis. 
Akt – protein kinase B, AMPK – AMP-activated protein kinase, Bim – Bcl2 like 11, CaMKKβ - 
Ca2+/calmodulin dependent kinase kinase β, GLUT3 – glucose transporter 3, LKB1 - Liver kinase B1, 




1.4. Mitochondrial calcium handling 
1.4.1. Importance of mitochondrial calcium handling 
The discovery that mitochondria can take up Ca2+ from the cytoplasm was made over 50 years 
ago (Deluca & Engstrom 1961) and since then the importance of mitochondrial Ca2+ uptake in 
regulating respiration (McCormack et al. 1990), buffering cytoplasmic Ca2+ (Hajnóczky et al. 
1999), and mediating cell death (Bernardi & Rasola 2007) has been firmly established. 
First, Ca2+ passes through the outer mitochondrial membrane (OMM) via the voltage 
dependent anion channel (VDAC) (Figure 1.7), which regulates the passage of ions and small 
molecules, including ATP and NADPH into the mitochondrial intermembrane space (IMS) 
(Shoshan-Barmatz & Gincel 2003). The inner mitochondrial membrane (IMM) has a battery 
of uniporters, exchangers and other proteins which regulate the influx and efflux of Ca2+ into 
the mitochondrial matrix.  
Ca2+ influx into the mitochondrial matrix occurs along the electrochemical gradient created by 
the respiratory chain across the IMM, mainly through the mitochondrial calcium uniporter 
(Mcu) (Figure 1.7). Long prior to the genetic identification of Mcu, the uniporter was known 
to have high selectivity, but low affinity for Ca2+ and exhibit sensitivity to ruthenium red 
(Vasington et al. 1972). Release of Ca2+ from intracellular stores, such as the endoplasmic 
reticulum, in close proximity to mitochondria or from the plasma membrane channels is 
thought to create high microdomains of Ca2+ near mitochondria, allowing for Ca2+ influx into 
mitochondria despite the low affinity of Mcu for Ca2+ (Rizzuto et al. 1993).  
Mitochondrial Ca2+ uptake through Mcu is thought to regulate metabolism in a number of 
ways, including activation of three mitochondrial dehydrogenases, pyruvate dehydrogenase 
(PDH), isocitrate dehydrogenase and oxoglutarate dehydrogenase (for a review see Glancy & 
Balaban 2012). Ca2+ activates PDH, by activating phosphatases responsible for its 
dephosphorylation, and is thought to directly bind the other two dehydrogenases increasing 
their activity (McCormack et al. 1990). Dehydrogenases increase cellular metabolism through 
converting NAD+ to NADH in the tricarboxylic acid (TCA) cycle, which is essential for the 
functioning of the ETC which pumps H+ into the IMS allowing ATP production by the 
mitochondrial ATPase (Glancy & Balaban 2012). Therefore, Ca2+ influx following synaptic 
activity could lead to mitochondrial Ca2+ uptake, thus upregulating ATP production upon 
increased demand. This is essential, since oxidative phosphorylation is the main source of ATP 
for neurons (Fernandez-Fernandez et al. 2012). 
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Mitochondria can buffer cytoplasmic Ca2+ transients when in close proximity to Ca2+ entry 
through plasma membrane channels, including the NMDAR and VGCCs, or release of Ca2+ 
from the ER, thus regulating Ca2+ transient duration and localisation (Rizzuto et al. 2012). 
Excessive mitochondrial Ca2+ uptake leads to a decrease in mitochondrial membrane potential 
and ATP depletion due to the reversal of the mitochondrial ATPase, causing bioenergetic 
failure and leading to delayed Ca2+ deregulation in culture (Duchen 2012; De Stefani et al. 
2016). Mitochondrial Ca2+ uptake can also lead to the collapse of the mitochondrial membrane 
potential and the release of cytochrome c following the opening of the mPTP and rupture of 
the OMM (Hardingham 2009; Orrenius et al. 2003; Bernardi & Rasola 2007).   
Thus, it is essential that mitochondrial Ca2+ levels are tightly controlled, to allow for correct 
functioning of mitochondria, but prevent mitochondrial dysfunction due to Ca2+ overload. 
Thus, it makes sense for a battery of genes to help control the regulation of mitochondrial Ca2+. 
Although the function and biochemical characteristics of the uniporter have been established, 
its molecular identity has only recently been found. A number of genes have been identified 
in the past few years, which are essential for mitochondrial calcium regulation both by 
modulating Mcu, or being Ca2+ channels and exchangers themselves. The discovery and 
function of these mitochondrial calcium regulatory genes (MCRGs) is described below in 
more detail.  
Recent work by our group has illuminated the importance of Mcu itself as an important 
mediator of the mitochondrial membrane potential loss and excitotoxic cell death (Qiu et al. 
2013). It is important to establish the function and expression of MCRGs in the CNS to better 
understand their role in mitochondrial Ca2+ regulation and excitotoxicity, and to be able to 
identify potential therapeutic targets for disease. In chapter 4 of this thesis the expression of 
MCRGs in different neural cell types and neuronal subtypes is investigated, as well as the 
function of Nclx in neurons and astrocytes. 
1.4.2. Mitochondrial calcium regulatory genes 
1.4.2.1. The Mcu channel complex 
Mcu, previously known as Ccdc109a, was simultaneously discovered by two research groups 
in 2011 as the likely pore of the Ru360-sensitive mitochondrial Ca2+ uniporter (Baughman et 
al. 2011; De Stefani et al. 2011). De Stefani et al. identified the protein by searching the 
MitoCarta database (a database of mitochondrial proteins) for a protein which had ubiquitous 
expression, two TMDs and was conserved in organisms known to exhibit ruthenium-red 
sensitive mitochondrial Ca2+ uptake; whilst Baughman et al. identified Mcu using three 
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computational techniques, which investigated evolutionary co-expression with Micu1 
(previously identified as a probable uniporter regulator), RNA co-expression with Micu1 in 
different cell types and protein co-expression with Micu1 in different tissues. The findings of 
the two groups confirmed that Mcu mediates mitochondrial Ca2+ uptake, demonstrating that 
Mcu KD leads to a decrease in mitochondrial Ca2+ uptake in vitro and in vivo, whilst keeping 
the mitochondrial membrane potential and respiration intact (Baughman et al. 2011; De 
Stefani et al. 2011). Mcu was further confirmed to be the pore-forming subunit of the Mcu 
channel complex by whole-mitoplast voltage-clamping, which showed decreased or increased 
mitochondrial Ca2+ currents following Mcu KD or OE, respectively (Chaudhuri et al. 2013). 
Mcu has two TMDs connected by a linker region with a DIME motif, containing negatively 
charged amino acids critical for Mcu function. The topology of Mcu has been debated, but it 
is now thought that the N and C termini of Mcu face the mitochondrial matrix (Chaudhuri et 
al. 2013; Baughman et al. 2011; Lee et al. 2015). 
The 40 kDa Mcu protein forms a tetramer in the IMM to create the Ru360-sensitive channel 
pore, allowing Ca2+ influx into the mitochondrial matrix (Lee et al. 2015; Raffaello et al. 2013; 
Chaudhuri et al. 2013; Kirichok et al. 2004; Vasington et al. 1972). This is supported by the 
presence of a 170 kDa band when running Mcu on a native gel, which is thought to be part of 
the large molecular weight Mcu channel complex (around 450 kDa) with other MCRGs 
(Raffaello et al. 2013; De Stefani et al. 2011; Baughman et al. 2011). The Mcu channel 
complex is thought to include mitochondrial Ca2+ uptake 1 (Micu1) and 2  (Micu2), which are 
anchored to Mcu by the single-pass membrane protein essential Mcu regulator (Emre) (Figure 
1.7; Plovanich et al. 2013; Sancak et al. 2013; Kamer & Mootha 2014). 
A negative regulator of Mcu, Mcub, is able to oligomerise with Mcu and can be incorporated 
into the tetramer formed (Marchi & Pinton 2014). Mcub, previously known as Ccdc109b, was 
identified by sequence analysis to be a closely related gene to Mcu, sharing 50% of its 
sequence identity (Raffaello et al. 2013). Mcub has two TMDs and amino acid changes in its 
pore region which are critical for Ca2+ uptake (Raffaello et al. 2013). Co-expression of Mcu 
and Mcub in lipid bilayers leads to a decreased probability of Ca2+ uptake, and Mcub KD has 
been shown to increase mitochondrial Ca2+ influx (Raffaello et al. 2013). This is further 
supported by Mcub KD being unable to rescue Ca2+ uptake during Mcu KD in permeabilised 
cells, and Mcu showing the same defect when critical amino acids in its pore regions are 
switched to those of Mcub (Raffaello et al. 2013). It is still unknown however how many Mcub 
and Mcu subunits make up the tetramer, and whether the presence of Mcub is dominantly 
negative and abolishes all Ca2+ uptake.  
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Micu1, previously Cbara1, was the first of the Mcu channel complex proteins to be identified 
in 2010 using the MitoCarta database (Perocchi et al. 2010). Micu1 is found on the IMM and 
consists of one TMD and two conserved Ca2+ sensing EF-hands. Micu2 and Micu3 previously 
known as Efha1 and Efha2, respectively, were identified as paralogs of Micu1 in vertebrates 
(Plovanich et al. 2013). Like Micu1, Micu2 and 3 also have EF-hands and an N-terminal 
mitochondrial targeting sequence, but only Micu2 has been confirmed experimentally to be 
localised to mitochondria (Plovanich et al. 2013). Micu2 and 3 share 25% sequence identity 
with Micu1, although their tissue expression patterns differ. Of note, Micu3 is thought to be 
highly expressed in the CNS, but its function has not been investigated and it was not found 
to be part of the Mcu channel complex, although this may be due to its low expression in the 
cells examined (Plovanich et al. 2013; Sancak et al. 2013). Both Micu1 and Micu2 can sense 
Ca2+ levels using their EF-hands (Perocchi et al. 2010; Csordás et al. 2013; Plovanich et al. 
2013; Wang et al. 2014; Sancak et al. 2013; Hoffman et al. 2013).  
Micu1 has been shown to be a gatekeeper of Mcu at basal cytoplasmic Ca2+ concentrations, 
and to positively cooperate with Mcu to allow greater Ca2+ influx following elevations in 
cytoplasmic Ca2+ levels (Csordás et al. 2013; Mallilankaraman et al. 2012b; Perocchi et al. 
2010; de la Fuente et al. 2014). Micu1 is thought to block the channel pore at low Ca2+ levels 
by forming hexamers, potentially dimerising with Micu2, thus inhibiting excessive basal Ca2+ 
influx thereby helping to maintain respiration and the mitochondrial membrane potential 
(Mallilankaraman et al. 2012b; Csordás et al. 2013; Kamer & Mootha 2014; Matesanz-Isabel 
et al. 2016; Petrungaro et al. 2015). Following higher Ca2+ levels, Micu1 is thought to undergo 
a conformational change due to Ca2+ binding to its EF-hands, thus allowing Ca2+ influx through 
the channel (Wang et al. 2014; Waldeck-Weiermair et al. 2015). This could explain Micu1’s 
dual function, controlling the threshold at low Ca2+ concentrations with its EF hands blocking 
Mcu’s pore, and allowing Ca2+ influx at higher concentrations when its EF hands move after 
sensing increased Ca2+ levels. Although Micu1 and 2 appear to have similar functions, KD 
studies show that they act independently of each other, and are thought to have distinct roles 
(Plovanich et al. 2013; Matesanz-Isabel et al. 2016).  
Micu1 KD increases the production of reactive oxygen species (ROS) by mitochondria basally 
in HeLa cells, inhibiting oxidative phosphorylation and triggering cell death (Mallilankaraman 
et al. 2012b). Micu1 KD also increases H2O2 levels and triggers loss of mitochondrial 
membrane potential, leading to cell death (Csordás et al. 2013). This is expected if Micu1 
controls Mcu’s threshold, since Micu1 KD will allow an increased Mcu-mediated Ca2+ influx, 
causing mitochondrial Ca2+ overload.  
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Micu1 is essential for mitochondrial Ca2+ handling, demonstrated by the death of Micu1 KO 
mice around birth, possibly due to increased excessive mitochondrial Ca2+ uptake leading to 
the opening of the mPTP (Antony et al. 2016). Interestingly, a mutation in Micu1 leading to 
the loss of its function has been implicated in a brain disorder (Logan et al. 2014). Loss of 
Micu1 in patient-derived fibroblasts lead to increased mitochondrial Ca2+ uptake following 
low cytosolic Ca2+, agreeing with the role of Micu1 as the gatekeeper of Mcu (Logan et al. 
2014). 
Emre, a 10 kDa single TMD protein, was first discovered in 2012 as a member of the Mcu 
channel complex (Sancak et al. 2013). Emre localises to the IMS where it physically interact 
with Mcu, activating Mcu-mediated mitochondrial Ca2+ uptake, and anchors Micu1 and Micu2 
near the Mcu pore allowing the proteins to carry out their gatekeeping function (Sancak et al. 
2013; Tsai et al. 2016; Vais et al. 2016; Yamamoto et al. 2016). Although Tsai et al. 
demonstrated that Emre only interacts with Micu1, with Micu2 likely attached to Micu1. Vais 
et al. suggested that the C terminus of Emre is in the mitochondrial matrix and the N terminus 
is located in the IMS, but both Yamamoto et al. and Tsai et al. have since shown that the 
topology is indeed the opposite (Vais et al. 2016; Yamamoto et al. 2016; Tsai et al. 2016). 
Vais et al. recently suggested that the C terminus of Emre senses mitochondrial matrix Ca2+ 
levels and controls Ca2+ influx through the uniporter basally. Since the C terminus of Emre 
faces the IMS and interacts with Micu1 at its C terminus, the observation by Vais et al. could 
be due to the loss of Micu1’s gatekeeping function on Mcu following mutation of Emre’s C 
terminus. 
1.4.2.2. Other Mcu regulatory genes 
Other Mcu regulators exist, which are not thought to be part of the Mcu channel complex. One 
such protein is Mcu regulator 1 (Mcur1), previously known as Ccdc90a, which was first 
identified during a screen of mitochondrial membrane proteins for their effect on 
mitochondrial Ca2+ uptake by RNA interference (Mallilankaraman et al. 2012a). The role of 
Mcur1 as a regulator of Mcu has been disputed by Paupe et al., but this has since been 
disproven by Vais et al. (Paupe et al. 2015; Vais et al. 2015). Mcur1 can be found on the IMM 
and contains two TMDs, with both of its termini facing the IMS, and has a similar tissue 
expression pattern to that of Mcu (Mallilankaraman et al. 2012a). Mcur1 regulates Mcu-
mediated Ca2+ uptake both basally and following rises in cytosolic Ca2+, with its KD causing 
decreases in mitochondrial Ca2+ influx (Mallilankaraman et al. 2012a; Vais et al. 2015). Mcur1 
physically interacts with Mcu, but was found not to be part of the Mcu-Emre-Micu1-Micu2 
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complex (Mallilankaraman et al. 2012a; Lee et al. 2015; Vais et al. 2015; Sancak et al. 2013). 
The role of Mcur1 is yet to be established in neural cells. 
Slc25a23, a solute carrier mediating Mg-ATP/Pi transport across the IMM, has been found to 
accelerate Mcu-mediated Ca2+ influx through its interaction with Mcu (Hoffman et al. 2014). 
Slc25a23 KD decreases cell death caused by oxidative stress in HeLa cells, an effect which 
was also present following mutation of Slc25a23’s EF-hands (Hoffman et al. 2014). Slc25a23 
is thought to be activated following high cytoplasmic Ca2+ levels in neurons (Rueda et al. 2015; 
Rueda et al. 2014). Slc25a23 KO in primary cortical neurons leads to an increase in excitotoxic 
cell death cause by glutamate application, showing the importance of Slc25a23 in preventing 
the depletion of adenine nucleotides, and thus mPTP opening (Rueda et al. 2015). 
1.4.2.3. Alternative routes of mitochondrial Ca2+ influx 
Although Mcu is thought to be the major pathway of Ca2+ influx into the mitochondria, other 
Mcu-independent routes of Ca2+ influx exist (Figure 1.7). Different types of mitochondrial 
single Ca2+ channels have been observed in mitoplasts, and Mcu was found to be responsible 
for intermediate and extra-large, but not bursting mitochondrial Ca2+ channel current 
(Bondarenko et al. 2013; Bondarenko et al. 2015). Extra-large mitochondrial Ca2+ current was 
shown to compensate for mitochondrial Ca2+ uptake following Mcu KD, but xl-MCC 
occurrence has now been found to be decreased when Emre is knocked down alongside Mcu 
(Bondarenko et al. 2015). 
Uncoupling protein 2 (Ucp2) and 3 (Ucp3) have been shown to play a role in mitochondrial 
Ca2+ influx (Trenker et al. 2007; Waldeck-Weiermair et al. 2010). Initially, Ucp2 was thought 
to be responsible for Ca2+ influx itself, but has since been found to regulate Mcu-mediated 
uptake of Ca2+ released from the ER, but not Ca2+ from store-operated Ca2+ entry (Waldeck-
Weiermair et al. 2010). Ucp2 was demonstrated to increase the occurrence of xl-mitochondrial 
Ca2+ currents dependent on Mcu-mediated Ca2+ uptake, but not be important in whole-cell Ca2+ 
currents (Bondarenko et al. 2015). Furthermore, Ucp2 KO was shown to reduce the rescue of 
cardiomyocytes from ischaemic cell death by Ru360, once again suggesting a regulatory role 
of Ucp2 on Mcu (Motloch et al. 2015). 
Transient receptor potential channel 3 (Trpc3) and ryanodine receptor (Ryr) have been 
implicated as possible alternative mitochondrial Ca2+ uptake routes. Both proteins are localised 
to different parts of the cell, Ryr to the ER and Trpc3 to the plasma membrane, and have only 
recently been shown to also be expressed on the IMM (Jakob et al. 2014; Feng et al. 2013; 
Amaral & Pozzo-Miller 2007). Ryr was demonstrated to allow Ca2+ influx into heart 
mitoplasts, and is expressed on the IMM in rat striatal neurons where it mediates Ca2+ influx 
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following rises in cytosolic Ca2+ (Ryu et al. 2011; Jakob et al. 2014). Trpc3 mediates 
mitochondrial Ca2+ influx at high cytoplasmic Ca2+ concentrations (>50 µM), thereby 
modulating the mitochondrial membrane potential, and has been shown to localise to the 
mitochondria in neurons (Feng et al. 2013). Interestingly, both channels are ruthenium red 
sensitive (Ryu et al. 2011; Feng et al. 2013). Thus, both Trpc3 and Ryr play a role in 
mitochondrial Ca2+ uptake, helping to regulate respiration and possibly cell death. It is likely 
that the importance of the co-existing mitochondrial Ca2+ uptake channels differs amongst 
different cells and tissues. 
1.4.2.4. Mitochondrial Ca2+ efflux pathways 
Mitochondrial Ca2+ efflux is essential for maintaining mitochondrial Ca2+ homeostasis, and is 
thought to be mediated by a Li+-dependent Na+/Ca2+ exchanger in excitable and H+/Ca2+ 
exchanger in non-excitable cells, the identity of which has remained elusive until recently 
(Figure 1.7; Fiskum & Lehninger 1979; Carafoli et al. 1974; Cai & Lytton 2004b; Cai & Lytton 
2004a).  
Letm1 was identified as the probable mitochondrial H+/Ca2+ exchanger by a genome-wide 
RNA interference screen in Drosophila (Jiang et al. 2009). Letm1 is localised to the IMM 
where it mediates mitochondrial Ca2+ efflux during high mitochondrial Ca2+ levels, while at 
low mitochondrial Ca2+ concentrations it is thought to mediate Ca2+ influx, thus possibly 
functioning as both an influx and efflux pathway depending on pH (Jiang et al. 2009; Doonan 
et al. 2014; Waldeck-Weiermair et al. 2011). Although a recent study which reconstituted 
Letm1 in liposomes suggested that it may only be responsible for Ca2+ efflux under basal 
conditions (Tsai et al. 2014). Letm1 has also been suggested to assist in the translation of 
mitochondrial proteins (Bauerschmitt et al. 2010; Lupo et al. 2011). Letm1 KO leads to 
embryonic death, suggesting that Letm1 plays an essential role in mitochondrial Ca2+ handling 
(Jiang et al. 2013).  
Letm1 is deleted in Wolf-Hirschhorn syndrome (WHS), a disorder in humans characterised by 
delayed growth and development, as well as seizures (Bergemann et al. 2005). Letm1 KD 
leads to decreased mitochondrial Ca2+ influx and efflux (without affecting Mcu-mediated Ca2+ 
uptake), as does mutation of its EF-hands and leads to loss of ATP, increased ROS production 
and bioenergetic failure (Doonan et al. 2014). Fibroblasts acquired from WHS patients had 
lower levels of Letm1, and showed decreased Ca2+ uptake, ATP levels and increased ROS 
production (Doonan et al. 2014). In contrast, a study by Waldeck-Weiermair et al. found no 
effect of Letm1 KD on ATP and mitochondrial membrane potential (Waldeck-Weiermair et 
al. 2011). Heterozygous KO of Letm1 results in the death of only half the animals, with the 
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other half developing seizures and showing alterations in respiration and ATP production in 
the brain (Jiang et al. 2013). Interestingly, a recent study found a 50% decrease in Letm1 in 
cell lines from WHS patients, leading to mitochondrial impairments including increased 
mitochondrial Ca2+, ROS production, hyperpolarisation of the mitochondrial membrane 
potential and alterations in mPTP opening (Hart et al. 2014). This implies that loss of Letm1 
is important in the aetiology of WHS, and suggests that Letm1 is essential in mitochondrial 
Ca2+ handling in the brain and is expressed in neural cells.  
The Na+/Ca2+ exchanger responsible for mitochondrial Ca2+ efflux in excitable cells is Nclx. 
Nclx was first identified in 2004 to be responsible for Li+/Ca2+ exchange, with a 55kDa and 
70 kDa isoforms, of which only the short isoform was detected in the rat brain (Palty et al. 
2004). After which Nclx was shown to be the Li+-sensitive Na+/Ca2+ exchanger on the IMM, 
sensitive to CGP-37157, which had previously been shown to block mitochondrial Ca2+ efflux 
(Palty et al. 2010). In line with this, Nclx OE in HeLa cells increases mitochondrial Ca2+ efflux 
(De Marchi et al. 2014). 
Although Nclx has been shown to be expressed in the brain, little is known its expression in 
different neural cells (Cai & Lytton 2004a). Nclx was shown to be expressed in mouse 
astrocytes, and found to contribute to cytoplasmic Ca2+ buffering, thereby influencing store-
operated Ca2+ entry and glutamate release, and was also found to play a role in proliferation 





















Figure 1.7. Mitochondrial Ca2+ levels are regulated by various uniporters, exchangers and other 
proteins. Ca2+ enters from the cytosol into the mitochondrial IMS through VDAC. Mcu forms a 
tetramer on the inner mitochondrial membrane, which can also include Mcub, to allow Ca2+ into 
the mitochondrial matrix. Mcu exists in a channel complex with Emre, Micu1 and Micu2, which 
help control Ca2+ uptake through Mcu. Other regulatory proteins, namely Mcur1, Slc25a23 and 
Ucp2 can also modulate Ca2+ uptake by Mcu. Alternative routes of Ca2+ influx into the matrix 
include Ryr and Trpc3. The Ca2+/H+ exchanger Letm1 is thought to be able to act in reverse and 
allow not only Ca2+ efflux, but also Ca2+ influx into the matrix. The Na+/Ca2+/Li+ exchanger Nclx is 
also thought to be responsible for Ca2+ efflux from the matrix. Ca2+ in the mitochondrial matrix 
activates several dehydrogenases, increasing respiration and the production of NADH which 
powers the ETC (I-IV). Excessive Ca2+ concentrations in the matrix can lead to cell death, for 
example due to the opening of the mPTP. Emre – essential Mcu regulator, ETC – electron transport 
chain, IMS – inner membrane space, Letm1 - Leucine Zipper-EF-Hand Containing Transmembrane 
Protein 1, Mcu – mitochondrial calcium uniporter, Mcur1 – Mcu regulator 1, Micu1/2/3 – 
mitochondrial calcium uptake 1/2/3, mPTP – mitochondrial permeability transition pore, NADH – 
Nicotinamide adenine dinucleotide, Nclx – Na+/Ca2+/Li+ exchanger, Ryr – ryanodine receptor, 
Slc25a23 - SCaMC3, TCA cycle – tricarboxylic acid cycle, Trpc3 – Transient receptor potential 
channel 3, Ucp2 – uncoupling protein 2, VDAC – voltage-dependent anion channel, I-IV – 





Although Ca2+ signalling, especially through the NMDAR, is known to be essential in 
mediating both neuronal survival and death, some of the downstream pathways are still not 
well understood, and neither is the potential influence of astrocytes in neuroprotection 
following neuronal activity. The understanding of these mechanisms is essential for 
developing therapeutic treatments for neurological diseases and brain injury. In this thesis I 
aim to better understand these Ca2+ signalling pathways, and the possible role of astrocytes in 
providing neuroprotection following neuronal activity. 
Our group has found Mcu to be an important mediator of excitotoxic cell death (Qiu et al. 
2013), but its downstream effectors remain undetermined. AMPK has been suggested to have 
a pro-death role in excitotoxicity, and to be activated following mitochondrial dysfunction and 
a drop in ATP levels in neurons (Concannon et al. 2010). Thus, in Chapter 3 I investigate the 
role of AMPK as a potential downstream effector of Mcu during excitotoxicity.  
Many MCRGs including Mcu have only been discovered in recent years, thus their expression 
and function in the CNS is not well characterised. MCRGs are essential for mitochondrial Ca2+ 
handling, and therefore play a role in mediating neuronal survival and death. In Chapter 4 I 
investigate whether MCRGs are differentially expressed in neural cells (neurons vs astrocytes) 
and neuronal subtypes (CA1 vs CA3 neurons of the hippocampus), and examine the functional 
importance of Nclx for mitochondrial Ca2+ efflux in neurons and astrocytes, following the 
discovery of its low expression in neurons. 
Neuronal activity is known to enhance endogenous antioxidant defences in neurons (Papadia 
et al. 2008), but recent reports suggest that it may also activate the Nrf2 pathway in astrocytes 
through the tripartite synapse (Habas et al. 2013). Thus, in Chapter 5 I investigate Nrf2 
expression in neurons, and whether Nrf2 target genes are activated in an Nrf2 and astrocyte 
















2.1. Neuronal cultures 
2.1.1. Preparation of primary cortical cultures 
Cortical cultures were prepared from wild-type E17.5 CD1 or C57BL/6 mouse embryos as 
previously described (Márkus et al. 2016). Briefly, 24-well plates were coated with laminin 
(Sigma) and poly-lysine (Sigma) for 2 hours, to allow cells to adhere to the surface of the 
wells. For calcium imaging experiments, 13 mm diameter coverslips (VWR) were placed into 
the wells before coating. Mouse embryos were decapitated, their brains removed and the 
cortices dissected in dissociation medium (DM; 81.8 mM Na2SO4, 30 mM K2SO4, 5.84 mM 
MgCl2, 252 µM CaCl2, 1 mM Hepes, 0. 1% Phenol Red, 20 mM Glucose (all Sigma) made up 
in H2O), with 1 mM kynurenic acid (Sigma), an NMDAR receptor antagonist, added to prevent 
excitotoxic cell death. The cortices were then digested with papain (with kynurenic acid 
present) for 2x20 min, washed with DM and 1% NBA (Neurobasal A solution (Life 
technologies) supplemented with 1x B27 (Life technologies Ltd.), 1 mM glutamine, 1x 
antibiotic/antimycotic (Life technologies Ltd.) and 1% rat serum (Harlan laboratories)) then 
homogenised in 1% NBA. The cell suspension was then diluted to a concentration of 0.28 
cortices/2 ml with OptiMEM (+20 mM glucose) and 0.5 ml media was plated down into each 
well, whilst astrocytes were plated at half that density. The media was aspirated off of the cells 
after 2.5 hours and replaced with 1 ml fresh 1% NBA or Dulbecco’s modified eagle medium 
(DMEM) supplemented with 10% fetal bovine serum and 1x antibiotic/antimycotic (all Life 
Technologies Ltd.) for growing pure astrocytes (>96% GFAP+ astrocytes) per well. Cells were 
fed again on day in vitro (DIV) 4 with 1 ml 1% NBA or DMEM. Arabinofuranoside cytosine 
(AraC) (4.8 µM, Sigma), which inhibits glial proliferation, was added on DIV0 to pure 
neuronal cultures (98% NeuN+ neurons and <0.2% GFAP+ astrocytes) and on DIV4 to mixed 
neuronal cultures (90% NeuN+ neurons and 10% GFAP+ astrocytes) (Deighton et al. 2014). In 
chapter 5, cultures with No AraC added (15% GFAP+ astrocytes) are used, and the mixed 
culture used for RNA sequencing had AraC added on DIV7. For calcium imaging experiments, 
primary astrocytes were grown in flasks, split twice (using 0.05% trypsin-EDTA, Life 
Technologies) before being plated on coverslips in 24-well plates. The cultures were kept at 
37°C with 5% CO2 in incubators. 
For mouse-neuron rat-astrocyte co-cultures, rat cultures were made as the mouse cultures, 
except rat embryos were used at E20.5 and cell suspensions were diluted to 1/7 cortices per 2 
ml. Primary rat astrocytes were plated down at half density and grown in a T75 flask, and split 
twice before being plated down onto 24-well plates. Mouse neurons were plated on top of the 
astrocytes and AraC added on DIV0 to obtain a culture with rat astrocytes and mouse neurons. 
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2.1.2. Neuronal cultures from transgenic mice 
Homozygous Nrf2 KO mice were taken from Prof. John D. Hayes at The University of 
Dundee, where the genotyping of the mice was carried out. Nrf2 KO pups were cultured as 
described above. In these mice, the bZip region of Nrf2 is replaced with a nuclear localisation 
signal-β-galactosidase LacZ recombinant gene, rendering Nrf2 non-functional (Itoh et al. 
1997). Nrf2 KO mice have been backcrossed onto a C57/BL6 background for several 
generations (Higgins et al. 2009), thus WT C57/BL6 cultures were used as controls for these 
mice. 
AMPKα1 and α2 floxed mice were obtained from the laboratory of Prof. Mark Evans at The 
University of Edinburgh, with the lab kindly carrying out the genotyping of the mice. These 
mice have loxP sites around the catalytic sequence of the α1 and 2 subunits of AMPK, and 
their removal by Cre administration inhibits AMPK’s catalytic activity (Mahmoud et al. 2016; 
Lantier et al. 2014). 
2.2. Stimulations  
For all stimulation, the media on cells was changed into a trophically deprived medium, TMO, 
consisting of 10% Minimum essential media (MEM, Life technologies) in a salt-glucose-
glycine medium (SGG) (containing 114 mM NaCl, 0.219% NaHCO3, 5.292 mM KCl, 1 mM 
MgCl2, 2 mM CaCl2, 10 mM HEPES, 1 mM Glycine, 30 mM Glucose, 0.5 mM sodium 
pyruvate, 0.1% Phenol Red; osmolarity 325 mosm/l) with 1x antibiotic/antimycotic for at least 
2 hours prior to stimulations, which were carried out on DIV8-10 unless otherwise stated. By 
this age, neurons develop a synaptic network and express NMDA and AMPA and kainite 
receptors. For some of the experiments, cells were placed into TMITS, which is TMO with 
insulin-transferrin-sodium selenite (ITS) (Sigma) added, to allow for increased neuronal 
viability. 
When keeping cells to DIV18, 50% of the media on cells was exchanged with NBA without 
rat serum, but with 10 mM glucose added on DIV9 and DIV12, and 50% of the media was 
exchanged with TMITS on DIV14, after which experiments were performed as normal. 
2.2.1. Inducing neuronal activity 
Synaptic activity was induced by application of GABAA inhibitor bicuculline with K+ channel 
antagonist 4-aminopyridine (Bic/4-AP) in neuronal cultures for 4 or 24h, which induces bursts 
of action potential firing, the effect of which is thought to be primarily mediated by synaptic 
NMDAR activation as previously described (Papadia et al. 2008).  
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Alternatively, neurons were depolarised by addition of 0.41 ml KCl depolarisation solution 
(final concentration used: 50 mM KCl; made from stock solution: 10mM HEPES, pH 7.2, 170 
mM KCl, 1mM MgCl2, 2mM CaCl2) in the presence of NMDAR antagonist MK-801 (5 µM, 
Abcam) with or without the L-type Ca2+ channel agonist FPL64176 (5 µM, Sigma) present to 
1 ml TMO in wells (Hardingham et al. 1999). 
2.2.2. Cell death assays 
Different concentrations of NMDA (0-100 µM) (Ascent Scientific) were applied to cultures 
in TMITS for 10 minutes or 1 hour on DIV9, after which 20 µM MK-801 (Abcam) was applied 
to block NMDAR activity, as previously described (Qiu et al. 2013; Concannon et al. 2010). 
Cells were fixed the following day for 20 min in a fixing solution (3% PFA, 4% sucrose in 1x 
phosphate buffered saline (PBS)), permeabilised with 0.5% NP40 (BDH Chemicals) PBS for 
5 minutes and stained with Vectashield mounting medium with DAPI (Vector labs), with a 
coverslip added to visualise the nuclei of cells. Several images were taken from each well with 
a DFC350 FX digital camera at 20x on a Leica fluorescence microscope using the Leica 
AF6000 LX imaging system, with at least 2 wells per condition in each replicate. Neurons 
showed signs of nuclear pyknosis, characteristic of apoptosis. The number of dead and alive 
neurons were counted blindly from the images using ImageJ and the percentage of dead 
neurons in the culture calculated.  
For AMPKα1/2flx cultures infected with AVV-GFP or AAV-Cre-GFP, cell death was also 
calculated by following the fate of single GFP infected cells over 2 consecutive days, after 
which the average percentage of death from 10 GFP-infected neurons/image was calculated. 
The first image of neurons was taken before NMDA application for 1h, with the positions of 
neurons saved, whilst the second image was taken the following day at the same position, 
before cells were fixed and stained for GFP and DAPI to confirm the death of neurons. 
2.2.3. Drugs used 
Drugs used: AICAR (Cell Signaling), MG-132 (Sigma), A79662 (Tocris bioscience), STO-
609-acetic acid (Sigma), Sulforaphane (Cayman chemical), CDDOTFEA (a gift from Michael 
Sporn, Dartmouth College), DMF (Sigma), H2O2 (Sigma), tBHQ (Sigma) 
2.3. Viral infection of cells  
Viruses were added to mixed culture on DIV2 in 1% NBA. Various adeno-associated viruses 
(AAV)-Cre-GFP and AAV-GFP (AAV1, 2, 3 and 6, Vector labs) were added to WT and 
AMPKα1/2flx mouse cultures in TMITS. The infection efficiency of the viruses was determined 
on DIV9, following the fixing of cells, staining them against GFP (anti-GFP antibody 
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(Invitrogen)) and imaging them. AAV6 added to AMPKα1/2flx cultures was imaged on DIV8-
9, prior to cells being fixed. 
Mcu-shRNA or scrambled shRNA virus (with an eGFP tag) was added to cultures on DIV2 to 
knock down Mcu, from which protein was extracted on DIV9. The generation of Mcu and Scr-
shRNA viruses has been previously described (Qiu et al. 2013). 
2.4. Transfections 
Transfections of neurons and astrocytes was carried out using lipofectamine 2000 (Invitrogen). 
0.65 µg of DNA plasmid and 2.33 µl lipofectamine were both mixed with 66 µl TMITS per 
well and left at room temperature for 20 min. The transfection mix was then diluted in 285 µl 
TMITS per well and 333 µl of the mix was added to each well from which media was aspirated. 
The mix was left on DIV7-8 neurons for 4h and for 1h on DIV3 astrocytes, after which neurons 
were placed back into conditioned 1% NBA and astrocytes into fresh DMEM. 
2.5. RNA isolation, RT-PCR and quantitative PCR 
2.5.1. RNA isolation 
RNA was isolated from neural cells in culture using the high pure RNA isolation kit (Roche), 
following the manufacturer’s instructions. Briefly, cells were lysed and transferred into the 
columns provided, the lysate was incubated with DNAse I for 15 minutes, after which the 
column was washed three times and the RNA eluted in RNAse free H2O. 
Hippocampal region CA1 and 3 tissue was dissected from adult mouse brain slices, and then 
placed into Roche lysis buffer and homogenized using the QIAGEN QIAshreddar (QIAGEN 
Ltd.), after which RNA was isolated following the manufacturer’s instructions for the Roche 
High Pure RNA Tissue Kit, including the optional 15 min DNase treatment to avoid DNA 
contamination. 
2.5.2. RT-PCR and quantitative PCR 
1-5 µg RNA was converted into cDNA using the Transcriptor First Strand cDNA Synthesis 
Kit (Roche), following the manufacturer’s instructions. Both anchored oligo(dT)18 primers and 
random hexamer primers from the kit were used for cDNA synthesis. The single-cycle Reverse 
transcription-PCR reaction was run at 25°C for 10 min, 55°C for 30 min and 85°C for 5 min, 
after which the mix was cooled down to 4°C. At least one No RT (reverse transcriptase) 
reaction was run with each sample set as a control. 
cDNA was diluted to 6ng/µl, of which 1 µl was used for a 15 µl qPCR reaction per gene using 
FastStart Universal SYBR Green Master Rox (Roche) for real time qPCR in a Stratagene 
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Mx3000P qPCR System (Agilent Technologies). Next to the cDNA, the qPCR mix contained 
0.6 µl of forward and reverse primers, 7.5 µl SYBR green master mix and 5.3 µl RNase free 
H2O. Primers were tested before use, and their efficiencies calculated. For each qPCR reaction, 
at least two replicates and a No RT control were run to avoid false results due to technical 
errors or DNA contamination. 40 cycles were run to determine the level of each gene of the 
sample, after which one cycle was run to create a dissociation curve. The cycle temperatures 
and times were: 
95 °C 10 min 
 
95 °C 30s* 
40 cycles 60 °C 40s* 
72 °C 30s 
95 °C 1 min* 
 
55 °C 30s* 
 
95 °C 30s*  
*detection of fluorescence 
 
Expression of genes was calculated from the Ct values of each gene using the primer 
efficiencies previously identified (method previously described in (Livak & Schmittgen 
2001)), then normalised to Gapdh or 18s levels in each sample, unless otherwise specified. 
2.5.3. Primers used 
The qPCR primers used in this thesis can be seen in Table 2.1. Note that some of these primers 




Gene name Also known as  Forward primer sequence Reverse primer sequence 
18s   GTGGAGCGATTTGTCTGGTT CAAGCTTATGACCCGCACTT 
Emre Smdt1 CCTGGGTTGCAGTTCGAC GTACCTGGCTGAGACCTGAG 
Gapdh   GGGTGTGAACCACGAGAAAT CCTTCCACAATGCCAAAGTT 
mGapdh   CACCAGGGCTGCCATTTG GCCTCACCCCATTTGATGTTA 
Gclc   CCAACCATCCGACCCTCTG TGTTCTGGCAGTGTGAATCC 
mH1f0   GTTTGTCTTCCAAGACTTTCTT CTTTGCCCCTTTAGACAATGGG 
Hmox1   AGCACAGGGTGACAGAAGAG GGAGCGGTGTCTGGGATG 
Letm1   TCCTGCGTTTCCAGCTCACCAT GTCTTCTGTGACACCGAGAGCT 
Mcu Ccdc109a CGCCAGGAATATGTTTATCCA CTTGTAATGGGTCTCTCAGTCTCTT 
Mcub Ccdc109b CACTCCATTATGGGACAGTGG CGACAACATCGGCTTGACTA 
Mcur1 Ccdc90a AGCCCTCAGAGCAGAAAATG CCAGCATCTTCTTCTCGTTCA 
Micu1 Efha3, Cbara1 GAACTAGCTGTGGGCTCTCG GGTGGCAAAATATCGGAAAA 
Micu2 Efha1 ACATGACACCCCGAGACTTC CGATCATCTCATTCCCATCC 
Micu3 Efha2 AACTCCACCAGTTTGGAAGG CACCATCTCATTTCCGTCAG 
NCLX Slc8b1,Slc24a6 GAGACCACTGTCCAGATCCTGA GAGCAGCAACAAGAACTCCACAG 
mNCLX   GCTGCAGATCATCAGGAACC CCTCAGGAGGCTAGCAGAATC 
Ndufs2   GGATCCGCTTGCCAAGTC CTCAATGAGCTTCTCCGTGC 
Ryr2   ACCTACTCCGAAGGCTGGTGTT TTCTTCCGAGGCAGCACCAAAG 
Slc25a23   TTGATTGGCAGGAATGGCGAGAC GTCAGGCATTCACCGATGTCCA 
Srxn1   GACGTCCTCTGGATCAAAG GCAGGAATGGTCTCTCTCTG 
Trpc3 Trp3 GCATACTTGTCGCTGTCCAG CGACTCAGTGACGCTTTGTG 
Ucp2 Slc25a8 TAAAGGTCCGCTTCCAGGCTCA ACGGGCAACATTGGGAGAAGTC 
Uqcrc2   TGCTCCTCTGTCAAGAATCG CAGTGTACGCCATGTTTTCC 





Table 2.1. qPCR primers. Forward and reverse sequences for primers used for real time qPCR. A 
small m indicates a mouse specific primer (against rat). Alternative gene names are provided in the 
second column for MCRGs recently renamed. 
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2.6. RNA sequencing 
RNA-sequencing (RNA-seq) results used in chapter 5, were from RNA-seq carried out on 
neuronal cultures (DIV0 AraC) and mixed cultures (DIV7 AraC) treated with tBHQ or Bic/4-
AP for 4 or 24h. RNA was extracted from three independent cultures and sent off for RNA-
seq. RNA-seq data used in chapter 4 were from pure neuronal and astrocyte cultures prepared 
by Mr. Philip Hasel. RNA was extracted from cultures as described in section 2.5.1. above. 
RNA-seq as well as the analysis of data was carried out by Edinburgh Genomics, as previously 
described in (Márkus et al. 2016) as follows: 
 “Total RNA from mouse cortical neurons was assessed for quality (Agilent Bioanalyzer) and 
quantity (Invitrogen Qubit) before library preparation. Illumina libraries were prepared from 
1 µg of total RNA using TruSeq RNA Sample Prep Kit v2 with a 10 cycle enrichment step as 
per the manufacturer's recommendations. Final libraries were pooled in equimolar proportions 
before Illumina sequencing on a HiSeq 2500 platform using 50 base paired-end reads. Raw 
reads were processed using RTA 1.17.21.3 and Casava 1.8.2 (Illumina).” 
Reads were mapped onto to the mouse reference genome (mm10) found in Ensembl release 
78, with alignment carried out using Tophat2 (version 2.0.13), using default settings. Htseq 
(version 0.6.0) was then used to calculate raw gene counts. Following this, differential 
expression analysis of the raw counts was estimated using DESeq2 (version 1.6.3) (Love et al. 
2014) using Ensembl release 78 for metainformation such as gene annotations. The 
normalisation function of DESeq2 was then used to normalise the read counts. Lastly, 
estimated gene mRNA expression values were converted to fragments per kilobase of exon 
per million fragments mapped (FPKM) units. 
2.7. Protein extraction and Western blotting 
2.7.1. Protein extraction 
Protein was collected from neuronal cultures (stimulated or unstimulated as indicated) by 
adding 40 µl of 1.5x sample buffer heated at 100°C (made up from NuPage sample reducing 
agent (10x) and NuPage LDS Sample buffer (4x) (Thermo Fisher Scientific)) to each well, 
with at least 2 wells pooled per sample. Samples were then boiled at 100°C for 10-15 minutes 
and loaded into wells or frozen at -20°C. 1.5x sample buffer was also directly added to 
hippocampal tissue dissected from brain slices of adult mice and boiled at 100°C to extract 
protein. 
2.7.2. Western blotting 
15-20 µl of protein samples were loaded into premade 4-12% NuPage Bis-Tris gels (Thermo 
Fisher Scientific) and run at 120 V for around 2 hours in 1xMOPS running buffer (NuPAGE 
MOPS SDS Running Buffer (20X), Thermo Fisher Scientific) in an XCell Surelock system 
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gel tank (Invitrogen). SeeBlue Plus2 protein standard (Thermo Fisher) was used as the ladder 
to indicate the molecular weight of proteins observed. 
Proteins were then transferred onto a Polyvinylidene fluoride (PVDF) membrane (Immobilon-
P PVDF membrane, 0.45 µm pore size (Millipore)) in 1x Transfer buffer (containing 96 mM 
glycine, 12 mM Tris (Trizma base) and 20% Methanol (all Sigma)) for 1 hour at 80V in a 
Criterion blotter tank (Bio-Rad). The PVDF membrane was activated for 1 minute in pure 
methanol before starting the transfer. 
Following the transfer, the blot was blocked in 5% milk (semi-skimmed milk powder, Tesco) 
TBS (made of 20 mM Tris, 137 mM NaCl (Sigma) and H2O, pH 7.6) with 0.1% Tween 20 
(Sigma) (TBS-T) for 1 hour, after which blots were incubated with the primary antibody in 
5% milk TBS-T overnight at 4°C on a roller. For the pAMPKα antibody, 5% BSA TBS-T was 
used instead of 5% milk TBS-T for all steps. The following day the blots were washed for 
2x15 min in TBS-T before the HRP-linked secondary antibody in 5% milk TBS-T was added 
for 1 hour at room temperature, after which the washing step was repeated. Enhanced 
chemiluminescence (ECL) solution (containing 100 mM Tris-base (pH 8.5), luminol, p-
coumaric acid and H2O2 (all Sigma)) was then added to the blot for 1 min, after which 
chemiluminescence of the membrane was detected on Carestream Kodak BioMax light or 
XAR film (Sigma), which was developed using Carestream Kodak autoradiography GBX 
developer/replenisher (Sigma) and fixed in Carestream Kodak autoradiography GBX 
fixer/replenisher (Sigma). Several exposures were taken for each blot to ensure that the 
samples were not saturated. The blots were scanned and the best exposures analysed by 
densitometric analysis using ImageJ, with values being normalised to β-actin levels in each 
sample as a loading control unless otherwise stated. Blots were stripped using 1x re-blot plus 
strong solution (Millipore) for 15 minutes after which blots were blocked again for 1 hour in 
5% milk TBS-T and then reprobed for another antibody. 
2.7.3. Antibodies used 
Antibodies used for Western blotting and immunocytochemistry in this thesis: 
Primary antibodies: AMPKα rabbit Ab (Cell Signaling, 1:2000), phospho-AMPKα rabbit Ab 
(Thr172) (Cell Signaling, 1:2000), anti-β-actin Ab (Abcam, 1:10000), anti-Mcu (Sigma, 
1:3000), Nrf2 (D1Z9C) rabbit mAb (Cell Signaling, 1:400), anti-Uqcrc2 Ab (Abcam, 




Secondary antibodies: Cy3-conjugated AffiniPure Donkey anti-Rabbit IgG (Jackson 
ImmunoResearch, 1:2000), anti-rabbit IgG, HRP-linked Ab (Cell Signaling, 1:2000), 
biotinylated anti-rabbit (Vector labs, 1:500) and Cy3-conjugated streptavidin (Stratech, 
1:500). 
2.8. Immunocytochemistry 
Cells were fixed with a fixing solution (containing 3% PFA, 4% sucrose in 1xPBS) for 20 
minutes, then permeabilised with PBS + 0.5% NP40 (BDH Chemicals) for 5 minutes, washed 
in 1xPBS and incubated with the primary antibody in 1xPBS overnight at 4°C on a shaker. 
Cells were washed 2x15 min with 1xPBS the following day, and the secondary antibody in 
1xPBS was added for 1 hour at room temperature on a shaker. The Neuro-Chrom FluoroPan 
neuronal marker (Merck Millipore) was added after these steps for 2 hours at room 
temperature. Vectashield+DAPI (Vector labs) and coverslips were then added to the wells and 
the plates were imaged. In the case of Nrf2 staining, images from all wells were taken at the 
same fluorescence intensity, to be able to quantify the relative level of the fluorescence 
intensity of the Nrf2 staining between different conditions. For antibodies used, see section 
above. 
2.9. Calcium imaging 
Neurons and astrocytes transfected with cytoplasmic GCamp2 (cytoGCamp2, gift from Karel 
Svoboda) (Mao et al. 2008) or mitochondrial GCamp2 (mitoGCamp2, gift from Xianhua 
Wang) (Chen et al. 2011) on DIV7 and were imaged in SGG (equilibrated in a 5% CO2 
incubator) on DIV9-11 using a standard GFP filter set (excitation 480±20; emission 527±15) 
at 20x on a fluorescent microscope using the Leica AF6000 LX imaging system. 
Cells were pre-incubated in the chambers for 10 minutes, with or without CGP-37157 (Sigma), 
after which the transfected cells were identified on the coverslips and imaged. Cells were 
imaged for around 2 minutes to allow for the recording of a steady baseline, after which 100 
µM ATP was added to astrocytes or KCl depolarisation solution (50 mM K+) (with MK-801 
present) added to neurons to induce an increase in cytosolic and mitochondrial Ca2+ levels. 
Cells were washed with SGG 1 minute after the stimulation and henceforth every 30 seconds 
for a few minutes, to allow for observation of the rate of Ca2+ decay from the cytosol and 
mitochondria. Ionomycin (Tocris, 50 µM), a plasma and mitochondrial membrane permeable 
Ca2+ ionophore, was added at the end of recordings to establish the maximal Ca2+ capacity of 
each cell Fmax (Nicholls 2006), following which EGTA was added to chelate Ca2+ in cells to 
give a minimum Ca2+ value for each cell Fmin. Changes in Ca2+ levels were then calculated as 
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(F-Fmin)/(Fmax-F), which has been shown to have a linear relationship with Ca2+ (Qiu et al. 
2013), and is based on the equation [Ca2+ ] = Kd*(F-Fmin)/(Fmax-F). 
2.10. Statistical analysis 
Data was analysed using paired or unpaired two-tailed t-tests, depending on whether the data 
acquired were independent or not. In a few cases ANOVAs were used with post-hoc tests, 
which is indicated in detail in the figure legends. Statistical analysis was carried out using 
Graphpad prism (Graphpad Software Inc., La Jolla, CA). All data shown in graphs is 







Chapter 3: AMPK is involved in excitotoxicity but is not 





Neuronal fate in response to NMDAR activation follows a bell shaped curve, with 
physiological activation promoting neuronal survival and too little or excessive activation 
promoting cell death (Hardingham 2009). Excessive activation of NMDARs leads to 
excitotoxicity, causing large amounts of Ca2+ influx into neurons which activates several pro-
death pathways, leading to neuronal dysfunction and death (Hardingham 2009). Mitochondrial 
dysfunction occurs following a severe excitotoxic insult due to excessive mitochondrial Ca2+ 
uptake by the mitochondrial calcium uniporter (Mcu). Mcu has long been thought to be 
involved in excitotoxic cell death, and the recent discovery of its molecular identity as the 
Ccdc109a gene (Baughman et al. 2011; De Stefani et al. 2011) allows for its knock-down (KD) 
instead of using pharmacological inhibitors with off target effects, such as Ru360, to inhibit 
Mcu. Mcu is located on the inner mitochondrial membrane and is the major route of Ca2+ influx 
into the mitochondrial matrix, thus helping to buffer cytoplasmic Ca2+ levels, regulate cellular 
bioenergetics and activate cell death signalling (McCormack et al. 1990; Hajnóczky et al. 
1999; Bernardi & Rasola 2007). Although Mcu has low affinity for Ca2+, it is highly selective 
for and has high capacity for Ca2+, thus allowing rapid Ca2+ entry into the mitochondria during 
excitotoxicity when cytosolic Ca2+ levels are high (Kirichok et al. 2004). Our lab has recently 
demonstrated that Mcu KD in primary neuronal culture reduces mitochondrial Ca2+ influx 
during excitotoxicity, decreasing mitochondrial depolarization and rescuing cells from 
excitotoxic cell death (Qiu et al. 2013). Overexpressing Mcu has the opposite effect, increasing 
mitochondrial depolarization and enhancing cell death. This establishes Mcu as an important 
mediator of excitotoxic cell death in cortical neurons, although its downstream targets 
promoting cell death remain elusive.  
AMP activated protein kinase (AMPK), a triheteromeric protein with a catalytic α and 
regulatory β and γ subunits, is an energy sensor that activates ATP-producing pathways and 
inhibits ATP-consuming pathways following cell stress (Hardie et al. 2012). AMPK is 
allosterically activated following an increased AMP:ATP ratio due to AMP binding to its γ 
subunit, preventing dephosphorylation of AMPK (Sanders et al. 2007; Fogarty et al. 2010), 
which promotes the phosphorylation of T172 on its catalytic α subunit by its upstream kinase 
LKB1, further activating AMPK (Carling et al. 2008; Hardie 2007; Woods et al. 2003; Hawley 
et al. 2003). Alternatively, AMPK can be phosphorylated and activated by CaMKKβ following 
increased cytoplasmic Ca2+ levels (Hawley et al. 1996; Carling et al. 2008; Green et al. 2011; 
Woods et al. 2005; Hawley et al. 2005). The activation of AMPK following a drop in ATP 
levels makes it an attractive candidate as a downstream target of mitochondrial dysfunction 
during excitotoxicity. Indeed, prolonged AMPK activation following an excitotoxic insult has 
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been shown to mediate apoptotic cell death. NMDA stimulation in mouse cortical neurons and 
glutamate stimulation in cerebellar granule neurons (CGNs) led to decreased ATP levels and 
mitochondrial membrane potential activating AMPK, which transcriptionally upregulated the 
BH3-only gene Bim causing neuronal apoptosis (Concannon et al. 2010). The upregulation of 
Bim was later found to be mediated by AMPK through its activation of FOXO3, in a two-step 
process (Davila et al. 2012). Firstly AMPK inhibits Akt, promoting FOXO3 nuclear 
translocation, and secondly AMPK phosphorylates FOXO3 in the nucleus inducing Bim 
transcription, a step which only occurs following prolonged AMPK activation (Davila et al. 
2012). Additionally, LKB1 has been suggested to be the upstream kinase of AMPK in CGNs 
(Weisová et al. 2012).  
Thus I hypothesise that AMPK is activated by LKB-1 due to an increase in AMP:ATP ratio 
following mitochondrial dysfunction caused by Mcu-mediated Ca2+ uptake during 
excitotoxicity in cortical neurons. Although the role of AMPK has been previously 
investigated in excitotoxicity following its KD by siRNA or pharmacological inhibition 
(Concannon et al. 2010; Anilkumar et al. 2013), there have been no studies employing neurons 
from AMPK KO mice to my knowledge. Here, I investigate the role of AMPK in promoting 
excitotoxic cell death employing primary cortical cultures from conditional AMPKα1 and 2 
double KO mice (Mahmoud et al. 2016; Lantier et al. 2014). Furthermore, I investigate AMPK 
as a potential downstream effector of Mcu-mediated Ca2+ uptake-induced cell death following 
excitotoxicity by Mcu KD. My results show that although AMPK helps to mediate 
excitotoxicity in primary cortical neurons, it is not activated by decreases in ATP due to Mcu-





3.2.1. AMPK gets activated following NMDA treatment 
Both Concannon et al. and Anilkumar et al. have previously shown that AMPK gets activated 
following an NMDA insult in neurons (Concannon et al. 2010; Anilkumar et al. 2013). I 
wanted to test whether this was the case in primary mixed neuronal cultures (90% NeuN+ 
neurons and 10% GFAP+ astrocytes) and if any time points and concentration of NMDA 
activated AMPK, to determine what concentration to use in subsequent experiments. Primary 
neuronal cultures were stimulated with a range of NMDA concentrations at different time-
points, and AMPK activator AICAR was applied for 1 hour or 30 minutes as a positive control. 
It was visually obvious that phosphorylated AMPKα (on Thr172) protein levels increase 
following NMDA stimulation, as seen in an example blot in Fig.3.1A.  pAMPKα levels were 
quantified and normalised to the total AMPKα in each sample (Fig.3.1B). The largest increase 
in AMPK activation was observed 30 minutes after stimulation with 30 µM NMDA. This was 
also the only stimulation which was significantly different compared to the control using a 
one-way ANOVA with Bonferroni post-hoc test (p<0.05). However, all stimulations showed 
an upward trend in pAMPK levels, and with many of the stimulations only performed a few 
times and the general variability of Western blots the lack of significance is not surprising. 
Since there was a clear visual increase in pAMPK protein levels and a significant increase 30 
µM NMDA applied for 30 min, I concluded that AMPK is activated by NMDA, and applied 
30 µM NMDA for 30 minutes to activate AMPK in subsequent experiments. 
 
Figure 3.1. pAMPK levels in neuronal culture increase following NMDA treatment. A. Example of 
a Western blot showing an increase in pAMPKα levels following application of 30 μM NMDA for 
10, 30 or 60 minutes, total pan-AMPKα is used as a loading control. B. The average values of AMPK 
activation following AICAR and NMDA treatment at different time points and doses. n=2 for 20 and 
60 min 30 μM NMDA treatment and 30 min 25 and 50 μM NMDA treatment, n=4 for the AICAR 
treatments and for 10 and 30 min 30 μM NMDA treatment, and n=10 for control. Data was 
normalised to the untreated control and the loading control AMPKα. Error bars=SEM. *p<0.05 
compared to the control, one-way ANOVA with a Bonferroni post-hoc test. 
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3.2.2. AMPKα gets knocked down by AAV6-Cre-GFP in AMPKα1 and 2 floxed mouse 
mixed neuronal cultures  
To study the role of AMPK in NMDA-mediated excitotoxicity, I used primary cortical cultures 
made from a conditional AMPKα1 and 2 KO mouse, in which the catalytic sites in AMPKα1 
and 2 are floxed (Lantier et al. 2014; Mahmoud et al. 2016). AMPKα1 and 2 are the two 
catalytic subunits, thus their KO will cease AMPK activity. Since AMPKα1 and 2 are floxed 
in the mouse, I needed to find a Cre virus which would efficiently knock down AMPKα1/2 in 
neurons in cortical culture. Thus, I tested the infection efficiency of various different viruses 
on primary neuronal cultures made from wild-type CD1 mice, which could later be used to 
infect cultures made from AMPKα1/2 floxed mice. Adeno-associated virus (AAV)1, 2, 5 and 
6 with a GFP-tag were added to cultures on day in vitro (DIV) 2 and the percentage of neurons 
infected was calculated by determining the percentage of GFP-positive neurons in the culture 
(Fig.3.2). AAV6-GFP had the highest infection rate of neurons out of the four AAVs tested, 
at 51.4% when adding 2.5x104 genome copies/cell, and even higher efficiencies when tested 
again. I then examined whether AAV6-GFP had a similar infection rate to that of AAV6-Cre-
GFP, and I found both viruses to infect around 55% of neurons on average in primary cortical 
cultures. This means that results between WT and AMPKα KO conditions will be easily 
comparable. 
I next tested AAV6-Cre-GFP and GFP in AMPKα1/2 floxed mouse primary cortical cultures. 
Neurons were infected with AAV6-Cre-GFP or AAV6-GFP on DIV2 and protein levels of 
AMPKα and pAMPK were determined on DIV9. As expected, there was a large reduction in 
AMPKα as well as pAMPK levels in samples treated with AAV6-Cre-GFP, compared to cells 
treated with control AAV6-GFP (Fig.3.3A). Control AMPK levels were quite high compared 
to AMPKα KD samples, so a serial dilution of the samples was carried out to better examine 
the amount of AMPKα KD (Fig.3.3B). This showed that there was approximately 75% KD of 
AMPKα levels in cells treated with AAV6-Cre-GFP compared to cells treated with AAV6-
GFP, which was consistent across samples. This is slightly higher than the percentage of 
neuronal infection observed following immunostaining, which may be due to neurons weakly 
expressing GFP not being picked up above background levels. 
Thus AMPKα as well as pAMPKα get knocked down following AAV6-Cre-GFP infection in 







Figure 3.2. The AAV6 virus has the best infection efficiency of neurons in culture out of the different 
viruses tested (AAV1, 2, 5 and 6). Pictures of neuronal cultures immunostained with GFP, DAPI and 
their overlay are shown for the four viruses (AAV1, 2, 5 and 6). The percentage of neurons infected 
with the virus was calculated from the images and the average percentage of neurons infected (from 
2 images) for each virus is shown on the right. 1010 genome copies (GC) were added/well for all 4 AAV 





Figure 3.3. AMPKα expression is decreased in AMPKα1 and 2 floxed mouse mixed neuronal 
cultures infected with AAV6-Cre-GFP. A. AMPKα KD by AAV6-Cre-GFP in AMPKα1/2flx mouse 
cultures causes a decrease in AMPKα expression as well as pAMPK levels compared to the controls 
infected with AAV6-GFP (n=4). A pan-AMPKα antibody was used. n1, 2 and 3 represent samples 
from different cultures. B. Titration of n1, showing that there is around a 75% AMPK KD in AAV6-
Cre-GFP treated samples compared to the control samples. Two different exposures of AMPKα 
are shown to portray the protein expression levels clearly for both ends of the serial dilution. A 
similar degree of AMPK KD was observed in the other three samples (not shown). 
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3.2.3. AMPKα knockdown is neuroprotective against excitotoxic cell death 
Next, I examined the effect of AMPK KD on NMDA-mediated excitotoxic cell death. AMPK 
has been shown to be a mediator of excitotoxic cell death through inducing transcription of 
the pro-apoptotic BH3-only gene Bim (Davila et al. 2012; Concannon et al. 2010). Our lab 
generally uses a cell death assay in which a range of NMDA concentrations (0-50 µM) are 
added for an hour to cultures followed by addition of NMDAR blocker MK-801, with cultures 
fixed the following day (Qiu et al. 2013). I also tested a different assay used by Concannon et 
al. to induce excitotoxic cell death, where different NMDA concentrations (0-100 µM) were 
added for 10 minutes followed by two washes instead of MK-801 application (Concannon et 
al. 2010). This protocol was suggested to kill neurons through apoptosis, unlike our protocol 
which induces neuronal death through several different pathways. I found the protocol used 
by Concannon et al. quite variable, thus I adapted a block with MK-801 following the 10 
minute NMDA insult instead of the washes, and found the results to be more consistent. 
Unfortunately, this cell death assay produced cell death levels which were too low to observe 
a rescue from, even at a 100 µM NMDA (Supplementary figure 1), thus I decided to use our 
1 hour NMDA cell death assay protocol. The EC50 concentration for the 1h NMDA stimulation 
was around 30 µM NMDA. 
The cell death assay was performed on primary cortical cultures from AMPKα1/2flx mice 
treated with either AAV6-Cre-GFP or AAV6-GFP (for AMPKα KD and control respectively). 
The percentage of neuronal death following NMDA application to cultures was calculated 
from images of DAPI staining (Fig 3.4B). There was a small but significant reduction in cell 
death following 30, 40 and 50 µM NMDA stimulation in AAV6-Cre-GFP treated samples 
compared to those treated with AAV6-GFP (Fig 3.4A). Thus, AMPKα KD in cortical cultures 







Figure 3.4. AMPKα KD in primary cortical cultures made from AMPKα1/2flx mice decreases cell 
death caused by excitotoxicity. A. Cell death was induced by different concentrations of NMDA (0-
50 µM) applied for 1 h. Cell death is shown as the overall percentage of dead neurons in the culture, 
calculated from 4 images/n, with each image containing around 3-400 neurons. n=4. Error 
bars=SEM. *p<0.05 between the control and AMPK KD samples at different concentrations of 
NMDA, analysed using a 2-way ANOVA with Bonferroni post-hoc test. B. Example pictures of the 




3.2.4. AAV6-Cre-GFP infected neurons in AMPKα1/2 floxed cultures are partially 
rescued from excitotoxic cell death 
Although a significant reduction in cell death following AMPKα KD in the whole culture was 
established, I wanted to examine whether this was due to the neurons in which AMPKα was 
knocked down themselves, since I only found 50-60% of cells to be infected with AAV6-Cre-
GFP and around a 75% KD of AMPKα protein in cultures (Section 3.2.2). Thus, the fate of 
individual GFP-infected neurons was followed over 2 consecutive days in the cultures 
described in section 3.2.3, to confirm that the cell death was caused by AMPK KD itself. 
Pictures were taken of GFP-infected neurons prior to the NMDA insult and before the cells 
were fixed, from which the fate of individual neurons was followed and the percentage of dead 
neurons was calculated. An example of following the fate of an individual neuron can be seen 
in Fig.3.5B. There was a reduction in cell death in neurons treated with AAV6-Cre-GFP 
following 30, 40 and 50 µM NMDA treatment compared to control neurons treated with 
AAV6-GFP, although the decrease in cell death was only significant following 30 or 40 µM 
NMDA application (Fig.3.5A). This may be due to following the fate of only a small number 
of neurons in these experiments. The basal cell death was much lower when following GFP-
infected neurons than in the whole culture. This was not due to GFP-infected neurons being 
healthier, but because only neurons which were alive before NMDA treatment were examined, 
whilst the whole culture will have had basal cell death prior to NMDA treatment and these 
cells were also counted. Although in both analyses, neuronal death was found to be similar in 
WT and AMPKα treated cultures at baseline and following mild NMDA treatment (20 µM 
NMDA). Cell death was much higher when following individual neurons, which was likely 
due to AAV6-infected neurons being much more vulnerable to cell death than other uninfected 
neurons in the culture. Thus, the neuroprotection observed following AMPKα KD against 




Figure 3.5. AAV6-Cre-GFP infected neurons in AMPKα1/2flx culture show decreased cell death 
following an excitotoxic insult. Cell death was induced by different concentrations of NMDA (0-50 
µM) applied for 1 h. Cell death was calculated from individual GFP infected neurons (n=10/image), by 
observing the viability of cells over the course of 2 consecutive days, and the mean cell death of 10 
neurons/image was calculated. A. Percentage cell death caused by different concentrations of NMDA 
in neurons with or without AMPKα. B. An example of how the number of dead cells was calculated. 
Images of the live GFP or Cre-GFP infected neurons untreated or treated with 40 μM NMDA on days 
1 and 2 are shown, as well as the corresponding DAPI pictures taken after fixing the cells to confirm 
cell death. Red arrows show cells which were still alive on Day 2, and yellow arrows show cells which 
died between Day 1 and Day 2. n=4. Error bars=SEM. *p<0.05 between GFP and Cre-GFP virus treated 




3.2.5. Mcu KD has no significant effect on pAMPK levels in neurons at baseline or 
following NMDA stimulation 
Mitochondrial dysfunction has long been known to help mediate excitotoxic cell death, and 
Mcu which has recently been identified as Ccdc109a was hypothesised to mediate this effect 
(Baughman et al. 2011; De Stefani et al. 2011). Our group recently confirmed the role of Mcu 
as an important mediator of excitotoxicity (Qiu et al., 2013). Mcu KD led to decreased 
mitochondrial Ca2+ influx, and rescued neurons from cell death and mitochondrial 
depolarisation. Although the role of Mcu in excitotoxic cell death is now established, which 
downstream pathways it targets to achieve this is still unclear.  
AMPK undergoes allosteric activation after AMP binds to its γ subunit, and can then be 
phosphorylated by its upstream kinase LKB-1 on Thr172 on its α subunit (Woods et al. 2003; 
Hawley et al. 2003). Decrease in ATP levels following mitochondrial dysfunction due to an 
excitotoxic insult has been shown to activate AMPK previously in CGNs (Concannon et al. 
2010; Davila et al. 2012). Following observations made in sections 3.2.3 and 3.2.4 that AMPK 
plays a destructive role in NMDA-mediated excitotoxicity, I hypothesised that AMPK may be 
a downstream effector of Mcu. 
To test whether AMPK is downstream of Mcu, Mcu was knocked down in WT mouse cortical 
cultures by Mcu-shRNA virus or Scrambled-shRNA virus was added to controls on DIV2, and 
their effect on pAMPKα and total pan-AMPKα protein levels was investigated. AMPKα levels 
were examined at baseline, as well as following 30 µM NMDA insult for 30 minutes with or 
without Mcu KD. For examples of blots see Fig.3.6A. Samples treated with Mcu-shRNA 
showed a marked significant decrease in Mcu levels compared to samples treated with Scr-
shRNA (Fig.3.6C).  pAMPK levels were quite variable in the Mcu-shRNA control compared 
to the Scr-shRNA control, but overall there was no significant effect on pAMPK levels 
between the Scr and Mcu KD in either the control or following 30 µM NMDA treatment for 
30 minutes (Fig.3.6B). Thus, these results show that activation of AMPK is not downstream 
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Figure 3.6.  Mcu KD by Mcu-shRNA has no significant effect on pAMPK levels in neurons. A. 
Example blot for two different experiments where Mcu protein levels were knocked down by Mcu-
shRNA virus. pAMPKα, pan-AMPKα, Mcu and β-actin are shown with no treatment and after 
treatment with 30 μM NMDA for 30 minutes. B. Analysis of Western blots for pAMPK protein levels 
when normalised to AMPKα C. Analysis of Western blots for Mcu protein levels when normalised to 
β-actin loading control. n=5 for both (b) and (c). Error bars=SEM. *p<0.05 compared to Scr-shRNA, 





3.3. Discussion  
3.3.1. Conclusion  
I hypothesised that AMPK would be a downstream effector of Mcu in excitotoxicity. The 
experiments presented in this chapter clearly demonstrate that AMPK plays a small, but 
significant role in mediating NMDA-induced excitotoxic cell death; but AMPK activation is 
not a result of Ca2+ influx through Mcu and the subsequent decrease in mitochondrial 
membrane potential leading to ATP depletion, as pAMPK protein levels are not significantly 
altered following Mcu KD. Thus even though AMPK plays a role in NMDA-induced 
excitotoxicity, its mode of activation as well as the downstream targets of Mcu-mediated cell 
death during excitotoxicity remain unknown. At basal and more physiological NMDA 
concentrations (20 µM), AMPKα1/2 KD did not induce cell death, possibly indicating that 
AMPK only promotes cell death following application of pathological NMDA concentrations. 
3.3.2. AMPK plays a small but significant role in NMDA-induced excitotoxicity in 
cortical neurons 
AMPK has previously been implicated to have a dual role in excitotoxic cell death. Transient 
AMPK activation has been shown to be neuroprotective during excitotoxicity (Anilkumar et 
al. 2013; Culmsee et al. 2001; Weisova et al. 2009; Weisová et al. 2012). Indeed, levels of cell 
death were not significantly different basally and following 20 µM NMDA application in 
AAV6-GFP and AAV6-Cre-GFP treated AMPKα1/2flx cortical culture Fig.3.5A and 3.6A. 
This indicates that AMPK does not mediate cell death at baseline or at low levels of NMDA 
treatment, which is in line with previous observations that AMPK does not induce cell death 
following transient increases in pAMPK (Davila et al. 2012). Although transient activation of 
AMPK is thought to have neuroprotective effects, I did not observe this following the addition 
of 20 µM NMDA, since there was no increase in cell death following AMPKα1/2 KD. 
AMPKα1/2 KD at higher NMDA concentrations (30, 40 and 50 µM NMDA) had a protective 
effect against excitotoxic cell death, both on the whole culture level and when following the 
fate of GFP-infected neurons. A higher overall cell death was detected in GFP-infected 
neurons, likely due to the viral infection making neurons more vulnerable to the excitotoxic 
insult. The protection provided by AAV6-Cre-GFP over AAV6-GFP to neurons against 
excitotoxic cell death following 30 and 40 µM NMDA was larger when looking at individual 
neurons than in the overall culture, showing that the protection in these culture was indeed due 
to AMPKα1/2 KD. These results agree with previous studies showing that prolonged AMPK 
activation mediates glutamate and NMDA-induced cell death in neurons (Concannon et al. 
2010; Davila et al. 2012).  
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AMPK promotes ATP-producing pathways, whilst downregulating ATP consuming pathways 
in cells (Hardie et al. 2012). This can be protective short term, but cannot help neurons recover 
from a severe excitotoxic insult. A two-step computational model proposed by Davila et al. 
attempts to explain the dual role of AMPK on neuronal fate following glutamate exposure 
(Davila et al. 2012). Firstly, AMPK downregulates the Akt pathway promoting the 
translocation of dephosphorylated FOXO3 to the nucleus, and secondly FOXO3 is 
phosphorylated by AMPK in the nucleus to promote increased expression of Bim. Since the 
first step of the process takes some time, the second step only occurs following prolonged 
AMPK activation. Although the pro-death role of prolonged AMPK activation in 
excitotoxicity has been demonstrated, it was done using AMPK KD by siRNA or 
pharmacological inhibition by Compound C, rather than using neurons from an AMPK KO 
mouse. For the first time, I show that AMPK plays a destructive role in NMDA-induced 
excitotoxicity in cortical neurons using an AMPKα1/2 conditional KO mouse. Further 
experiments will need to be carried out to establish the role of AMPK in excitotoxicity in vivo.  
It is important to note, that my excitotoxic cell death assay differed from that used by 
Concannon et al., and that my approach leads to a number of cell death pathways, and not only 
delayed apoptotic cell death (Concannon et al. 2010). Thus, it is possible that using this assay 
AMPK mediates cell death not only through Bim-mediated apoptosis as seen by Concannon 
et al., but also through other pathways. Therefore, the downstream mediators of AMPK during 
excitotoxicity in cortical cultures should be further investigated. 
Although I found AMPK activation to have pro-death effects during excitotoxicity, its 
potential pro-survival effects under different experimental conditions cannot be ruled out. 
Preconditioning with FCCP to activate AMPK has been shown to be neuroprotective against 
subsequent excitotoxic insult, whilst preconditioning with low levels of AICAR to activate 
AMPK is neuroprotective against oxidative, excitotoxic and metabolic insults in neurons 
(Weisová et al. 2012; Culmsee et al. 2001; Anilkumar et al. 2013), similarly to neuroprotection 
provided by NMDAR activation following ischaemic preconditioning or preconditioning by 
neuronal activity. Thus, it is tempting to speculate that preconditioning with synaptic activity 
may transiently activate AMPK, providing the neuron with protective effects against later 
insults. AMPK activation may follow the dual role of NMDAR activation whereby it exerts 
neuroprotective effects following transient activation by synaptic activity and neurodestructive 
effects following excessive NMDAR activation.  
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3.3.3. AMPK activation is not dependent on Mcu during excitotoxicity  
Mitochondrial dysfunction plays a large role in excitotoxic cell death, and has long been 
thought to be mediated by Mcu allowing Ca2+ influx into the mitochondria following an 
excitotoxic insult (Hardingham 2009). Due to the recent molecular identification of Mcu (De 
Stefani et al. 2011; Baughman et al. 2011), our group was able to KD Mcu and demonstrate 
that it mediates mitochondrial dysfunction and subsequent cell death following NMDA-
induced excitotoxicity (Qiu et al. 2013). Thus, I investigated whether AMPK was a 
downstream effector of Mcu during excitotoxicity. Various groups have shown a decrease in 
ATP levels and mitochondrial dysfunction following NMDA or glutamate exposure leading 
to an increase in AMPK levels (Weisova et al. 2009; Concannon et al. 2010). I demonstrate in 
this chapter that AMPK is activated by different NMDA concentrations, and our group 
recently showed a decrease in ATP levels following exposure of neurons to 100 µM NMDA 
as well as after milder synaptic activity (Hasel et al. 2015). This could explain transient AMPK 
activation being neuroprotective and prolonged AMPK activation leading to excitotoxic cell 
death, as both milder and more severe stimuli decrease ATP levels and most likely increase 
pAMPK levels. Decreased ATP levels following NMDA stimulation leads to increased ADP 
and AMP levels, which bind to AMPK allosterically activating it and triggering AMPKα 
phosphorylation at Thr172 by LKB-1 (Carling et al. 2008). Surprisingly, my results showed 
that Mcu KD does not affect pAMPK levels basally or following NMDA stimulation, 
suggesting that AMPK is not downstream of Mcu-mediated decrease in ATP levels during 
excitotoxicity.  
Previous research has implicated Mcu upstream of AMPK activation. Blocking Mcu with 
Ru360 was shown to increase pAMPK levels, whilst Mcur1 KD, a protein thought to regulate 
Mcu, has been shown to result in an increased AMP:ATP ratio leading to AMPK activation  
(Cárdenas et al. 2010; Mallilankaraman et al. 2012a). Both of these results suggest that AMPK 
is activated following decreased mitochondrial Ca2+ influx. This is likely due to the dual role 
of mitochondrial Ca2+ in regulating cell fate, since physiological mitochondrial Ca2+ levels 
promote cell survival, whilst both too little and too much mitochondrial Ca2+ influx promote 
cell death. Overactivation of Mcu leads to mitochondrial depolarisation and decreases in ATP, 
whilst Mcu block may decrease respiration resulting in decreased ATP production, thus both 
could lead to AMPK activation. Additionally, Ru360 and Mcur1 KD could have off target 
effects causing AMPK activation. The results shown in this thesis using a direct Mcu KD, 
rather than pharmacological inhibition is more likely to be accurate. 
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It is a possibility that Mcu KD was not sufficient enough to effect pAMPK levels, and perhaps 
using an Mcu KO mouse may give more conclusive results. KD of Mcu in AMPKα1/2 mouse 
cultures could help to determine whether these two pathways are distinct and whether they 
mediate additive neurodestructive effects during excitotoxicity. It is quite likely that AMPK is 
activated through a different pathway, possibilities of which are outlined below.  
The lack of change in AMPK activation upon Mcu KD means that the search for the 
downstream effector(s) of Mcu continues. There are several possible pathways through which 
Mcu could mediate its effect. One possibility is the activation of PARP-1, which is activated 
following DNA damage caused by peroxynitrite (Duchen 2012). Peroxynitrite is formed by 
NO, produced by nNOS, and superoxide, which is released primarily from mitochondria 
following an excitotoxic insult leading to mitochondrial depolarisation due to Mcu-mediated 
Ca2+ uptake, but can also be produced by NADPH oxidase (Duan et al. 2007; Duchen et al. 
2008; Duchen 2012). Thus, peroxynitrite activates PARP-1, which forms poly-ADP ribose 
(PAR) polymers, which promote the release of the apoptosis-inducing factor (AIF) from 
mitochondria leading to PARP-1 dependent (caspase-independent) cell death (Duan et al. 
2007; Yu et al. 2002). Furthermore, PARP-1 activation depletes NAD+ which may help induce 
mitochondrial depolarisation (Duchen 2012). c-Jun N-terminal protein kinase (JNK) has also 
been shown to be activated by ROS production by mitochondria, making it another potential 
downstream effector of Mcu-mediated Ca2+ uptake-induced cell death (Soriano et al. 2008b). 
Ca2+ uptake through Mcu following an excitotoxic insults causes  Ca2+ accumulation in the 
mitochondria, and may lead to the opening of the mitochondrial permeability transition pore 
(mPTP) resulting in the release of cytochrome C from mitochondria initiating apoptosis 
(Brustovetsky et al. 2002; White & Reynolds 1996; Ichas & Mazat 1998; Orrenius et al. 2003; 
Bernardi & Rasola 2007; Abramov & Duchen 2008). 
3.3.4. Possible alternative pathways of AMPK activation in cortical neurons 
Since I found that AMPK helps to mediate excitotoxicity, but is not downstream of Mcu, 
alternative pathways playing a possible role in its activation need to be further explored.  
3.3.4.1. Which upstream kinase is responsible for AMPK activation? 
Results by Concannon et al. and Davila et al. point to AMPK activation following 
mitochondrial dysfunction and an increased AMP:ATP ratio, likely mediated by LKB-1 which 
phosphorylates AMPK following AMP binding (Davila et al. 2012; Concannon et al. 2010). 
Indeed, Weisova et al. demonstrated that CaMKKβ blocker KN-93 did not inhibit GLUT3 
translocation mediated by AMPK activation, implicating LKB1 as the upstream kinase of 
AMPK in CGNs (Weisova et al. 2009). Although there is a definite drop in ATP levels 
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following NMDA stimulation that would lead to an increase in ADP and AMP levels, whether 
this decrease in ATP levels is downstream of Mcu and mitochondrial dysfunction is unclear. 
Our group recently demonstrated using the genetically encoded probe AT1.03 that ATP levels 
in neurons drop within minutes, prior to mitochondrial dysfunction occurring (Hasel et al. 
2015). This suggests that the initial drop in ATP levels is not downstream of Mcu-mediated 
Ca2+ uptake leading to mitochondrial depolarisation and the reversal of the mitochondrial 
ATPase, but stems from a different source. Indeed, overactivation of the Na+/K+ ATPase on 
the plasma membrane following an excitotoxic insult can cause increases in the AMP:ATP 
ratio (Greenwood & Connolly 2007), which could lead to activation of AMPK by LKB-1, 
independently of Mcu and mitochondrial dysfunction. 
Although Weisova et al. did not find CaMKKβ to be important in activating AMPK in CGNs 
(Weisova et al. 2009), it does not mean that it cannot phosphorylate AMPK in other neuronal 
subtypes, at different developmental time points or using different excitotoxic cell death 
assays. CaMKKβ is an attractive candidate for AMPK phosphorylation following 
excitotoxicity, due to its activation following rises in intracellular Ca2+ (Woods et al. 2005). 
CamKKβ has been shown to have high expression levels in the brain (Woods et al. 2005), and 
I found both LKB1 and CaMKKβ mRNA to be expressed in our primary cortical cultures 
(Márkus and Hardingham unpublished RNA-seq data). AMPK activation by CaMKKβ has 
been demonstrated by a number of groups in different neuronal subtypes. CamKKβ was shown 
to be involved in activating AMPK in the hypothalamus (K. Anderson et al. 2008), while 
Mairet-Coello et al. showed that AMPK phosphorylation following NMDA activation is 
eliminated by CaMKK inhibitor STO-609 in mature mouse primary cortical and hippocampal 
neurons (DIV21) (Mairet-Coello et al. 2013). STO-609 also inhibited the AMPK 
phosphorylation in rat cortical slices following high K+ induced depolarisation leading to Ca2+ 
influx, which was independent of ATP loss (Hawley et al. 2005); confirming previous findings 
that the presence of AMP is not required for AMPK activation by CaMKKβ (Woods et al. 
2005). Thus, it is entirely possible that AMPK is activated by CaMKKβ in our cortical cultures, 
independently of ATP loss and this should be further investigated. 
AMPK has been suggested to translocate to the nucleus following insults in HeLa cells 
(Kodiha et al. 2007). Interestingly, AMPKα2 was shown to preferentially localise to the 
nucleus in neurons and other cells, suggesting a possible subunit specific effect of AMPKα2 
activation on mediating changes in gene transcription (Turnley et al. 1999; Salt et al. 1998). If 
AMPKα2 is localised to the nucleus basally, it may need nuclear Ca2+ to be activated by 
CaMKKβ, which would mean that excessive activation of NMDARs would be required for 
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the second step of FOXO3 activation suggested by Davila et al. and may be subunit specific. 
The subunit specificity of AMPK would be intriguing to investigate, since the two different α 
subunits may effect different downstream cascades. The spatio-temporal profile of AMPK 
activation could be tested to allow for a better understanding of the cellular location of AMPK. 
I tried imaging AMPK in real-time using an AMPK FRET probe (Tsou et al. 2011), but found 
it to have narrow dynamic range; nevertheless similar probes could be used to test AMPK 
activity following NMDA application in real-time. 
It is possible that AMPK is activated by both LKB1 and CaMKKβ in cortical neurons, and 
that the mode of activation depends on the duration and intensity of NMDAR activation, as 
well as the NMDAR subunit composition or possibly the site of Ca2+ entry. These factors could 
determine the duration of AMPK activation and thus whether this activation provides 
neuroprotection or contributes to neuronal death. It is also possible that activation of AMPK 
by CaMKKβ only occurs following excessive NMDAR activation and large influxes of Ca2+, 
mediating its pro-death effect. Inhibition of CamKKβ with STO-609 or other CaMKK 
inhibitors during NMDA application should show whether the CamKKβ pathway is involved 
in activating AMPK during excitotoxicity in our cortical cultures. It is also likely that 
expression of LKB1 and CaMKKβ differs in neuronal subtypes, such as CGNs and cortical 
neurons, which may result in activation of AMPK through different pathways in these neurons. 
3.3.4.2. AMPK activation in neurological disorders involving excitotoxicity 
AMPK has been implicated in a number of different neurodegenerative conditions, such as 
Alzheimer’s disease (AD). Thornton et al. and Mairet-Coello et al. demonstrated that toxic 
amyloid β (Aβ) activates AMPK via CaMKKβ promoting phosphorylation of Tau in mature 
neurons, the hyperphosphorylation of which plays an important role in AD (Mairet-Coello et 
al. 2013; Thornton et al. 2011). Mairet-Coello et al. demonstrated that activation of the 
CaMKKβ-AMPK pathway by toxic Aβ mediates the loss of dendritic spines through 
phosphorylation of Tau both in hippocampal neurons in vitro and in a mouse model of AD in 
vivo (Mairet-Coello et al. 2013). Both groups found that toxic Aβ exerted its effect through 
NMDAR activation. Intriguingly, Thornton et al. showed that pre-treatment of neurons with 
memantine, a mild NMDAR antagonist licensed for AD treatment, inhibited NMDA-induced 
activation of AMPK by CaMKKβ (Thornton et al. 2011). This is of interest, since memantine 
is thought to allow synaptic NMDAR activity, whilst preferentially blocking pathological 
NMDAR activation, suggesting that AMPK may be preferentially activated following 
excessive NMDAR activation.  
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Intriguingly, AMPK was found to be phosphorylated following middle cerebral artery 
occlusion (MCAO), which was abolished in an nNOS KO mouse, suggesting that AMPK 
activation may be activated downstream of nNOS (McCullough et al. 2005). McCullough et 
al. found that KO of PARP-1 did not abolish AMPK phosphorylation by MCAO, suggesting 
that AMPK is downstream of nNOS, but not PARP-1. Of note, AMPK has been suggested to 
be activated by peroxynitrite itself, independently of AMP, in endothelial cells (Zou et al. 
2003), providing a potential explanation for the above results. Although, superoxide used in 
the formation of peroxynitrite is thought to be primarily mitochondrial in origin, possibly 
implicating Mcu in this pathway (Duan et al. 2007). It is possible that AMPK is activated due 
to NO production itself, since AMPK has been shown to be phosphorylated by CaMKKβ 
following rises in ROS following hypoxia, independently of changes in ATP levels (Mungai 
et al. 2011). This further suggests that prolonged AMPK activation may be coupled to 
pathological NMDAR activation, since nNOS is known to associate with the C terminal of the 
NMDA GluN2B subunit via PSD-95, which is preferentially coupled to excitotoxic cell death 
(Martel et al. 2012). The possibility of AMPK being preferentially activated downstream of 
Glun2B containing NMDARs could be tested using a knock-in mouse previously employed 
by our group, in which the C terminal tail of the GluN2B subunit is switched with that of 
GluN2A (Martel et al. 2012).  
Thus, how AMPK is activated during excitotoxicity is yet to be established. It is entirely 
possible that the AMPK phosphorylation in neurons is controlled by multiple pathways, the 
activation of which may depend on the duration and intensity of NMDAR activation as well 
as the neuronal subtype and developmental stage, and may decide the duration of AMPK 
activation and whether it has pro-survival or pro-death consequences. Various groups have 
demonstrated a role for AMPK in stroke, as well as in Alzheimer’s and Huntington’s disease 
(Mairet-Coello et al. 2013; Ju et al. 2012; Thornton et al. 2011; Manwani & McCullough 2013; 
Cai et al. 2012; McCullough et al. 2005). Although AMPK is shown to be protective in some 
diseases, it is not in others. Nevertheless, I find AMPK to have a destructive role in NMDA 
excitotoxicity in vitro in primary cortical cultures, making it a potential therapeutic target 
alongside Mcu, as well as their downstream effectors, in treating diseases involving NMDAR-
mediated excitotoxic cell death, such as stroke and chronic neurodegenerative diseases. It 
would be interesting to examine AMPK downstream of pathological NMDA receptor 
activation in vivo in the conditional AMPKα1/2 KO mouse, to determine whether these results 







Chapter 4: Mitochondrial Ca2+ regulatory genes are 
differentially expressed in neurons and astrocytes and in 





Mitochondrial Ca2+ uptake plays a role in regulating energy production, buffering cytosolic 
Ca2+ as well as mediating cell death (McCormack et al. 1990; Hajnóczky et al. 1999; Bernardi 
& Rasola 2007). Thus, the handling of mitochondrial Ca2+ basally and following cytoplasmic 
Ca2+ influx from the plasma membrane or intracellular stores is key to cell survival, especially 
in neurons which have a high metabolic demand and rely heavily on oxidative phosphorylation 
as their source of ATP (Fernandez-Fernandez et al. 2012; Harris et al. 2012; Kann & Kovács 
2007). The molecular identity of several mitochondrial Ca2+ regulatory genes (MCRGs) has 
come to light in recent years, which influence mitochondrial Ca2+ influx and efflux thereby 
playing a role in maintaining mitochondrial health and neuronal survival. 
Mcu was identified as the channel pore of the mitochondrial Ca2+ uniporter on the IMM (De 
Stefani et al. 2011; Baughman et al. 2011). Mcu is predicted to oligomerise into tetramers to 
create the channel pore, allowing Ca2+ uptake into the mitochondrial matrix (Lee et al. 2015; 
Raffaello et al. 2013; Chaudhuri et al. 2013). Several genes have been identified which are 
present in the Mcu complex (Emre, Micu1 and Micu2), thought to be around 450 kDa, or that 
regulate Mcu in some other way (Baughman et al. 2011). Mcub is the dominant negative 
isoform of Mcu, which can oligomerise with Mcu preventing Ca2+ influx through the channel 
pore (Raffaello et al. 2013). Emre anchors Micu1 and Micu2 to Mcu and is essential for Mcu 
function (Sancak et al. 2013; Tsai et al. 2016; Vais et al. 2016; Yamamoto et al. 2016). Micu1 
and 2 are gatekeepers of Ca2+ influx at low cytosolic Ca2+ concentrations, blocking Mcu’s pore 
using their Ca2+-sensing EF-hands, and Micu1 positively cooperates with Mcu at higher 
cytosolic Ca2+ concentrations, allowing increased Ca2+ influx, following Ca2+ binding to its 
EF-hands inducing a conformational change  (Perocchi et al. 2010; Csordás et al. 2013; 
Plovanich et al. 2013; Wang et al. 2014; Sancak et al. 2013; Kamer & Mootha 2014; 
Mallilankaraman et al. 2012b; Matesanz-Isabel et al. 2016; de la Fuente et al. 2014; Waldeck-
Weiermair et al. 2015). Micu3, a paralogue of Micu1 and 2, has been described as a probable 
Mcu regulator in the CNS, but its function has not been further investigated (Plovanich et al. 
2013). Mcur1 is another possible regulator of Mcu, although it does not appear to be part of 
the Mcu-Emre-Micu1/2 uniporter complex (Mallilankaraman et al. 2012a; Paupe et al. 2015; 
Sancak et al. 2013; Lee et al. 2015). Slc25a23 is a solute carrier which mediates Mg-ATP/Pi 
exchange across the IMM, and has recently been shown to accelerate Mcu-mediated Ca2+ 
influx during high cytoplasmic Ca2+ levels in neurons (Hoffman et al. 2014; Llorente-Folch et 
al. 2015; Rueda et al. 2014). Uncoupling protein 2 (Ucp2) and 3 (Ucp3) have also been 
suggested to regulate Mcu-dependent mitochondrial Ca2+ uptake following large cytoplasmic 
Ca2+ influxes (Trenker et al. 2007; Waldeck-Weiermair et al. 2010; Waldeck-Weiermair et al. 
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2011; Bondarenko et al. 2015). Several possible routes of Ca2+ entry into the mitochondrial 
matrix independent of Mcu have been described, including Ryr and Trpc3 (Jakob et al. 2014; 
Feng et al. 2013). Mitochondrial Ca2+ efflux is thought to occur through a Li+-sensitive 
Na+/Ca2+ exchanger in excitable and H+/Ca2+ exchanger in non-excitable cells (Palty & Sekler 
2012). Letm1, thought to be the Ca2+/H+ exchanger, has been found to mediate not only Ca2+ 
efflux, but also Ca2+ influx at low mitochondrial Ca2+ concentrations (Jiang et al. 2009; Tsai 
et al. 2014). Nclx was identified as the Na+/Ca2+ exchanger in 2010, and shown to mediate 
mitochondrial Ca2+ efflux through the IMM (Palty et al. 2010).  
Although many MCRGs have been shown to be expressed in the brain (Raffaello et al. 2013; 
Plovanich et al. 2013; Mallilankaraman et al. 2012a; De Stefani et al. 2011; De Stefani et al. 
2016), their mRNA expression pattern and function in different neural cells and neuronal 
subtypes has not been investigated and may vary, potentially influencing mitochondrial Ca2+ 
handling in these cell types. Since multiple different mitochondrial Ca2+ influx and efflux 
pathways, as well as different regulators of Mcu seem to co-exist, it would be important to 
determine which MCRGs are highly expressed in neurons, and whether a different expression 
profile of MCRGs may make certain subtypes of neurons more vulnerable to insults.  
In chapter 3, I examined the possible role of AMPK downstream of Mcu following an 
excitotoxic insult, and although I found AMPK to help mediate excitotoxic cell death, Mcu 
KD had no effect on AMPK phosphorylation. Nevertheless, Mcu’s importance in 
excitotoxicity has been previously demonstrated by our group (Qiu et al. 2013). It is likely that 
other MCRGs also play a role in NMDA-mediated excitotoxic cell death in neurons. 
Interestingly, neurons of the CA1 region of the hippocampus show higher sensitivity to 
superoxide and NMDA-mediated excitotoxic insult, than CA3 neurons (Strasser & Fischer 
1995; Ikegaya & Matsuki 2002; Cronberg et al. 2005; Gee et al. 2006; Yang et al. 2000; Wilde 
et al. 1997), to which neuronal subtype-specific MCRG expression may contribute. 
In this chapter I investigate the expression pattern of MCRG mRNA in different neural cells 
(mouse primary cortical neurons vs astrocytes) as well as in different neuronal subtypes (CA1 
vs CA3 neurons of the adult mouse hippocampus). I found differential MCRG mRNA 
expression patterns in different neural cells and neuronal subtypes. Of note, I found Nclx 
mRNA to be expressed at very low levels in neurons compared to astrocytes, questioning 
whether Nclx is indeed the major mitochondrial Ca2+ efflux pathway in neurons; and thus 
investigated its function in neurons vs astrocytes further using Nclx inhibitor CGP-37157, and 
surprisingly found that it inhibited Ca2+ efflux in both neurons and astrocytes.  
Some of the results in this chapter have been published in:  
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4.2.1. mRNA expression of MCRGs differs between cortical neurons and astrocytes 
I examined the mRNA expression of MCRGs by real-time (RT)-qPCR in a mouse primary 
cortical astrocyte-free neuronal culture (<0.2% GFAP+ astrocytes) compared to a primary 
cortical astrocytic culture (>96% GFAP+ astrocytes). All genes were normalised to 18s and 
then to mRNA levels in a mixed neuronal culture (90% NeuN+ neurons, 10% GFAP+ 
astrocytes). The results were then expressed as a ratio of astrocyte to neuronal mRNA 
expression for each MCRG (Fig.4.1A). The mRNA expression of some of the essential 
components of the Mcu complex, Mcu, Mcub, Emre, as well as Letm1 and Slc25a23 did not 
significantly differ between neurons and astrocytes. The mRNA expression of potential Mcu 
regulator Micu3, and alternative mitochondrial Ca2+ uptake channels Ryr2 and Trpc3, was 
significantly higher in neurons than astrocytes. The mRNA expression of Mcu regulators 
Micu1, Micu2 and Mcur1, as well as Ucp2 and Nclx was significantly higher in astrocytes 
than in neurons. Notably, the expression of Ucp2 and Nclx (Slc8b1) was much higher in 
astrocytes than neurons.  
I next examined the mRNA expression of these genes using an RNA sequencing dataset made 
from primary mouse neuronal and astrocytic cultures by Mr. Philip Hasel (Fig.4.1B). The 
RNA-seq reads for each gene were normalised to the total number of reads, and an 
astrocyte:neuron expression ratio for each MCRG was calculated. Qualitatively, the 
expression profile of MCRGs looked very similar by both methods. Several genes, Mcu, Mcub 
and Slc25a23, which showed no significant change in expression in the RT-qPCR samples 
were expressed significantly higher in neurons in the RNA-seq data, although these changes 
were modest.  
Since the data was normalised to 18s rather than a mitochondrial protein encoding genes, the 
question remained whether these changes observed could have been due to chance or changes 
in the mitochondrial number. Thus I examined genes from the nuclear-encoded mitochondrial 
electron transport chain (ETC) complexes II-V in the RNA-seq data set between primary 
neurons and astrocytes (Fig.4.1C). The results clearly show that there were only small changes 
between the genes of ETC complexes II-V between neurons and astrocytes, suggesting that 
the difference in MCRG mRNA expression will lead to differential mitochondrial Ca2+ 




Figure 4.1. The mRNA expression levels of MCRGs differ between primary mouse cortical 
neurons and astrocytes. A. RT-qPCR expression of the mRNA levels of MCRGs in cortical astrocytes 
vs neurons. mRNA levels of the MCRGs in neuronal and astrocytic samples was normalised to 18s, 
and an astrocyte:neuron ratio of gene expression in relation to a mixed neuronal culture was 
calculated. Two-tailed paired t-test. *p≤0.05. p-values, respectively: 0.019, 0.030, 0.004, 0.002, 
0.034, 1E-07, 0.007, 0.0002 (n=6 for Slc8b1 and Trpc3 and n=7 for the rest). B. Read densities for 
MCRGs shown in (A) analysed from an RNA-seq data set of pure neurons and astrocytes, with a 
ratio of astrocytes to neurons calculated. *p≤0.05. p-values, respectively: 0.001, 0.014, 2E-4, 
0.023, 4E-4, 0.002, 0.043, 0.004, 0.005, 0.005, 5E-4. n=3. C. RNA-seq data set showing 
astrocyte:neuron ratio of MCRGs in ETC complexes II-V. n=3. Error bars=SEM. Note that all graphs 
are on a logarithmic scale. Note that Nclx is shown as Slc8b1. 
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4.2.2. mRNA expression of MCRGs and Mcu protein expression differs between the 
CA1 and CA3 regions of the hippocampus 
I also wanted to investigate whether MCRGs are differentially expressed in different neuronal 
subtypes, and used neurons in the CA1 vs CA3 region of the hippocampus as a model. The 
CA1 and CA3 regions of the hippocampus have previously been shown to have differential 
basal gene expression in mice (Newrzella et al. 2007).  
I extracted the CA1 and CA3 regions from adult mouse hippocampal slices and examined their 
MCRG mRNA expression by RT-qPCR. I found that MCRG expression differed between the 
two regions. Mcu, Micu3, Mcur1 and Ryr2 mRNA were all expressed at significantly higher 
levels in the CA3 region, whilst Micu2, Ucp2, Trpc3 and Nclx (Slc8b1) showed significantly 
higher expression in the CA1 region of the hippocampus (Fig.4.2.A). Although significant, 
most of these changes were small, but Mcu expression was around two-fold higher in the CA3 
region, whilst Trpc3 was around two-fold higher in the CA1 region of the hippocampus. 
Bcl-2 related ovarian killer (Bok) was included as a positive control, since it is known to be 
expressed at much higher levels in CA3 than in CA1 neurons, which I also observed, validating 
the extraction method (Newrzella et al. 2007) (Fig.4.2.A). The mRNA levels of MCRGs were 
normalised to Gapdh, but I also examined the mRNA levels of the ETC genes Uqcrc2 
(mitochondrial complex III) and Ndufs2 (mitochondrial complex I), as well as 18s to control 
for possible changes of mitochondrial expression between these regions, but found no 
significant differences between their expression in CA1 and CA3 (Fig.4.2.A).  
Since I found Mcu mRNA levels to be two-fold higher in CA3 neurons, I investigated whether 
this difference could be observed at the protein level. Indeed, I found Mcu protein levels to be 
significantly higher in samples taken from the CA3 region of the hippocampus, than from the 
CA1 region (Fig.4.2B,C). The results were normalised to mitochondrial complex III protein 
Uqcrc2, but I also found the same results when normalising to β-actin levels (data not shown).  
Thus, the data shows that MCRG mRNA expression levels differ between the CA1 and CA3 




4.2.3. The relative expression of MCRGs compared to each other differs in cortical 
neurons  
Although I examined changes in MCRG mRNA expression in cortical neurons vs astrocytes 
and between CA1 and CA3 regions of the hippocampus, I did not examine the relative 
expression of these genes to each other in culture. Unlike RT-qPCR, RNA-seq allows for direct 
comparison between the relative levels of the different genes in samples. Thus, using an RNA-
seq data set, I looked at the relative expression of MCRGs to each other in astrocyte-free 
cortical neurons, by plotting the FPKM values for each MCRG. FPKM is calculated as the 
number of fragments per kilobase of exon per million fragments mapped. 
This revealed large differences in MCRG mRNA expression levels, and that Mcur1, Ucp2 and 
Slc8b1 (Nclx) are expressed at very low levels in primary neuronal culture (Fig.4.3). These 
Figure 4.2. The mRNA expression levels of MCRGs, as well as Mcu protein levels, differ between 
the CA1 and CA3 regions of the adult mouse hippocampus. Paired mRNA and protein samples 
from the CA1 and CA3 region of the hippocampus were obtained from adult mouse brain slices. 
A. MCRGs mRNA expression in the CA1 and CA3 region of the adult mouse hippocampus. mRNA 
levels were normalised to Gapdh and the CA1:CA3 expression ratio was calculated for each gene. 
Bok, which is known to be highly enriched in CA3 neurons, was included as a positive control. 
Mitochondrial ETC genes Uqcrc2 and Ndufs2, as well as 18s expression levels are shown to exclude 
the possibility of Gapdh mRNA expression differing largely between the two regions. Two-tailed 
paired t-test. *p≤0.05. p-values, respectively: 3E-06, 0.033, 0.024, 0.0001, 0.005, 0.005, 0.015, 
0.021, 2E-08. Micu3, Mcur1, Trpc3, Bok, Uqcrc2, Ndufs2, 18s (n=7), Mcub (n=9), Slc8b1 (n=10), 
n=11 for the rest. B. Western blots showing Mcu protein levels in CA1 and CA3 taken from the 
hippocampus of one mouse for each sample pair with mitochondrial ETC protein Uqcrc2 used as 
a loading control. n=5. C. Analysis of (B) showing Mcu levels in CA1 normalised to CA3. Two-tailed 
paired t-test. *p=0.006. n=5. Error bars=SEM. Note that Nclx is shown as Slc8b1. 
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genes showed a much higher expression in astrocytes than neurons, suggesting that these genes 
are very weakly expressed in neurons, thus it is tempting to speculate that they probably have 
low protein expression in neurons and may only be functional in astrocytes.   
This finding is very interesting considering that the Na+/Ca2+ exchanger Nclx is thought to 
mediate Ca2+ efflux from mitochondria in excitable cells, thus neurons (Nita et al. 2015). I 
therefore investigated the role of Nclx in neurons and astrocytes further. 
 
4.2.4. Neuronal Nclx mRNA expression is low in the presence or absence of astrocytes  
Since I found Nclx mRNA levels to be low in neurons compared to astrocytes, as well as 
compared to other MCRGs, I investigated whether Nclx expression in neurons was perhaps 
dependent on the presence of astrocytes. I found levels of Nclx mRNA in mixed culture to be 
higher than in an astrocyte-free neuronal culture by qPCR, but whether this rise in Nclx levels 
was indeed due to neurons, or due to the small percentage of astrocytes (10%) present in the 
mixed cortical culture was unclear. Thus, I used a co-culturing technique developed by our 
group, where primary mouse neurons are overlaid on top of confluent rat astrocytes, enabling 

















































































Figure 4.3. Relative mRNA expression of MCRGs differs in neurons in a cortical neuronal culture. 
FPKM values of MCRGs in neurons show the relative levels of these genes to each other. Note the 
very low expression of Slc8b1 (Nclx). n=3. Error bars=SEM. 
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Nclx mRNA in mouse neurons in mixed co-culture were similar to levels in astrocyte-free 
neuronal culture, with Nclx expression in mixed culture being 14-fold and in astrocytes 400-
fold higher on average than in astrocyte-free neuronal culture (Fig.4.4). Results were 
normalised to mouse-specific histone protein H1f0 primers, but similar results were seen when 
normalising to mouse-specific Gapdh (data not shown). This suggests that Nclx is not 
upregulated in neurons in the presence of astrocytes, which may indicate low protein 





4.2.5. The Nclx inhibitor CGP-37157 partially inhibits mitochondrial Ca2+ efflux in 
astrocytes  
I next tested whether Nclx was functionally present in the astrocytes, using the genetically 
encoded mitochondrial GCamp2 (mitoGCamp2) to visualise mitochondrial Ca2+ levels, and 
cytoplasmic GCamp2 (cytoGCamp2) to monitor cytoplasmic Ca2+ levels in astrocytes in real 
time (Mao et al. 2008; Chen et al. 2011). ATP has been shown to increase cytoplasmic Ca2+ 
levels in astrocytes through its activation of metabotropic receptors prompting Ca2+ release 
from the ER and subsequently activation of store-operated Ca2+ channels on the plasma 
membrane, leading to further rises in intracellular Ca2+ (Kresse et al. 2005; Parnis et al. 2013). 
Thus, I used ATP to increase cytoplasmic and mitochondrial Ca2+ levels in astrocytes and 
monitored the Ca2+ decay which followed. I used CGP-37157 which is an inhibitor of Nclx, 
although it has some off target effects on other Ca2+ channels in cells, such as voltage gated 
Ca2+ channels (including L-type Ca2+ channels), store-operated Ca2+ channels and the ER Ca2+ 
ATPase (Ruiz et al. 2014; Parnis et al. 2013). 
Figure 4.4. Neurons in the presence of 
astrocytes express similar levels of 
Nclx mRNA as neurons in an astrocyte-
free culture, but much less than 
astrocytes. Samples were normalised 
to mouse-specific H1f0, a histone 
protein. n=3. *p=0.0435. Paired two-
tailed t-test. Note the logarithmic scale. 
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The percentage of (F-Fmin)/(Fmax-F) was calculated, where Fmax was determined by the 
addition of ionomycin (Nicholls 2006), and Fmin was calculated as the minimal amount of 
Ca2+ following Ca2+ chelation by EGTA. The results are presented as the percentage of Ca2+ 
out of the maximum mitochondrial or cytosolic Ca2+ level reached after ATP application, every 
minute for four minutes.  
I found that pre-treatment of astrocytes with CGP-37157 for 10 minutes significantly delayed 
the recovery of Ca2+ levels in mitochondria following ATP-mediated mitochondrial Ca2+ 
influx, compared to control astrocytes (Fig.4.5A). Slower decay of Ca2+ was observed even 
four minutes after ATP application to astrocytes pre-treated with CGP-37157 compared to 
control. I also examined the cytoplasmic Ca2+ decay kinetics following ATP-mediated rises in 
cytoplasmic Ca2+, and found a small, but significantly faster Ca2+ decay in CGP-37157 treated 
astrocytes compared to untreated astrocytes (Fig.4.5B). This may have been the result of less 
Ca2+ efflux from mitochondria, thus less Ca2+ in the cytoplasm. For example raw traces from 
calcium imaging, see Supplementary figure 2. 
I found mitochondrial Ca2+ levels to be significantly lower in CGP-37157 treated astrocytes 
both at baseline and after ATP-mediated Ca2+ influx (Fig.4.5.C,D). The total amount of 
mitochondrial Ca2+ influx, calculated from the peak mitochondrial Ca2+ levels minus the 
average baseline Ca2+, was also significantly larger in control astrocytes (Fig.4.5E). This 
suggests that CGP-37157 may have a slight inhibitory effect on mitochondrial Ca2+ uptake, 
and raises the question of whether lower amount of mitochondrial Ca2+ influx delays Ca2+ 
decay kinetics. Thus, I examined the top and bottom 50% of CGP-37157 pre-treated astrocytes 
stimulated with ATP according to their total amount of mitochondrial Ca2+ influx, and found 
the top 50% to have a similar average total Ca2+ influx to control astrocytes (Supplementary 
figure 3A). The higher level of Ca2+ influx in these top 50% of CGP-37157 treated astrocytes 
led to quicker mitochondrial Ca2+ decay than the average of all CGP-37157 treated astrocytes, 
but Ca2+ decay kinetics were still significantly delayed compared to control astrocytes 
(Supplementary figure 3B). Thus, although the amount of mitochondrial Ca2+ influx influences 
Ca2+ decay, this does not explain the inhibition of mitochondrial Ca2+ efflux seen by CGP-
37157. Cytoplasmic Ca2+ levels at baseline and after Ca2+ influx were unchanged (Fig.4.5F-
H).  
Thus, the data shows that CGP-37157 does indeed inhibit mitochondrial Ca2+ efflux in 




Figure 4.5. Mitochondrial Ca2+ efflux is diminished by Nclx inhibitor CGP-37157 following ATP-
induced rises in Ca2+ levels in astrocytes. A. Mitochondrial Ca2+ decay 1-4 minutes after the peak 
of ATP-induced mitochondrial Ca2+ influx in pure cortical astrocytes, ± pre-treatment with CGP-
37157 (10 µM). ATP was applied for 1 minute to the astrocytes before it was washed out. 
Mitochondrial Ca2+ was measured using mitoGCamp2, which was transfected into astrocytes. All 
Ca2+ imaging values were calculated as (F-Fmin)/(Fmax-F), where Fmax was determined as the 
total Ca2+ capacity of the astrocyte and Fmin was determined by EGTA application to chelate all 
the Ca2+. Ca2+ decay in each astrocyte was normalised to the peak of the mitochondrial Ca2+ influx 
as 100%, with the minimal calcium at baseline set as 0%. Two-way ANOVA with Bonferroni post-
hoc correction. *p≤0.05. p=0.0005 for the first time point, p<0.0001 for the others. n=71 for 
control and n=58 for CGP-37517 treated astrocytes (9 coverslips from 3 separate cultures). B. 
Cytoplasmic Ca2+ decay in astrocytes following ATP treatment. Analysis was done as described in 
(A). Cytoplasmic Ca2+ levels were measured using cytoGCamp2. ANOVA with Bonferroni post-hoc 
correction. *p≤0.05. p-values, respectively: 0.0015, 0.0009, 0.0029. n=166 for control and n=176 
for CGP treated astrocytes (14 coverslips from 4 separate cultures). C-E. Mitochondrial Ca2+ levels 
±CGP treatment. Average baseline Ca2+ levels (C) *p=0.0261, maximal Ca2+ level (D) *p=0.0008 and 
the total rise in Ca2+ levels in each astrocyte calculated by the peak-average baseline Ca2+ (E) 
*p=0.0018. Unpaired two-tailed t-test. F-H. As in (C-E), respectively, except cytoplasmic Ca2+ levels 
shown. Unpaired two-tailed t-tests (C-H). Mean+SEM. 
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4.2.6. The Nclx inhibitor CGP-37157 partially inhibits mitochondrial Ca2+ efflux in 
neurons 
I next examined whether CGP-37157 could also inhibit mitochondrial Ca2+ efflux in neurons 
in a mixed neuronal culture. I used mitoGCamp2 and cytoGCamp2 to image neurons as 
described in section 4.2.5. Instead of ATP, I applied a KCl depolarisation solution (50 mM 
K+) to depolarise neurons and induce Ca2+ influx through L-type Ca2+ channels, with MK-801 
present to prevent excessive NMDAR activation. One minute following application of high 
K+, cells were washed to increase the rate of Ca2+ decay. I found that as in astrocytes, there 
was a large significant delay in mitochondrial Ca2+ decay following pre-treatment of neurons 
with CGP-37157 compared to untreated neurons (Fig.4.6A). This large difference could be 
observed and was significant even four minutes following KCl application. Similarly to 
astrocytes, there was a significantly quicker decay in cytoplasmic Ca2+ levels in CGP-37157 
treated neurons compared to control (Fig.4.6B). For example traces of Ca2+ decay in neurons 
in a mixed culture, see Supplementary figure 4. Interestingly, unlike in astrocytes, in neurons 
there was no difference in mitochondrial Ca2+ levels at baseline or following depolarization-
mediated rises in Ca2+ levels (Fig.4.6C-E). However, there was a decreased rise in cytoplasmic 
Ca2+ levels following depolarization in CGP-37157 treated neurons (Fig.4.6F-H). This is likely 
due to the off-target effect of CGP-37157 on VGCCs, including L-type Ca2+ channels, 
previously demonstrated in neurons (Ruiz et al. 2014; Baron & Thayer 1997). 
Since I observed partial inhibition of mitochondrial Ca2+ efflux by CGP-37157 in neurons in 
a mixed culture, I investigated whether this was also the case in neurons in an astrocyte-free 
neuronal culture (<0.2% astrocytes). Neurons in pure neuronal cultures were treated the same 
way as neurons in mixed culture. Interestingly, I saw the same results in neurons in a pure 
neuronal culture as with neurons in mixed culture; mitochondrial Ca2+ decay kinetics were 
largely and significantly reduced following pre-treatment of neurons with CGP-37157 
(Fig.4.7A). Similarly to astrocytes and neurons in mixed culture, there was a quicker recovery 
in cytoplasmic Ca2+ levels in neurons in astrocyte-free neuronal culture pre-treated with CGP-
37157 (Fig.4.7B). Note that in neurons, cytoplasmic Ca2+ levels dropped below baseline Ca2+ 
levels after stimulation (Fig.4.6B and 4.7B). For example traces of Ca2+ decay in neurons in 
an astrocyte-free culture, see Supplementary figure 5. Interestingly, mitochondrial baseline 
Ca2+ levels in CGP-37157 treated neurons in pure neuronal culture and mitochondrial Ca2+ 
influx following KCl application was decreased compared to control (Fig.4.7C-E). Since the 
total mitochondrial Ca2+ influx was lower in CGP-37157 treated neurons than in control 
neurons following KCl stimulation, I examined the top and bottom 50% of CGP-37157 treated 
neurons according to their total mitochondrial Ca2+ uptake, and found that the top 50% showed 
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similar levels of total mitochondrial Ca2+ influx to untreated neurons (Supplementary figure 
3C). As in astrocytes, the top 50% of CGP-37157 treated neurons showed increased Ca2+ decay 
kinetics compared to all CGP-37157 treated neurons, but Ca2+ decay was still significantly 
delayed compared to untreated neurons (Supplementary figure 3D), showing that although the 
amount of mitochondrial Ca2+ influx influences mitochondrial Ca2+ decay, it is not responsible 
for the delay seen due to CGP-37157 pre-treatment of neurons. As in neurons in mixed culture, 
the rise in cytoplasmic Ca2+ levels was decreased following KCl-treatment in CGP-37157 
treated neurons compared to control (Fig.4.7F-H). 
Thus, CGP-37157 pre-treatment partially inhibits mitochondrial Ca2+ efflux in neurons, 





Figure 4.6. Mitochondrial Ca2+ efflux is diminished by Nclx inhibitor CGP-37157 following a KCl-
induced depolarisation of neurons in a mixed culture. A. Mitochondrial Ca2+ efflux at the times 
indicated following exposure of neurons to high K+ (50 mM) ± 10-minute pre-treatment with CGP-
37157. Mitochondrial Ca2+ was measured using mitoGCamp2. All Ca2+ imaging values were 
calculated as (F-Fmin)/(Fmax-F), where Fmax was determined as the total amount of Ca2+ entering 
neurons following addition of ionomycin, whilst Fmin was determined by addition of EGTA to 
chelate all the Ca2+ in neurons. Ca2+ efflux was normalised to the peak of mitochondrial Ca2+ levels 
as 100% in each neuron with the minimal Ca2+ level at baseline set as 0%. Two-way ANOVA with 
Bonferroni post-hoc correction. *p≤0.05. p=0.0441 for the first time point, p<0.0001 for the 
others. n=80 for control and n=88 for CGP-37157 treated neurons (16 coverslips from 6 distinct 
cultures). B. Cytoplasmic Ca2+ efflux in neurons following KCl treatment. Analysis was done as 
described in (A). Cytoplasmic Ca2+ levels were measured using cytoGCamp2. Two-way ANOVA with 
Bonferroni post-hoc correction. *p≤0.05. p<0.0001 for the first three timepoints, thereafter 
p=0.0003. n=81 for control and n=73 for CGP treated neurons (11 coverslips from 4 separate 
cultures). C -E. Mitochondrial Ca2+ levels ±CGP treatment in neurons. Average baseline Ca2+ levels 
(C), maximal Ca2+ level (D), and the total Ca2+ influx in each astrocyte calculated by the peak-
average baseline Ca2+ (E). F-H. As in (C-E), respectively, but cytoplasmic Ca2+ levels. *p<0.0001. 





Figure 4.7. Mitochondrial Ca2+ efflux is diminished by Nclx inhibitor CGP-37157 following KCl-
induced depolarisation of neurons in an astrocyte-free neuronal culture. A. The Ca2+ efflux from 
mitochondria after the times indicated ± 10-minute CGP-37157 pre-treatment, following KCl-
induced rises in Ca2+ levels. Mitochondrial Ca2+ was measured using mitoGCamp2. All Ca2+ imaging 
values were calculated as (F-Fmin)/(Fmax-F), where Fmax was determined as the total amount of 
Ca2+ in neurons following ionomycin application, whilst Fmin was determined by adding EGTA to 
chelate all the Ca2+. Ca2+ efflux was normalised to the peak of mitochondrial Ca2+ levels following 
KCl addition as 100% in each neuron with the minimum Ca2+ at baseline set as 0%. Two-way 
ANOVA with Bonferroni post-hoc correction. *p<0.0001. n=64 for control and n=65 for CGP-37517 
treated (12 coverslips from 5 separate cultures). B. Cytoplasmic Ca2+ efflux in neurons following 
KCl treatment. Analysis was done as described in (A). Cytoplasmic Ca2+ levels were measured using 
cytoGCamp2. Two-way ANOVA with Bonferroni post-hoc correction. *p≤0.05. p<0.0001 for the 
first 3 timepoints, then p=0.0019. respectively. n=60 for control and n=42 for CGP treated (7 and 
8 coverslips, respectively from 3 separate cultures). C-E. Mitochondrial Ca2+ levels ±CGP treatment 
in neurons. Average baseline Ca2+ levels (C) *p=0.0009, maximal Ca2+ level (D) *p=0.0033, and the 
total Ca2+ influx in each astrocyte calculated by the peak-average baseline Ca2+ (E) *p=0.0001. F-






I show in this chapter that mRNA expression of MCRGs differs between different neural cells 
(neurons and astrocytes), as well as between different neuronal subtypes (CA1 and CA3 
neurons of the hippocampus), probably influencing the mitochondrial Ca2+ handling in these 
cells. I found that expression of the Na+/Ca2+ exchanger Nclx was very low in cortical neurons 
compared to astrocytes and relative to the expression levels of other MCRGs in neurons. Thus 
I investigated whether mitochondrial Ca2+ efflux occurred in our cortical neurons, and whether 
it was mediated by Nclx. I found mitochondrial Ca2+ efflux to be attenuated in the presence of 
Nclx inhibitor CGP-37157 after the stimulation of astrocytes or neurons, both in a pure 
neuronal and a mixed neuronal culture. Although whether mitochondrial Ca2+ efflux in 
neurons was mediated by Nclx or another Ca2+ exchanger is still unclear. 
4.3.2. MCRG mRNA expression differs between neurons and astrocytes 
Several MCRGs have been shown to be expressed in the brain, but their expression and 
function in different neural cells is still unknown (Raffaello et al. 2013; Plovanich et al. 2013; 
Mallilankaraman et al. 2012a; De Stefani et al. 2011; De Stefani et al. 2016). I compared the 
mRNA expression of MCRGs in two different neural cells, cortical neurons and astrocytes, 
and found that several of the genes were differentially expressed. This differential expression 
was not due to chance or the abundance of mitochondria, since mRNA levels of mitochondrial 
ETC complexes II-V did not exhibit large changes between neurons and astrocytes. Micu3 has 
previously been shown to have high mRNA expression in the nervous system and skeletal 
muscle (Plovanich et al. 2013). I found Micu3 mRNA expression to be significantly higher in 
cortical neurons than in astrocytes, suggesting that the high expression of Micu3 observed in 
the nervous system is dependent on neurons. Both Trpc3 and Ryr2 had significantly higher 
mRNA expression in neurons than astrocytes, however this result should be treated with 
caution, since although both of these proteins have been found to be expressed on the IMM in 
neural cells, they are also expressed in other parts of the cell, Ryr2 in the ER and Trpc3 on the 
plasma membrane (Jakob et al. 2014; Feng et al. 2013). Therefore, expression of these genes 
in mitochondria needs to be further investigated, either by mRNA extraction from 
mitochondrial fractions or quantification of these genes in mitochondria by 
immunocytochemistry, to determine whether these genes are indeed differentially expressed 
in mitochondria in different neural cells. 
Interestingly, some of the core components of the Mcu complex, Mcu, Mcub and Emre, which 
are thought to be essential for Mcu function are expressed at similar levels in neurons and 
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astrocytes. Although I observed a small but significant increase in Mcu and Mcub expression 
in neurons with RNA-seq, I found Mcub levels to be lower than Mcu levels in neurons, 
bringing into question the functional importance of Mcub in neurons and astrocytes. Mcub is 
known to be the dominant-negative isoform of Mcu, and is thought to oligomerise with Mcu 
and inhibit Ca2+ uptake through the channel pore (Raffaello et al. 2013). Indeed, the Mcu:Mcub 
ratio seems to differ between different tissues in adult mice, which may point to Mcub only 
playing an important role in some cell types (Raffaello et al. 2013). Furthermore, results by 
our group show that Mcub KO in neurons does not influence Ca2+ levels basally or following 
NMDA-mediated Ca2+ influx (Márkus et al. 2016). Since Raffaello et al. showed lower 
expression of Mcub than Mcu in the adult mouse brain, it is unlikely that this expression 
pattern changes throughout development, suggesting that Mcub may not play an important 
role in neurons. Although it is possible that Mcub expression is dynamically induced under 
certain conditions, such as KCl-mediated neuronal depolarisation which our group has 
demonstrated (Márkus et al. 2016). 
Expression of Slc25a23, a solute carrier mediating Mg-ATP/Pi exchanger which helps to 
enhance Mcu-mediated Ca2+ uptake in neurons (Hoffman et al. 2014), also showed similar 
expression in the two cell types. Letm1, which is thought to be the H+/Ca2+ exchanger and has 
been shown to mediate both mitochondrial Ca2+ influx and efflux (Jiang et al. 2009; Doonan 
et al. 2014; Waldeck-Weiermair et al. 2011), also showed similar mRNA expression in 
neurons and astrocytes. 
The mRNA expression of mitochondrial regulators Micu1, Micu2 and Mcur1 was higher in 
astrocytes. Micu1 and 2 are responsible for gatekeeping of Mcu, and Micu1 is also thought to 
positively cooperate with Mcu at higher cytoplasmic Ca2+ levels, to allow increased 
mitochondrial Ca2+ influx (Perocchi et al. 2010; Csordás et al. 2013; Plovanich et al. 2013). 
Thus, it is possible that Mcu is repressed more at baseline Ca2+ levels, and shows increased 
Ca2+ uptake at higher cytoplasmic Ca2+ concentrations, but this should be functionally 
investigated. It is important to know that Micu1, 2 and 3 are expressed at similarly high levels 
in neurons. This suggests that Micu1 and 2 levels in astrocytes may be higher to compensate 
for the low expression of Micu3, the function of which has not been investigated. 
Both Ucp2 and Nclx had much higher mRNA expression in astrocytes than neurons, and 
interestingly both of these genes were expressed at very low levels in neurons when comparing 
FPKM values of MCRGs. This implies that these genes are present in astrocytes, but may have 
low protein expression and lower functional importance in neurons. Ucp2 helps to regulate 
Mcu-mediated Ca2+ influx (Waldeck-Weiermair et al. 2010), whilst Nclx is responsible for 
96 
 
mitochondrial Ca2+ efflux (Palty et al. 2010). The low expression of Nclx in neurons is highly 
unexpected, since mitochondrial Ca2+ efflux in excitable cells has been suggested to be 
mediated by a Na+/Ca2+ exchanger (Palty & Sekler 2012). This poses the question of whether 
Nclx is expressed at all in neurons, and if it is not which other exchanger mediates neuronal 
mitochondrial Ca2+ efflux. 
It is important to note that mRNA levels do not always reflect protein levels in cells, thus these 
findings may not necessarily translate to the protein level. Further experiments are needed to 
determine protein level changes between different neural cell types. Unfortunately, there are 
no antibodies available for many of these genes, and I found commercially available antibodies 
I tested to be unspecific. If these results translate to the protein level, the functional 
consequences of the differential gene expression in neurons vs astrocytes could be examined.  
It is quite possible that MCRG expression profile is also different in other neural cells, such 
as microglia and oligodendrocytes. 
Our group has shown that MCRG mRNA expression is also influenced by neuronal activity, 
KCl/FPL-induced Ca2+ influx repressed both Letm1 and Mcu mRNA levels in neurons, and 
Bic/4-AP-induced Ca2+ influx also led to decreased Mcu mRNA expression (Márkus et al. 
2016; Qiu et al. 2013). This shows that the expression profile of MCRGs is dynamically 
regulated by neuronal activity. This suggests that mitochondria are slightly decoupled from 
cytoplasmic Ca2+ influxes following synaptic activity, taking up less Ca2+ due to decreased 
Mcu expression, which is likely to play a neuroprotective role. It would be interesting to 
investigate the expression profile of MCRGs following pathological NMDAR activation, 
which is known to lead to neuronal death and may influence MCRGs to increase the coupling 
of cytoplasmic Ca2+ influx to mitochondrial Ca2+ uptake. 
4.3.3 MCRG mRNA expression differs between neuronal subtypes 
To examine whether MCRG mRNA expression differs between different neuronal subtypes, I 
compared neurons of the CA1 and CA3 region of the adult mouse hippocampus. I found these 
two neuronal subtypes to have differential MCRG mRNA expression profiles. Micu2, Ucp2, 
Trpc3 and Nclx were expressed significantly higher in CA1 neurons of the hippocampus, 
whilst Mcu, Micu3, Mcur1 and Ryr2 mRNA were expressed at significantly higher levels in 
CA3 neurons. 
The functional significance of Micu2 is still debated, although it has been suggested to 
function as a gatekeeper of Mcu at low cytoplasmic Ca2+ levels (Plovanich et al. 2013; 
Matesanz-Isabel et al. 2016). This, coupled with lower expression of Mcu itself may point to 
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lower mitochondrial Ca2+ influx in CA1 neurons at baseline. Although both Ucp2 and Nclx 
mRNA seem to be expressed at a higher level in CA1 neurons, they are both expressed at very 
low levels in neurons (according to our RNA-seq data), thus this change may not bear 
functional significance. As mentioned above, the change in Ryr2 levels needs to be confirmed 
to be in mitochondrial Ryr2 expression and not changes in its expression on the ER. The 
function of Micu3 is still unknown, thus its functional significance cannot be determined, 
although Micu3 was only expressed at slightly higher levels in CA3 neurons. Mcur1 has been 
suggested to increase mitochondrial Ca2+ influx through its regulation of Mcu 
(Mallilankaraman et al. 2012a; Vais et al. 2015), however expression levels of both Mcur1 
and Mcu are higher in CA3 neurons than CA1, thus these changes are likely not to lead to 
alterations in Mcu regulation.  
The higher mRNA expression levels of Mcu in CA3 neurons agrees with results from the Allen 
Mouse Brain Atlas (experiment ID: 69608519, see mouse.brain-map.org) (Lein et al. 2007), 
as well as the Allen Human Brain Atlas (probe ID: A_23_P346405, see www.brain-map.org) 
(Hawrylycz et al. 2012), suggesting that the result translates to humans. I also found Mcu 
protein levels to be higher in the CA3 compared to the CA1 neurons. This shows that at least 
some mRNA levels reflect the protein levels of these genes. It is possible that the differential 
expression of Mcu in these two neuronal subtypes will lead to different amounts of 
mitochondrial Ca2+ uptake. Physiologically this could mean increased cytoplasmic Ca2+ 
buffering and increased neuronal metabolism in CA3 neurons, whilst it may be detrimental 
during excessive cytoplasmic Ca2+ uptake. 
CA1 neurons are known to have higher vulnerability to transient ischaemic insults, NMDA 
excitotoxicity and ROS induced death than CA3 neurons (Strasser & Fischer 1995; Ikegaya & 
Matsuki 2002; Cronberg et al. 2005; Gee et al. 2006; Yang et al. 2000; Wilde et al. 1997). 
Although some explanations for this have been suggested (Cronberg et al. 2005; Coultrap et 
al. 2005; Gee et al. 2006), it is tempting to speculate that differential MCRGs may contribute 
to this effect. Our group has previously shown that Mcu KD leads to decreased NMDA-
mediated excitotoxic death in cortical neurons (Qiu et al. 2013). I found Mcu to be expressed 
at lower levels in CA1 than in CA3 neurons, which is the opposite of what I would expect to 
cause increased susceptibility to NMDA-induced excitotoxicity, unless the downregulation of 
Mcu is an adaptive response in these neurons.  
A number of other mitochondrial Ca2+ uptake routes have been described, and results by our 
group also suggest that Mcu is not the only Ca2+ uptake pathway in mitochondria (Qiu et al. 
2013). Interestingly, Trpc3 is expressed two-fold higher in CA1 than the CA3 neurons, whilst 
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Mcu is expressed two-fold lower. Trpc3 has recently been shown to be localised to the IMM 
in neurons and not just to the plasma membrane, and has been suggested to be an alternative 
mitochondrial Ca2+ influx route independent of Mcu-mediated Ca2+ uptake. Since Trpc3 was 
shown to mediate mitochondrial Ca2+ influx mostly following high cytoplasmic Ca2+ levels 
(Feng et al. 2013), it is possible that Trpc3 allows for greater mitochondrial Ca2+ influx than 
Mcu. Since CA1 neurons express less Mcu and more Trpc3 than CA3 neurons, it is possible 
that Trpc3 may be a more prominent route of mitochondrial Ca2+ influx in CA1 neurons, whilst 
Mcu-mediated Ca2+ uptake may be more important in CA3 neurons. It is tempting to speculate 
that this increased Trpc3 expression in CA1 neurons may cause increased mitochondrial Ca2+ 
overload following application of NMDA, leading to the selective vulnerability of these 
neurons. Although this hypothesis should be taken with caution, considering that Trpc3 mRNA 
expression may reflect changes of Trpc3 expression on the plasma membrane rather than the 
IMM. Nevertheless, the role of increased Trpc3 expression in CA1 neurons is an intriguing 
topic for further investigation. 
It is likely that other subtypes of neurons also show differential expression patterns of MCRGs, 
which may influence mitochondrial Ca2+ handling in these cells, potentially influencing their 
vulnerability to certain insults. Many ND diseases which involve excitotoxicity are known to 
impact specific neuronal subtypes in the brain (Hardingham & Bading 2010; Zhang et al. 
2016), thus the possible role of neuronal subtype-specific MCRG expression in these neurons 
would be interesting to investigate. 
4.3.4. Is Nclx responsible for mitochondrial Ca2+ efflux in neurons? 
I show that pre-treatment with Nclx inhibitor CGP-37157 decreases mitochondrial Ca2+ efflux 
in astrocytes and neurons following stimulation with ATP or KCl, respectively. CGP-37157 
has previously been shown to block mitochondrial Ca2+ efflux in astrocytes, along with siRNA 
KD of Nclx (Parnis et al. 2013), suggesting that Nclx is indeed responsible for mitochondrial 
Ca2+ efflux in astrocytes. This agrees with my findings that Nclx is expressed in astrocytes at 
the mRNA level, and that mitochondrial Ca2+ efflux is decreased following pre-treatment with 
CGP-37157.  
Surprisingly, I found CGP-37157 to also partially inhibits mitochondrial Ca2+ efflux in 
neurons, both in a mixed culture (10% astrocytes) and in astrocyte-free neuronal culture 
(<0.2% astrocytes). This is unexpected given my finding that Nclx mRNA expression is very 
low in neurons, not only in comparison to astrocytes, but also in relation to the expression of 
other MCRGs. Additionally, Nclx mRNA expression was not increased in neurons in the 
presence of astrocytes. I found cytoplasmic Ca2+ influx to be lower in neurons treated with 
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CGP-37157 following KCl application, which may be due its off target effects on VGCCs 
previously described in cortical and dorsal root ganglion neurons (Ruiz et al. 2014; Baron & 
Thayer 1997). Use of CGP-37157 has also been credited with reducing excitotoxic cell death, 
due to its blockage of VGCCs reducing Ca2+ influx following NMDA application (Ruiz et al. 
2014). The increased cytoplasmic Ca2+ decay observed in both neurons and astrocytes may be 
due to increased mitochondrial Ca2+ retention.  
CGP-37157 has previously been shown to partially inhibit mitochondrial Ca2+ efflux in 
cortical and dorsal root ganglion neurons (Ruiz et al. 2014; Baron & Thayer 1997). I also only 
see a partial block of mitochondrial Ca2+ efflux in neurons and astrocytes, suggesting that other 
Ca2+ efflux pathways are present, or that CGP-37157 does not fully block Nclx-mediated Ca2+ 
efflux.  
Although Ruiz et al. showed Nclx expression by immunoblotting in cortical neurons, the 
results do not look convincing, and they did not validate their Nclx antibody (Ruiz et al. 2014). 
The low Nclx mRNA expression in neurons suggests that at least one alternative mitochondrial 
Ca2+ efflux pathway must exist. It is also possible that the decrease I observe in mitochondrial 
Ca2+ efflux following high K+ in CGP-37157 pre-treated neurons is due to off-target effects of 
CGP-37157 on known or unknown mitochondrial Ca2+ efflux pathways other than Nclx. 
Indeed, the probable mitochondrial Ca2+/H+ exchanger Letm1 has been suggested to be 
partially inhibited by CGP-37157 (Jiang et al. 2009). Additionally, Letm1 has been implicated 
in the aetiology of Wolf-Hirschhorn syndrome (WHS), a disorder characterised by delayed 
growth and development, as well as seizures (Bergemann et al. 2005; Doonan et al. 2014). 
Heterozygous KO of Letm1 in mice has been shown to cause seizures (Jiang et al. 2013), and 
cell lines from WHS patients have shown decreases in Letm1 and mitochondrial impairments 
(Hart et al. 2014), making it tempting to speculate that Letm1 plays an important role in 
mitochondrial Ca2+ handling in the brain and is expressed in neural cells. Three other Na+/Ca2+ 
exchanger family members, Ncx1, 2 and 3, have been shown to have mitochondrial 
localisation in neurons and astrocytes, with Ncx3 shown to be localised to the OMM in cortical 
neurons (Gobbi et al. 2007; Scorziello et al. 2013; Wood-Kaczmar et al. 2013). Additionally 
Ncx2 and 3 have recently been demonstrated to mediate mitochondrial Ca2+ efflux in cortical 
and dopaminergic neurons (Scorziello et al. 2013; Wood-Kaczmar et al. 2013), and would be 
interesting genes to investigate. Since Ncx1, 2 and 3 belong to the same family of exchangers 




This could be further investigated using an Nclx KO mouse. Indeed, our group has acquired 
an Nclx KO mouse, in which a 13 base-pair deletion causes a frameshift mutation, rendering 
Nclx non-functional. Mitochondrial Ca2+ decay could be monitored following ATP or KCl 
stimulation of Nclx KO astrocytes or neurons, respectively. Additionally, the effect of CGP-
37157 could be tested on Nclx KO cultures. If Nclx KO has no effect on mitochondrial Ca2+ 
efflux in neurons, but CGP-37157 inhibits Ca2+ efflux, I could be certain that mitochondrial 
Ca2+ efflux is mediated by another exchanger in neurons which is also inhibited by CGP-
37157. Identification of this pathway would be important in neurons, given the importance of 
mitochondrial Ca2+ handling in these cells. Our group has shown that Mcu KD results in 
decreased excitotoxic cell death following NMDA application to cortical neurons (Qiu et al. 
2013). Thus, it is tempting to speculate that blockade of mitochondrial Ca2+ efflux during 
excitotoxicity would exacerbate neuronal death due to excessive mitochondrial Ca2+ overload. 
In astrocytes, Nclx was shown to be important for buffering cytoplasmic Ca2+ levels, release 
of neurotransmitters as well as for astrocyte proliferation (Parnis et al. 2013). 
A recent paper suggested that Nclx is expressed in dopaminergic neurons and is inhibited in 
Parkinson’s disease leading to mitochondrial dysfunction due to loss of Pink1, which mediates 
Nclx’s phosphorylation by PKA (Kostic et al. 2015). Kostic et al. show that Pink1 KO 
decreases mitochondrial Ca2+ efflux in dopaminergic neurons leading to cell death, and that 
this is rescued by Nclx expression, however they do not demonstrate the endogenous presence 
of Nclx in dopaminergic neurons. Thus, it is possible that Pink1 KO also influences other 
mitochondrial Ca2+ efflux pathways other than Nclx in neurons, but can still be rescued by 
exogenous Nclx expression. It is also possible that although I observe very low Nclx levels in 
cortical neurons, Nclx may be expressed at higher levels in other brain regions. Interestingly, 
Wood-Kaczmar et al. has previously implicated Ncx2 and 3 to be the mitochondrial Ca2+ 
efflux proteins downstream of Pink1 signalling in human dopaminergic neurons (Wood-
Kaczmar et al. 2013). Thus, Ncx2 and 3 could be examined as potential alternative routes of 








Chapter 5: Nrf2 target genes can be controlled by neuronal 





Nrf2 is the master regulator of antioxidant defences (Lee et al. 2005; Loboda et al. 2016). Nrf2 
is basally bound to Keap1 in the cytoplasm and targeted for degradation, but upon oxidative 
stress or small molecule activators of Nrf2, it dissociates from Keap1 and translocates to the 
nucleus (Vargas & Johnson 2009; Kensler et al. 2007; Loboda et al. 2016), where it binds to 
the antioxidant responsive element (ARE) in the promoter region of antioxidant and phase II 
detoxifying genes, many of which are components of the Trx-Prx and the glutathione (GSH) 
antioxidant systems, initiating their transcription (Loboda et al. 2016; Itoh et al. 1997; Jain et 
al. 2005). 
The Nrf2 pathway is known to be active in astrocytes (Vargas & Johnson 2009), whilst Nrf2 
mRNA levels and Nrf2 target gene induction following pharmacological activation of Nrf2 
have been shown to be low in neurons (Bell, Al-Mubarak, et al. 2011; Shih et al. 2003; Kraft 
et al. 2004; Jimenez-Blasco et al. 2015), although this has been debated by some groups (Satoh 
et al. 2006; Yin et al. 2010; Zhang et al. 2009a). Yin et al. for instance observed upregulation 
of Nrf2 target genes and Nrf2 itself in neuronal hippocampal culture, which they attributed to 
Nrf2 activation in neurons (Yin et al. 2010). Our group has demonstrated that H2O2 activates 
Nrf2 target genes in a mixed cortical culture (10% astrocytes), but not in neuronal cortical 
cultures (<0.2% astrocytes), showing that activation of the pathway is astrocyte dependent 
(Bell, Al-Mubarak, et al. 2011). In this chapter I show using Western blotting and 
immunocytochemistry that the Nrf2 pathway is active in astrocytes in cortical cultures, but not 
in neurons.  
Reactive oxygen species (ROS) are a by-product of cellular metabolism, produced following 
oxidative phosphorylation in mitochondria and by NADPH oxidase in the cytoplasm in 
neurons (Brennan et al. 2009; Hongpaisan et al. 2004). Small amounts of ROS are important 
for various cellular functions, such as cell signalling, but excessive ROS formation can lead to 
oxidative stress and cell death (Popa-Wagner et al. 2013). Despite their high metabolic 
demand, neurons have lower antioxidant capacity than astrocytes (Findlay et al. 2005; Dringen 
et al. 1999). The knock-out (KO) of Nrf2 has been shown to result in increased neuronal death 
following oxidative insults (Kensler et al. 2007). Thus, astrocytes provide neurons with non-
cell autonomous neuroprotection against oxidative insults through the activation of the Nrf2 
pathway, such as the supply of GSH precursors to neurons, to boost their antioxidant defences 
(Shih et al. 2003; Escartin et al. 2011). 
A recent paper by Habas et al. suggested that neuronal activity modulates the Nrf2 pathway in 
astrocytes through the tripartite synapse, upregulating Nrf2 target genes and providing 
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neuroprotection to hippocampal neurons in culture (Habas et al. 2013). They showed 
upregulation of Nrf2 target genes and increased Nrf2 protein levels following neuronal 
activity. Since ROS production is increased in neurons following neuronal activity, due to 
increased metabolism, neuronal signalling to astrocytes could couple antioxidant support from 
astrocytes to neuronal activity. 
However, neuronal activity through the activation of synaptic NMDA receptors (NMDARs) 
can induce neuroprotective effects in neurons themselves. Synaptic NMDAR activity inhibits 
pro-death gene expression, such as activation of the PI3K/Akt pathway promoting the nuclear 
export of FOXO, and promotes pro-survival gene expression, such as the activation of the 
ERK1/2 pathway and CaMKIV to induce CREB-dependent gene expression (Hardingham & 
Bading 2010; Papadia & Hardingham 2007). Neuronal activity through synaptic NMDAR-
mediated Ca2+ influx also upregulates antioxidant defences in neurons themselves, such as 
genes involved in the Trx-Prx and GSH antioxidant systems, some of which are known Nrf2 
target genes (Papadia et al. 2008; Baxter et al. 2015). As Nrf2 is present at low levels in 
neurons, which I confirm in this chapter, upregulation of Nrf2 target genes in neurons will 
need to be mediated by transcription factors other than Nrf2. Indeed our group showed that 
Nrf2 target gene sulfiredoxin 1 (Srxn1) is activated by neuronal activity in neurons by acting 
on promoter elements that have consensus sequences for AP-1, as well as Nrf2 (Papadia et al. 
2008; Soriano et al. 2009). Therefore, I wanted to examine whether induction of Nrf2 target 
genes shown by Habas et al. following neuronal activity, is indeed dependent on Nrf2 and 
astrocytes, or whether these Nrf2 target genes can be activated in neurons themselves.  
Thus, I hypothesise that Nrf2 target genes can be activated cell-autonomously in neurons 
following neuronal activity, independently of both astrocytes and Nrf2. The results presented 
in this chapter show that some Nrf2 target genes, but not all can be activated in neurons 
themselves by neuronal activity, the activation of which is independent of the presence of Nrf2 
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5.2.1. Nrf2 is weakly expressed in neurons 
The presence of Nrf2 in astrocytes is well established (Vargas & Johnson 2009). However, 
whether the Nrf2 pathway is active in neurons has been a source of controversy. Some groups 
such as Yin et al. have shown Nrf2 induction in neurons, but many of these experiments were 
carried out using primary mixed neuronal culture (around 10% astrocytes) (Yin et al. 2010), 
which our group has found to contain enough astrocytes to activate Nrf2 target genes (Bell, 
Al-Mubarak, et al. 2011). Here, I examined Nrf2 protein levels in a mouse primary cortical 
astrocytes, a mixed (10% astrocytes, 90% neurons) and an astrocyte-free pure neuronal culture 
(<0.2% astrocytes) (Fig.5.1A). Nrf2 levels were elevated in astrocytes compared to mixed and 
neuronal culture, but were almost undetectable in neurons, even after treatment with Nrf2 
activator tert-Butylhydroquinone (tBHQ) or the proteasome inhibitor MG-132 (Fig.5.1A). 
Since MG-132 inhibits degradation of proteins in the cell (Cui et al. 2013), Nrf2 levels just 
above the point of detection after its addition demonstrates the weak expression of Nrf2 in 
neurons. Although Nrf2 levels in neuronal culture are very low, Nrf2 is still present in mixed 
culture. To examine whether expression of Nrf2 in mixed culture is due to the presence of 
astrocytes or if Nrf2 is upregulated in the neurons themselves, I examined Nrf2 levels in 
neurons and astrocytes in a mixed culture by immunocytochemistry (Fig.5.1B). The results 
show that Nrf2 levels are elevated in astrocytes by tBHQ or MG-132 in mixed culture, but not 
in neurons (pointed out by white arrows). This shows that the Nrf2 pathway is active in 





Figure 5.1. Nrf2 is present in astrocytes, but is only weakly expressed in neurons in mouse 
primary cortical culture. A. Western blot of Nrf2 protein levels in astrocytes compared to mixed 
and neuronal culture at baseline and following addition of Nrf2 activator tBHQ (10 µM, 8h) and 
proteasomal inhibitor MG-132 (5 µM, 16h). Note that long exposure times were needed to detect 
the bands. Representative blot of n=3. B. Nrf2 is activated by tBHQ and MG-132 in astrocytes, but 
not in neurons in a mixed culture. Cultures stained for anti-Nrf2 (red), neuronal marker (green) 




5.2.2. Srxn1, xCT, Hmox1, Gclc and Nqo1 are Nrf2 target genes 
I  decided to examine the effect of synaptic activity on a number of well-known Nrf2 target 
genes, Srxn1 (which reactivates hyperoxidised peroxiredoxins), system xc- (xCT) (a 
glutamate-cystine transporter), glutamate-cysteine ligase catalytic subunit (Gclc) (which 
catalyses the rate-limiting step in GSH synthesis), haem-oxygenase 1 (Hmox1) (which breaks 
down the haem group) and NAD(P)H quinone dehydrogenase 1 (Nqo1) (responsible for the 
reduction of quinones) (Soriano et al. 2008a; Soriano et al. 2009; Bell, Al-Mubarak, et al. 
2011; Sasaki et al. 2002; Lacher et al. 2015; Vargas & Johnson 2009; Kensler et al. 2007; 
Loboda et al. 2016), two of which Habas et al. had studied (Habas et al. 2013). To confirm 
that these genes were indeed targets of the Nrf2 pathway in astrocytes, but not in neurons, I 
examined their mRNA expression in mouse cortical mixed WT and Nrf2 knock-out (KO) 
cultures made from an Nrf2 KO mouse (Itoh et al. 1997) with or without addition of Nrf2 
activator tBHQ, and found all five genes to be induced by tBHQ in an Nrf2-dependent manner 
(Fig.5.2). Since I found activation of the Nrf2 pathway to be weak in neurons (Section 5.2.1.), 
I wanted to confirm that these genes were activated by tBHQ in an astrocyte-dependent 
manner. Thus, I applied tBHQ to neuronal and astrocyte enriched cultures (AE; ~15% 
astrocytes), to which no AraC was added to stop glial proliferation, to recreate culture 
conditions used by Habas et al. (Habas et al. 2013). I found all five genes to be largely 
significantly increased following tBHQ treatment of astrocytes (Fig.5.3). Although there was 
a significant increase in Srxn1 and Hmox1 mRNA levels in neuronal culture following tBHQ 
treatment (Fig.5.3.A,C), these changes were very small in comparison to induction in AE 
culture, thus were likely due to the small number of astrocytes present in pure neuronal culture. 
Therefore, Srxn1, xCT, Hmox1, Gclc and Nqo1 are Nrf2 target genes which are activated in 




Figure 5.2. Srxn1, xCT, Hmox1, Gclc and Nqo1 are induced by Nrf2 activator tBHQ in an Nrf2 dependent 
manner. mRNA levels of Srxn1, xCT, Hmox1, Gclc and Nqo1 were detected using real-time (RT)-qPCR in 
WT or Nrf2 KO mixed culture (A-E, respectively). Values were normalised to Gapdh and then to the WT 
control. n=6 for WT, n=7 for Nrf2 KO (Srxn1 and xCT) and n=4 Nrf2 KO (Hmox1, Gclc, Nqo1), paired two-
tailed t-test. *p≤0.05 compared to their own control. p-values, respectively: 0.0079, 0.0012, 0.0032, 






Figure 5.3. Srxn1, xCT, Hmox1, Gclc and Nqo1 are induced by Nrf2 activator tBHQ in an astrocyte 
dependent manner. mRNA levels of Srxn1, xCT, Hmox1, Gclc and Nqo1 (A-E, respectively) measured 
by RT-qPCR in a neuronal or AE culture. Values were normalised to 18s and then to the AE control. 
n=6. Paired two-tailed t-test. *p≤0.05 compared to their own control. p-values, respectively: 0.0216, 
0.0090, 0.0023, 0.0217, 0.0012, 0.0146, 0.0017. Error bars=SEM. 
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5.2.3. Srxn1, xCT, Hmox1 and Gclc are induced by neuronal activity independently of 
astrocytes 
Neurons are known to possess some of their own antioxidant defences, many of which are 
activated downstream of synaptic NMDARs (Papadia et al. 2008). Some of the antioxidant 
genes upregulated in neurons following neuronal activity are known Nrf2 target genes, such 
as Srxn1 (Papadia et al. 2008). Habas et al. recently suggested that Nrf2 target genes Gclc and 
Nqo1 are upregulated following neuronal activity by neurons signalling to astrocytes and 
activating the Nrf2 pathway (Habas et al. 2013). I wanted to examine whether induction of 
Nrf2 target genes seen by Habas et al. could be due to the activation of these genes in neurons 
themselves in response to increased synaptic activity. I applied GABAA receptor antagonist 
bicuculline and K+ channel antagonist 4-aminopyridine (Bic/4-AP) to cultures, which 
increases neuronal AP firing, by blocking inhibitory inputs to neurons and elevates burst 
frequency, leading to synaptic NMDAR-mediated Ca2+ influx into neurons (Papadia et al. 
2008). I compared mRNA levels of Nrf2 target genes Srxn1, xCT, Hmox1, Gclc and Nqo1 
following Bic/4-AP treatment in a neuronal (<0.2% astrocytes) and AE (15% astrocytes) 
culture (Fig.5.4). Srxn1 levels were significantly higher following 4 and 24h Bic/4-AP 
treatment in both neuronal and AE culture (Fig.5.4A). xCT levels were significantly 
upregulated after 24h in both cultures and after 4h in neuronal culture (Fig.5.4B.). Levels of 
Hmox1 were significantly induced after 24h Bic/4-AP treatment in neuronal culture and there 
was a strong, but non-significant increase (p=0.0538) in Hmox1 levels following 24h Bic/4-
AP activity in AE culture (Fig.5.4C). Note that 24h Bic/4-AP activity does significantly 
increase Hmox1 levels in a mixed culture (Fig.5.5C). Gclc mRNA levels were significantly 
induced following 24h Bic/4-AP stimulation and there was an upward trend following 4h 
stimulation (Fig.5.4D). Levels of Nqo1 remained unchanged following Bic/4-AP stimulation 
both in neuronal and AE culture (Fig.5.4E). Thus, some Nrf2 target genes, but not all, can be 
activated by neuronal activity, the activation of which is independent of the presence of 





Figure 5.4. Srxn1, xCT, Hmox1 and Gclc, but not Nqo1, are induced by Bic/4-AP in neuronal and 
AE culture. mRNA levels of Srxn1, xCT, Hmox1, Gclc and Nqo1 (A-E, respectively) detected using 
RT-qPCR in neuronal or AE culture following Bic/4-AP treatment for 4h or 24h. Values were 
normalised to 18s and then to the AE control. n=6. Paired two-tailed t-test. *p≤0.05 compared to 
their own control. p-values, respectively: 0.0003, 0.0238, 0.0031, 0.0005, <0.0001, 0.0018, 0.0334, 
0.0290, 0.0224, 0.0081. Error bars=SEM. 
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5.2.4. Srxn1, xCT, Hmox1 and Gclc are induced by neuronal activity independently of 
Nrf2 
Since Nrf2 is mainly expressed in astrocytes (section 5.2.1.), and Nrf2 target genes can be 
activated by neuronal activity independently of astrocytes (section 5.2.3.), I hypothesised that 
these Nrf2 target genes can be activated independently of Nrf2 itself. I tested this by applying 
Bic/4-AP to mixed WT or Nrf2 KO cultures and measured mRNA levels of Nrf2 target genes 
by RT-qPCR (Fig.5.5). Srxn1 and xCT levels were significantly increased following 4h and 
24h Bic/4-AP treatment in both WT and Nrf2 KO cultures (Fig.5.5A,B). Hmox1 levels were 
significantly increased following 24h Bic/4-AP treatment (Fig.5.5C), while Gclc was 
significantly induced following 4h Bic/4-AP treatment in both cultures (Fig.5.5D). In contrast, 
Nqo1 levels were not increased in either culture following neuronal activity (Fig.5.5E). Note 
that these results reflect the induction pattern seen in neuronal and AE culture (Fig.5.4), with 
the exception of Gclc which was increased after 24h Bic/4-AP in neuronal and AE culture, 
although in all cultures, it showed an upward trend at both time points. This demonstrates that 
these Nrf2 target genes, except for Nqo1, are upregulated independently of Nrf2 following 






Figure 5.5. Nrf2 target genes Srxn1, xCT, Hmox1 and Gclc are induced by Bic/4-AP in WT and Nrf2 
KO culture. mRNA levels of Srxn1, xCT, Hmox1, Gclc and Nqo1 (A-E, respectively) were tested 
following 4 and 24h Bic/4-AP treatment in WT and Nrf2 KO mixed cultures by RT-qPCR. Values were 
normalised to Gapdh and then to the WT control. n=6 for WT, n=7 for Nrf2 KO (Srxn1 and xCT) and 
n=4 for Nrf2 KO (Hmox1, Gclc, Nqo1). Paired two-tailed t-test. *p≤0.05 compared to their own 
control. p-values, respectively: 0.0002, 0.0003, 0.0014, <0.0001, 0.0182, 0.0135, <0.0001, 0.0007, 




5.2.5. Nrf2 protein levels are not increased by neuronal activity 
Habas et al. found increased nuclear Nrf2 protein levels in AE culture following neuronal 
activity, and suggested this to be the result of neuronal signalling to astrocytes via the tripartite 
synapse (Habas et al. 2013). Since I found Nrf2 target gene induction following neuronal 
activity to be independent of astrocytes and Nrf2 (Sections 5.2.3 and 4), I hypothesised that 
Nrf2 protein levels would likely be unaffected. The Nrf2 antibody used by Habas et al. 
produced many non-specific bands in my hands (data not shown), thus I used a different Nrf2 
antibody (D1Z9C, Cell Signaling). I validated the antibody using WT and Nrf2 KO primary 
mouse astrocyte cultures, and indeed found the band present at the expected molecular weight 
of ~66kDa for Nrf2 to be absent from the Nrf2 KO samples (Fig.5.6A). Note that the faint 
band at a slightly higher molecular weight than Nrf2 seen in many of the blots is unspecific. 
Nrf2 protein levels on day in vitro (DIV) 10 were not significantly increased by either Bic/4-
AP treatment or depolarization with high K+ (with NMDAR antagonist MK-801 present) in 
the presence or absence of L-type Ca2+ channel agonist FPL-64176 (KCl or KCl/FPL 
treatment) in an AE culture (Fig.5.6B-C). High K+ treatment is known to depolarise neurons 
and lead to L-type Ca2+ channel mediated Ca2+ influx (Hardingham et al. 1999). In contrast, 
Nrf2 protein levels were significantly increased following addition of Nrf2 activators 
sulforaphane (SLF) and tBHQ, as well MG-132 (Fig.5.6B-C).  
Since Habas et al. only saw an increase in Nrf2 levels following 24h neuronal activity at a 
more mature developmental stage (DIV14), I also examined Nrf2 levels at a later 
developmental time point (DIV18). I observed no significant increase in Nrf2 protein levels 
following Bic/4-AP or KCl(/FPL) treatment of DIV18 AE cultures (Fig.5.7), whilst Nrf2 
protein levels were significantly increased after tBHQ and MG-132 treatment and there was a 
strong trend for Nrf2 activation by SLF (p=0.0532). 
Thus, Nrf2 protein levels are not significantly increased by neuronal activity in AE culture, 





Figure 5.6. Nrf2 protein levels are not significantly induced following Bic/4-AP treatment of DIV10 
AE culture. A. The Nrf2 antibody is specific for Nrf2. An example blot is shown of WT and Nrf2 KO 
astrocyte samples untreated or treated with Nrf2 activators tBHQ (10 µM), SLF (5 µM) or MG-132 
(10 µM) for 16h. The bands seen at a higher molecular weight in the Nrf2 KO samples is due to the 
KO process, part of the Nrf2 gene is replaced with 5.8 kb LacZ cDNA resulting in the production of 
the first 301 residues of Nrf2 bound to LacZ (Itoh et al. 1997). Since the Nrf2 antibody targets human 
Nrf2 around Ala275, Nrf2 bound to LacZ is detected. B. Densitometric analysis of Nrf2 levels following 
Bic/4-AP (24h) or KCl(/FPL) treatment of DIV10 AE culture from Western blots, as well as treatment 
with Nrf2 activators, an example trace of which can be seen in C. Note that the MG-132 treated lane 
is oversaturated. Results were normalised to β-actin and the control. Note that the faint band seen 
slightly above Nrf2 is non-specific. n=5 for con, MG, SLF, Bic-4AP, KCl and KCl/FPL 4h, n=4 for KCl and 
KCl/FPL 24h, and n=3 for tBHQ. Paired two-tailed t-tests. *p≤0.05 compared to control. p-values, 







Figure 5.7. Nrf2 protein levels are not significantly induced following Bic/4-AP treatment of 
DIV18 AE culture. A. Densitometric analysis of Nrf2 protein levels following Bic/4-AP or KCl(/FPL) 
treatment, or treatment with Nrf2 activators of DIV18 AE culture from Western blots, an example 
exposure of which can be seen in B. Note that the MG-132 lane is over saturated. Results were 
normalised to β-actin and the control. n=5. Paired two-tailed t-tests. *p≤0.05 compared to control. 
p-values, respectively: 0.0454, 0.0045. Error bars=SEM. 
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5.2.6. Nrf2 protein levels are not significantly induced by neuronal activity in astrocytes 
in a mixed culture 
Nrf2 target genes can be activated independently of Nrf2 and astrocytes (section 5.2.5.), but 
this does not mean that Nrf2 target genes are not activated by Nrf2 in astrocytes to some extent 
in a mixed culture. Thus, I examined Nrf2 protein levels in neurons and astrocytes in a WT 
mixed culture using immunocytochemistry (example images can be seen in Fig.5.1.). The 
relative intensity of the staining was compared between different conditions in neurons and 
astrocytes. Nrf2 activators, SLF, tBHQ, MG-132 and CDDOTFEA significantly increased Nrf2 
levels in astrocytes, but not in neurons, further supporting results shown in section 5.2.1 
(Fig.5.8A-C,F). Interestingly, application of hydrogen peroxide (H2O2) also significantly 
increased Nrf2 protein levels in astrocytes (Fig.5.8E). H2O2 is known to produce oxidative 
stress which activates Nrf2, and our group has previously shown that H2O2 induces Nrf2 target 
gene expression in an astrocyte dependent manner (Bell, Al-Mubarak, et al. 2011), but this is 
the first time this is shown on the protein level. Nrf2 levels were not significantly increased in 
neurons or astrocytes following Bic/4-AP application, although there was a slight increase in 
Nrf2 levels in astrocytes (Fig.5.8D). This further confirms findings from section 5.2.5., that 
Nrf2 protein levels are not significantly increased following Bic/4-AP treatment, and supports 
the idea that the Nrf2 target genes are activated by neuronal activity independently of Nrf2 
and astrocytes. Furthermore, this further proves that the Nrf2 pathway is activated in 




Figure 5.8. Nrf2 levels are increased by Nrf2 activators and H2O2 in astrocytes in a mixed culture, 
but not increased following Bic/4-AP treatment in either neurons or astrocytes. A-F. The relative 
Nrf2 level intensity was quantified in neurons and astrocytes in Nrf2 immunostained mixed culture 
from mean grey values (at least 25 neurons and astrocytes/image, 3 images/n) and normalised to 
control astrocyte Nrf2 values. Secondary antibody-only controls were subtracted from the results 
to avoid bleed-through from the GFP channel. Nrf2 levels were significantly increased in astrocytes 
by Nrf2 activators MG-132 (5 µM, 16h), SLF (10 µM, 8h), tBHQ (10 µM, 8h) and CDDOTFEA (8h) 
(A,B,C,F respectively), as well as 50 and 100 µM H2O2 (E), but not by Bic/4-AP treatment (24h) (D). 
n=4 for control, tBHQ, SLF, 100 µM H2O2, and n=3 for 25 and 50 µM H2O2, DMF, F3, Bic/4-AP. Two-
tailed paired t-tests, except for H2O2 and CDDOTFEA where a one-way ANOVA with Dunnett’s post-
hoc test was used. *p≤0.05 compared to their own control. p-values, respectively: 0.0114, 0.0424, 
0.0101, 0.0025, 0.0004, 0.0045. For example images of Nrf2 immunostaining in a mixed culture 




5.2.7. Some, but not all, Nrf2 target genes are upregulated by neuronal activity  
Although I examined five Nrf2 target genes, the question remained whether other Nrf2 target 
genes are also upregulated by neuronal activity, and if their activation is Nrf2 and astrocyte 
dependent.  
Thus, I used an RNA-seq data set of neuronal and mixed cultures treated with tBHQ or Bic/4-
AP for 4 or 24h, to look at a wider range of Nrf2 target genes.  
I identified a group of 154 genes which were induced by Nrf2 activator tBHQ in mixed, but 
not in neuronal culture. Note that only one gene, Jun, was significantly upregulated by tBHQ 
in neuronal culture, and was therefore excluded from the list of tBHQ-induced genes. Of the 
154 genes, 55 known genes were significantly induced ≥1.5-fold by tBHQ in mixed culture, 
but not in pure neuronal culture (Fig.5.9A-B) (For the list of genes, see supplementary table 
1). Of note, I found these 55 tBHQ-induced Nrf2 target genes to have a higher basal expression 
in mixed, then in neuronal culture, indicating that they are likely expressed at higher levels 
basally in astrocytes (Fig.5.9C). 
From the 55 tBHQ-induced Nrf2 target genes I identified, I found 16 to be significantly 
induced by 4h Bic/4-AP treatment (Fig.5.10A), and 17 genes to be induced by 24h Bic/4-AP 
treatment in pure neuronal culture (Fig.5.10B) (For the list of genes, see supplementary table 
2 and 3). Of interest, the genes I examined in sections 5.2.3 and 5.2.4 were also upregulated 
by neuronal activity in the RNA-seq data set, Srxn1 and xCT were induced following 4 and 
24h Bic/4-AP, whilst Gclc was induced after 4h and Hmox1 after 24h Bic/4-AP treatment in 
neuronal culture. As I observed in sections 5.2.3 and 5.2.4, Nqo1 was not significantly 
upregulated following neuronal activity in either neuronal or mixed culture. Thus, neuronal 
activity induces a significant percentage of Nrf2 target genes in pure neuronal culture, despite 
neurons having a non-functional Nrf2 pathway. 
Although some of the 55 tBHQ-induced Nrf2 target genes were upregulated following 
neuronal activity in pure neuronal culture, 35 were not (For the list of genes, see supplementary 
table 4). If Nrf2 is activated in astrocytes following neuronal activity as suggested by Habas 
et al., these 35 tBHQ-induced Nrf2 target genes should show increased expression following 
Bic/4-AP treatment in mixed culture. Thus, I studied the expression of this group of genes in 
mixed culture following 4 and 24h Bic/4-AP treatment, and found them not to be significantly 
induced, with the average log2 fold change of the genes around 0 (Fig.5.10A-C). In contrast, 
these 35 genes showed robust significant upregulation following tBHQ treatment, with a log2 
fold change around 1 (Fig.5.10C).  
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This indicates that neuronal activity does not induce Nrf2 in astrocytes, since activation of 
Nrf2 would lead to a significant upregulation of these genes, as is observed with tBHQ 
stimulation.  
 
Figure 5.9. There are 55 Nrf2 target genes which are significantly induced ≥1.5-fold by tBHQ in 
mixed, but not in neuronal culture. A. Raw reads for the 55 genes significantly induced ≥1.5-fold 
by tBHQ (8h, 10 µM) in mixed culture, indicated in red, and genes not significantly induced by tBHQ 
in mixed culture, indicated in grey, compared to the untreated mixed culture. Note that only genes 
with over a 100 raw reads on average between the two conditions have been included. B. The raw 
reads for the genes from (A) in pure neuronal culture treated with tBHQ. Note that the 55 Nrf2 
target genes (red) are not significantly upregulated. C. The 55 tBHQ-induced Nrf2 target genes are 




Figure 5.10. Some tBHQ-induced Nrf2 target genes are induced by Bic/4-AP treatment in 
neuronal culture, whilst the other Nrf2 target genes are not significantly upregulated in mixed 
culture. A. Raw reads of the 16 significantly upregulated genes following 4h Bic/4-AP treatment in 
neuronal culture shown in red, with the rest of the 55 tBHQ-induced Nrf2 target genes shown in 
grey. B. 17 of the 55 tBHQ-induced Nrf2 target genes are significantly upregulated in neuronal 
culture following 24h Bic/4-AP treatment. Shown as in (A) C. The group of 35 tBHQ-induced Nrf2 
target genes not upregulated in pure neuronal culture following Bic/4-AP are not significantly 
upregulated in mixed culture following 4 or 24h Bic/4-AP. In contrast, this group of genes are 
significantly upregulated following tBHQ (10 µM, 8h) treatment in mixed culture. Data shown as 
the log2 fold-change of genes following Bic/4-AP or tBHQ treatment compared to the control mixed 





I found that the Nrf2 pathway is active in astrocytes, but not in neurons due to their weak 
expression of Nrf2; and that Srxn1, xCT, Hmox1 and Gclc are indeed Nrf2 target genes in 
astrocytes. I did not observe a significant increase in Nrf2 protein levels following neuronal 
activity during development or in more mature cultures; and found that some, but not all Nrf2 
target genes can be induced by neuronal activity independently of astrocytes and Nrf2. 
Furthermore, I did not find a significant increase in the expression of a group of tBHQ-induced 
Nrf2 target genes (which were not upregulated in neurons following neuronal activity) 
following neuronal activity in a mixed culture, providing further evidence against Nrf2 
activation in astrocytes following neuronal activity.  
5.3.2. The Nrf2 pathway is active in astrocytes, but not in neurons 
The role of the Nrf2 pathway in astrocytes has been well established (Vargas & Johnson 2009), 
and many studies show that Nrf2 is expressed at much lower levels in neurons than astrocytes 
(Bell, Al-Mubarak, et al. 2011; Shih et al. 2003; Kraft et al. 2004; Jimenez-Blasco et al. 2015). 
However, some groups such as Yin et al., have suggested that the Nrf2 pathway is active in 
neurons (Satoh et al. 2006; Yin et al. 2010; Zhang et al. 2009a). The observation by Yin et al. 
is likely due to their use of “neuronal” cultures which can contain up to 10% astrocytes, which 
is equivalent to the astrocyte content of my mixed culture. I show in this chapter by Western 
blotting that Nrf2 is present at very low levels in neurons, and that Nrf2 activation by tBHQ 
has minimal effect in neuronal culture and only produces a small increase in mixed culture 
compared to astrocytes. I show by immunocytochemistry that the increase in Nrf2 levels in 
mixed culture following the addition of Nrf2 activators is due to astrocytes. Thus, the source 
of controversy in the field likely stems from the ability of a small percentage of astrocytes 
being able to induce Nrf2 target gene expression in culture, even though the Nrf2 pathway is 
not active in neurons. Our group has recently shown that Nrf2 is epigenetically silenced early 
in development in neurons to allow for correct neuronal development (Bell et al. 2015), which 
explains my observations. It would be interesting to examine Nrf2 levels in vivo in aged 
animals, to see if perhaps the epigenetic repression of Nrf2 is reversed. 
5.3.3. Neuronal activity does not significantly increase Nrf2 protein levels, but can 
activate some Nrf2 target genes, independently of Nrf2 and astrocytes 
Neurons have low antioxidant defences, expressing low levels of catalase and GSH, and are 
known to receive non-cell autonomous support from astrocytes whose antioxidant defences 
are much stronger (Kraft et al. 2004; Vargas & Johnson 2009; Shih et al. 2003), often through 
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activation of the Nrf2 pathway which I show is mostly restricted to astrocytes. However, 
neurons do have their own antioxidant defences. Physiological neuronal activity via synaptic 
NMDARs leads to Ca2+ influx, as well as Ca2+ release from intracellular stores (Hardingham 
et al. 2001b), promoting pro-survival CREB-dependent gene expression in neurons, 
upregulating antioxidant systems, and shutting down pro-death pathways (Papadia et al. 2008; 
Hardingham & Bading 2010; Baxter et al. 2015). Neurons have a high metabolic demand, 
especially during neuronal activity, thus it makes sense for neuronal activity to be coupled to 
mitochondrial metabolism, since more active neurons require more ATP, for example for 
restoring ionic gradients following Ca2+ influx (Harris et al. 2012; Kann & Kovács 2007). 
Mitochondria are known to be anchored upon increased Ca2+ influx, helping to meet neurons’ 
elevated ATP demand (Harris et al. 2012). Increased production of ATP by oxidative 
phosphorylation results in elevated ROS production in mitochondria themselves and by 
NADPH oxidase in the cytoplasm following NMDAR activation (Hongpaisan et al. 2004; 
Brennan et al. 2009). Small amounts of ROS are important for signalling and other vital 
cellular functions, but excessive ROS production leads to oxidative damage, mitochondrial 
dysfunction and cell death (Popa-Wagner et al. 2013). Thus, it is understandable for neuronal 
activity to be coupled to increased antioxidant defences to help eliminate excess ROS formed.  
Habas et al. recently found that Nrf2 target genes Gclc and Nqo1 were increased following 
neuronal activity, which they attributed to neuronal signalling to astrocytes through the 
tripartite synapse, Nrf2 being activated and inducing the transcription of its target genes in 
astrocytes, providing non-cell autonomous neuroprotection (Habas et al. 2013). Contrary to 
this, my results show that neuronal activity can induce several Nrf2 target genes, including as 
Srxn1, xCT, Hmox1 and Gclc, not only independently of Nrf2, but also of astrocytes. 
Furthermore, unlike Habas et al., I found Nrf2 protein levels not to be significantly induced 
following neuronal activity in mixed culture. Moreover, I studied a group of 35 tBHQ-induced 
Nrf2 target genes, which were not induced following neuronal activity in pure neuronal 
culture, and found them not to be significantly upregulated following neuronal activity in 
mixed culture (Fig.5.11). Although some of these genes showed an increase in response to 
activity, others showed a decrease, and overall the profile of fold inductions was normally 
distributed around log2FC=zero, strongly suggesting no induction of the Nrf2 pathway in 
astrocytes.  
Thus, some antioxidant genes which are targets of Nrf2 in astrocytes are upregulated in 
neurons following NMDAR-mediated Ca2+ influx, showing that neurons have cell-
autonomous antioxidant defences similar to Nrf2-mediated antioxidant defences in astrocytes, 
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helping to maintain redox balance and eliminate ROS formed following increased metabolic 
demand. Neurons possessing activity-dependent antioxidant defences is understandable, since 
it would be energetically costly to keep antioxidant pathways continuously activated, and 
excessive antioxidant support may inhibit important redox signalling from occurring. This way 
antioxidant genes are only transcribed when required, and non-cell autonomous protection via 
the Nrf2 pathway in astrocytes provides basal protection for neurons, for instance through the 
supply of GSH precursors (Shih et al. 2003). 
 
5.3.3.1 The antioxidant pathways affected by the upregulation of Nrf2 target genes 
following neuronal activity 
The Nrf2 target genes I examined are involved in several different antioxidant pathways, 
including the Trx-Prx system and GSH synthesis. Srxn1 is responsible for catalysing the 
reduction of hyperoxidised Prxs in an ATP dependent manner, which is essential for neurons 
to keep Prxs active. Our group has previously shown that Srxn1 can be activated by neuronal 
activity through promoter elements containing AP-1 sites (Papadia et al. 2008). The results in 
Figure 5.11. Neuronal activity induces the expression of some, but not all tBHQ-induced Nrf2 
target genes. tBHQ induced a group of 55 Nrf2 target genes in astrocytes, 20 of which were 
induced following neuronal activity in pure neuronal culture. Most likely tBHQ-induced Nrf2 target 
genes containing consensus sequences for the binding of transcription factors (TFs) other than 
Nrf2, such as AP-1 and ATF4, are activated by neuronal activity, whilst ARE-only containing Nrf2 
target genes are not. It is possible that some Nrf2 target genes are activated in astrocytes following 
neuronal activity, but this is likely independent of Nrf2 activation. 
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this chapter are in agreement with this, showing that Srxn1 is upregulated following 4 and 24h 
Bic/4-AP treatment, independently of astrocytes and Nrf2.  
Our lab has recently published work confirming that synthesis and recycling of GSH is 
controlled by synaptic NMDAR-mediated Ca2+ influx in neurons (Baxter et al. 2015). 
Transcription of xCT, a cystine/glutamate exchanger which helps supply cysteine for 
glutathione synthesis, has been shown to be induced in primary cortical neuronal cultures 
independently of Nrf2, by activating transcription factor 4 (ATF4), whose translation is 
upregulated following PI3K activation by synaptic NMDAR activity (Lewerenz et al. 2014). 
Here I show that both xCT and Gclc, responsible for catalysing the rate-limiting step in GSH 
synthesis, are upregulated following neuronal activity in an Nrf2 and astrocyte independent 
manner, further confirming the role of NMDAR-mediated Ca2+ influx in modulating 
glutathione use and synthesis, helping to eliminate ROS cell autonomously to achieve redox 
balance. The PI3K pathway has also been shown to activate Nrf2 itself (Lee et al. 2001), but 
Lewerenz et al. found xCT activation in cortical neurons to be independent of Nrf2 (Lewerenz 
et al. 2014). I found Nrf2 expression levels to be low in neurons themselves, which explains 
why activation of the PI3K pathway downstream of synaptic NMDAR activation will not lead 
to Nrf2 activation. Astrocytes provide the precursors needed by neurons to synthesise their 
own GSH (Shih et al. 2003). Thus, when the demand for antioxidant is higher, neurons 
upregulate genes important for GSH synthesis, such as Gclc and xCT, to boost their intrinsic 
antioxidant defences. 
Hmox1 is involved in the breakdown of the haem group into iron, carbon monoxide and 
biliverdin, which can be further broken down into bilirubin by biliverdin reductase, with both 
biliverdin and bilirubin having antioxidant properties (Schipper et al. 2009; Vargas & Johnson 
2009; Loboda et al. 2016). I show that Hmox1 is activated in neurons themselves 
independently of astrocytes or Nrf2. Interestingly, it has been suggested that Hmox1 is an 
ATF4 target gene, and the ARE of Hmox1 was shown to have AP-1-like binding sites (Harding 
et al. 2003; Soriano et al. 2008a; Inamdar et al. 1996). Thus, Hmox1 could be activated by the 
same pathway as Srxn1 or xCT. Interestingly, Yin et al. observed an increase in Hmox1 and 
neuroprotection against oxidative stress following addition of geniposide, and found that cell 
death was increased with a PI3K inhibitor, suggesting that Hmox1 may be downstream of 
PI3K and ATF4 in hippocampal neurons (Yin et al. 2010). Furthermore, I found biliverdin 
reductase (Blvrb) to be increased following 4 and 24h Bic/4-AP treatment of neuronal cultures 
using RNA-seq (Supplementary tables 2 and 3). 
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Nqo1, which is responsible for reduction of quinones, is thought to be an Nrf2 specific target 
gene (Dinkova-Kostova & Talalay 2010). Indeed, Nqo1 mRNA levels were upregulated 
following treatment with tBHQ, however there was no increase of Nqo1 in WT or Nrf2 KO 
cultures following neuronal activity, suggesting that Nqo1 is indeed Nrf2 specific and cannot 
be induced by neuronal activity. Unlike me, Habas et al. saw an increase in Nqo1 levels 
following neuronal activity. Additionally, I found 35 of the 55 tBHQ-induced Nrf2 target 
genes, identified by RNA-seq, to not be significantly induced following neuronal activity in 
pure neuronal cultures, indicating that not all Nrf2 target genes can be activated by neuronal 
activity. 
5.3.3.2. Why do the findings in this thesis differ from those of Habas et al.? 
There were several differences between the techniques used in this thesis and those used by 
Habas et al. (Habas et al. 2013), some of which are outlined below and may help to explain 
the discrepancies between our results.  
Habas et al. examined the Nrf2 dependence of Nrf2 target gene induction by siRNA-mediated 
knock-down, which can result in incomplete Nrf2 KD and unwanted off-target effects. Since 
I employed an Nrf2 KO mouse in which Nrf2 is completely genetically eliminated (Itoh et al. 
1997), my results are more likely to truly reflect the Nrf2 requirement of gene induction 
following neuronal activity.  
Habas et al. saw increased Nrf2 target gene mRNA expression in their neuronal culture, which 
they attributed to the presence of astrocytes. Their neuronal culture contained 4% astrocytes, 
whilst my neuronal cultures contain <0.2% astrocytes, making contamination from astrocytes 
unlikely. I observed Nrf2 target gene induction in neuronal culture at similar levels to that in 
mixed and AE cultures (10 and 15% astrocytes, respectively), suggesting that gene induction 
is independent of astrocytes themselves, which was further proven by Nrf2 target gene 
induction following neuronal activity in Nrf2 KO cultures. Furthermore, I show using an 
RNA-seq data set that the group of tBHQ-induced Nrf2 target genes which were not 
significantly upregulated in pure neuronal culture following neuronal activity, were not 
significantly induced in mixed culture following neuronal activity, suggesting that Nrf2 is not 
the transcription factor responsible for inducing Nrf2 target gene expression following 
neuronal activity. Moreover, Habas et al. did not detect increased Nrf2 protein levels in their 
neuronal culture, thus it is unclear how they came to the conclusion that the gene induction 
they observed in neuronal culture was due to Nrf2 activation in astrocytes. 
However, Habas et al. did show increased nuclear Nrf2 levels in astrocytes following neuronal 
activity in AE cultures. In contrast, I found Nrf2 protein levels not to be significantly increased 
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following neuronal activity, either by Bic/4-AP or KCL(/FPL) treatment, in AE culture. Habas 
et al. used an Nrf2 antibody (H300, Santa Cruz Biotechnology) which produced multiple 
unspecific bands, making the identification of Nrf2 in some blots difficult. The H300 antibody 
failed to work in my hands, thus I used a more specific Nrf2 antibody (D1Z9C, Cell Signaling), 
which I validated using Nrf2 KO cultures (Itoh et al. 1997). A recent paper comparing different 
Nrf2 antibodies confirms that the D1Z9C antibody is highly specific for Nrf2, more so than 
the H300 Nrf2 antibody which produces numerous non-specific bands (Kemmerer et al. 2015). 
Habas et al. examined nuclear Nrf2 levels separately, and suggested in their reply to our paper 
that this may be the cause of the differences in our results (Habas et al. 2014).  Although they 
examined cytoplasmic levels separately, Nrf2 levels seemed undetectable in their cytoplasmic 
fractions, thus looking at total Nrf2 levels should only show nuclear Nrf2 levels; which in my 
hands indicated no significant increase in Nrf2 levels following neuronal activity. 
Additionally, unlike Habas et al., I also examined Nrf2 levels by immunocytochemistry 
(DIV9), and found no significant increase in Nrf2 levels in astrocytes or neurons following 
Bic/4-AP treatment of a mixed culture, although there was a trend for increased Nrf2 levels in 
astrocytes. Thus, these experiments should be repeated to determine whether this effect 
persists, and if it does whether it is due to neuronal activity or perhaps an indirect effect of 4-
AP on astrocytes. Possible indirect effects of 4-AP on astrocytes could be tested by addition 
of tetrodotoxin alongside Bic/4-AP treatment to silence neuronal activity.  
Habas et al. used their cultures at a later developmental stage (DIV14) than I did (DIV10), 
arguing that GABAergic neurons are not yet mature at early developmental stages, thus 
GABAA receptor antagonist bicuculline could not fully exert its effect. But, even in DIV18 
AE culture, I did not observe a significant increase in Nrf2 protein levels following Bic/4-AP 
treatment. Furthermore, I saw no significant effect of 4 or 24h KCl(/FPL) treatment on Nrf2 
protein levels at either developmental stage. Habas et al. also examined the transcription of 
Nrf2 target genes at this later developmental stage (DIV14), whilst I examined them at DIV9. 
Despite this, I found several Nrf2 target genes, including Gclc which Habas et al. examined, 
to be induced following neuronal activity in DIV9 culture, independently of Nrf2 or astrocytes. 
Interestingly, Habas et al. reported seeing an effect on Nrf2 protein levels with high K+ in 
immature neurons. However, my results showed that KCl/FPL treatment induced Nrf2 target 
gene expression in an Nrf2 and astrocyte independent manner (data not shown), which together 
with no significant increase seen in Nrf2 protein levels following neuronal activity in immature 
(DIV10) or more mature neurons (DIV18), suggests that the differences in the developmental 
stage of neurons used is unlikely to be the cause of the discrepancies in our results. Although 
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it is possible that some of the Nrf2 target genes may not be induced in more mature neurons. 
xCT for instance has been shown to be expressed on immature neurons, contributing to their 
survival, but not on mature neurons which are thought to be unable to take up cystine, and will 
only transport cysteine for GSH synthesis through EAAC1 transporters (Bridges et al. 2012; 
Robert et al. 2014). xCT has been shown to be expressed in mature neurons in culture, but this 
seems to be an effect of culturing itself (Aoyama et al. 2008; Bridges et al. 2012). Thus, 
whether the upregulation of Nrf2 target gene expression persist at a more mature 
developmental stage should be further investigated, as well as the effects of neuronal activity 
on astrocytes and the Nrf2 pathway in vivo, since neuronal cultures cannot reproduce the in 
vivo environment, and communication between astrocytes and neurons may differ in vivo.  
It is possible that Nrf2 is upregulated following neuronal activity in certain neuronal subtypes, 
brain regions or in different species, since Habas et al. worked on primary rat hippocampal 
whilst I used primary mouse cortical cultures. Additionally, different cellular environments 
may also influence gene expression, of note Habas et al. used aCSF to carry out their 
experiments whilst I used TMo. Thus comparison of Nrf2 levels following neuronal activity 
in different brain regions would be of interest. It is important to note that even with a small 
significant effect of neuronal activity on Nrf2 in astrocytes, Nrf2 levels will be much lower 
than with Nrf2 activators tBHQ and SLF, and most likely cannot be picked up by Western 
blotting. 
5.3.4. Possible cooperation of neuronal activity and the Nrf2 pathway in 
neuroprotection, and their potential clinical implications 
Neurons have a high metabolic demand, but low antioxidant defences, and are therefore 
susceptible to oxidative damage (Harris et al. 2012). As I show in this chapter, neuronal 
activity can induce the transcription of some Nrf2 target genes, some of which are involved in 
the Trx-Prx and the GSH antioxidant systems. Thus, both neuronal activity and Nrf2 activation 
are potential therapeutic targets for treatments of conditions involving oxidative stress. ROS-
mediated oxidative damage and excitotoxicity have been implicated in ND disorders, stroke 
and TBI (Popa-Wagner et al. 2013; Bell & Hardingham 2011a; Bell & Hardingham 2011b). 
Additionally, ROS have been hypothesised by the “free-radical theory of ageing” to 
accumulate oxidative damage gradually over time, making neurons more vulnerable to insults 
as they age (Schipper 2004). Therefore, it is likely that the Nrf2 pathway and synaptic activity 
both play a neuroprotective role in ageing. 
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5.3.4.1. Potential clinical implications of neuronal activity in neurodegenerative diseases 
Neuronal activity has been shown to have protective effects both in vitro and in vivo. 
Preconditioning neuronal cultures with Bic/4-AP is neuroprotective against H2O2-mediated 
cell death and excitotoxicity, independently of the presence of astrocytes (Baxter et al. 2015; 
Qiu et al. 2013). Srxn1, a target gene I examined in this chapter, has been shown to be 
responsible for some of the neuroprotective effects of synaptic NMDAR activity against H2O2-
induced cell death (Papadia et al. 2008). Preconditioning with Bic/4-AP also provides 
protection against OGD, a technique used to recreate stroke in vitro, up to 3 days after Bic/4-
AP application (Tauskela et al. 2008). It will be interesting to see whether other Nrf2 target 
genes induced by neuronal activity contribute to the neuroprotection provided by synaptic 
NMDAR activity against H2O2-induced and excitotoxic cell death. 
Environmental enrichment (EE) in rats, such as enriching the cages of animals with novel 
objects, has been shown to induce Bdnf and phosphorylate CREB, providing neuroprotection 
against spontaneous apoptotic cell death and excitotoxicity (Young et al. 1999). Furthermore, 
EE along with exercise was shown to decrease age-related spatial learning decline, partly via 
reversing decreased Bdnf expression (O’Callaghan et al. 2009). CREB phosphorylation and 
Bdnf activation are known downstream protective effects of synaptic NMDAR activity, and 
Nichols et al. found EE in rats to increase glutamatergic synaptic signalling (Nichols et al. 
2007). Thus, one may propose that EE increases neuronal activity, which partly through 
synaptic NMDAR activity activates anti-apoptotic pathways and upregulates antioxidant 
defences, such as antioxidant Nrf2 target genes induced in neurons via neuronal activity shown 
in this chapter. Indeed, Young et al. has shown EE to increase learning and memory, known 
to involve NMDARs. Thus, it is plausible that EE could help to reduce ROS build up during 
ageing and neurodegeneration, through antioxidant gene expression mediated by synaptic 
NMDAR activity. Indeed, EE has been found to delay the onset of symptoms and disease 
progression in different mouse models of HD, and to help combat oxidative stress by 
increasing antioxidant defences in a mouse model of AD, whilst cognitively stimulating 
activities in humans are thought to reduce the likelihood of developing AD (Spires & Hannan 
2005; Herring et al. 2010). Neurons experiencing increased neuronal activity throughout their 
lifetime due to EE may accumulate less ROS, in line with the “free-radical theory of ageing”, 
and thus may be less susceptible to neurodegeneration and cognitive decline. Thus, synaptic 
NMDAR activity could be targeted to enhance antioxidant defences in different disease 
models in neurons themselves rather than in astrocytes. The neuroprotective effects of synaptic 
NMDAR activity helps to explain the clinical failure of most NMDAR antagonists, which 
inhibit the activation of all NMDARs (Hardingham & Bading 2010). In contrast to traditional 
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NMDAR antagonist, memantine, which has been licensed for the treatment of AD, is an 
uncompetitive NMDAR antagonist which blocks extrasynaptic NMDAR activity following 
bath application of glutamate, whilst allowing physiological synaptic NMDAR activity (Xia 
et al. 2010; Lipton 2006). Thus, memantine does not inhibit synaptic NMDAR-mediated 
antioxidant defences, such as the upregulation of Srxn1, demonstrated by our group in vitro 
and in vivo (Papadia et al. 2008). Therefore, the protective effect of memantine lies in its ability 
to only inhibit toxic NMDAR activation, whilst sparing neuroprotective synaptic NMDAR-
mediated pathways important for cell survival. Furthermore, enhancing neuronal activity, for 
instance by increasing cognitive stimulation, may also increase neurons’ antioxidant defences 
and have a neuroprotective effect against diseases involving oxidative stress. 
5.3.4.2. The neuroprotective effect of Nrf2 upregulation in neurodegenerative diseases 
Nrf2 is activated in astrocytes by oxidative stress as well as by Nrf2 activators such as tBHQ 
and CDDOTFEA in vitro and in vivo, mediating the induction of several antioxidant and 
detoxifying genes in astrocytes, providing non-cell autonomous neuroprotection against 
oxidative stress (Kraft et al. 2004). Nrf2 target genes, Hmox1 and Srxn1, have been shown to 
be induced by mild oxidative stress by exogenous H2O2 application in vitro in primary mouse 
mixed cultures and human embryonic-stem cell (hESC) derived astrocytes; activation of which 
was found to be astrocyte and Nrf2 dependent in mouse mixed cultures (Bell, Al-Mubarak, et 
al. 2011). Additionally, Shih et al. showed that neuroprotection against oxidative stress by 
Nrf2 OE or tBHQ administration is conferred by astrocytes (Shih et al. 2003). Indeed, I 
confirmed by immunostaining that Nrf2 is directly activated by H2O2 in astrocytes, but not in 
neurons in mixed culture. Furthermore, Nrf2 activation by CDDOTFEA is neuroprotective 
against H2O2-induced cell death, dependent on astrocytes through the induction of the GSH 
system both in mouse primary neuronal cultures and hESC-derived neurons (Gupta et al. 
2012). This is thought to be due to the supply of GSH precursors by astrocytes to neurons 
(Shih et al. 2003).  
The Nrf2 pathway has been shown to provide neuroprotection during stroke, by activation of 
its target genes such as Srxn1 and Gclc (Jiang et al. 2016; Xue et al. 2016; Zhou et al. 2015b; 
Bell, Fowler, et al. 2011). Nrf2 target genes are upregulated following OGD contributing to 
ischemic preconditioning in vitro, and following middle cerebral artery occlusion (MCAO) in 
vivo (Bell, Al-Mubarak, et al. 2011). Furthermore, injection of SLF or tBHQ into rodents 
showed neuroprotective effects against MCAO in various experiments (Jiang et al. 2016). 
Moreover, Nrf2 target gene expression by Nrf2 has also been shown to be protective in TBI 
(Hong et al. 2010; Shu et al. 2016).  
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Pharmacological activation of the Nrf2 pathway and Nrf2 overexpression (OE) have been 
shown to provide neuroprotection against oxidative stress and inflammation in several ND 
diseases, such as AD, HD and PD (Buendia et al. 2016; Gan & Johnson 2014; Johnson et al. 
2008; Esteras et al. 2016). For instance, Nrf2-GFAP mice which overexpress Nrf2 in 
astrocytes, have been shown to have neuroprotective effects when crossed with mouse models 
of neurodegenerative diseases, such as ALS (Vargas et al. 2008) and PD (Gan et al. 2012; 
Chen et al. 2009). Of interest, an Nrf2 activator, DMF, has been approved for the treatment of 
multiple sclerosis (Brennan et al. 2015; Linker et al. 2011). 
5.3.4.3. Does the activation of both pathways provide added neuroprotection? 
As both the Nrf2 pathway and neuronal activity through activation of synaptic NMDARs can 
induce Nrf2 target genes providing neuroprotective effects against several insults involved in 
diseases (discussed above), the question arises whether the two pathways are distinct or have 
additive neuroprotective effect against various insults.  
Our group recently showed that not only is the GSH system regulated by neuronal activity in 
neurons themselves, but preconditioning with neuronal activity and CDDOTFEA combined has 
an additive neuroprotective effect against H2O2-induced cell death (Baxter et al. 2015). Thus, 
the two pathways do cooperate to protect neurons against oxidative stress. The Nrf2 target 
genes found to be upregulated by neuronal activity in this chapter, some of which are involved 
in the Trx-Prx and GSH antioxidant systems, may help mediate this effect. It is possible that 
Nrf2 target genes are upregulated following neuronal activity cell autonomously to allow 
neurons to eliminate ROS formed due to increased metabolism, whilst the astrocytic Nrf2 
pathway provides general support to neurons following oxidative stress and other insults, such 
as by supplying precursors for GSH synthesis (Shih et al. 2003). It will be important to 
investigate the interaction of these two pathways in disease, and determine the biological 
purpose for the dual control of some of these Nrf2 target genes. 
5.3.4.4. The potential additive neuroprotective effect of targeting the two pathways 
simultaneously in neurological diseases 
Since the two pathways are distinct and provide additive neuroprotection against oxidative 
stress in vitro (Baxter et al. 2015), it would be intriguing to see whether enhancing the two 
pathways simultaneously has an additive protective effect against stroke, cognitive decline or 
in ND diseases. It is possible that Nrf2 activators, such as CDDOTFEA or DMF in conjunction 
with EE could produce additive protective effect in these conditions. Furthermore, memantine, 
which would allow for synaptic NMDAR-mediated antioxidant gene expression whilst 
blocking excitotoxicity, could also be used in conjunction with Nrf2 activators in various 
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diseases to provide increased neuroprotection. Whether the Nrf2 pathway in astrocytes can 
provide additional protection to neurons during excitotoxicity should also be examined, since 
excitotoxicity is known to be involved in several ND diseases as well as stroke (Hardingham 
& Bading 2010; Hardingham et al. 2002). Bic/4-AP preconditioning has been shown to be 
neuroprotective against NMDA-induced excitotoxicity (Qiu et al. 2013), and it would be 
interesting to see whether this protection is Nrf2 and astrocytes independent, and if Nrf2 target 
genes contribute to neuroprotection. To test this, preconditioning with Bic/4-AP in conjunction 
with CDDOTFEA could be applied to WT and Nrf2 KO cultures in vitro. The dependence of 
these protective effects on different Nrf2 target genes could also be investigated, by knocking 
down the genes. If these approaches have an additive neuroprotective effect, whether they 
persist in aged mice and in vivo should also be investigated. 
Thus, the Nrf2 pathway and neuronal activity can be activated to provide additive 









Chapter 6: Concluding remarks 
134 
 
The research presented in this thesis aims to provide better insight into neuroprotective and 
neurodestructive Ca2+ signalling pathways, largely mediated by NMDARs in neurons, as well 
as the possible effect of neuronal activity on inducing antioxidant gene transcription in 
astrocytes. The key conclusions are: 
- AMPK is involved in mediating excitotoxicity, but is not activated downstream of 
Mcu. 
- MCRGs are differentially expressed in different neural cells (neurons vs astrocytes) 
and neuronal subtypes (CA1 vs CA3 neurons of the hippocampus). Of note the 
Na+/Ca2+ exchanger Nclx is expressed at very low levels in neurons. 
- Nrf2 is weakly expressed in neurons, nevertheless some Nrf2 target genes can be 
activated cell autonomously in neurons following neuronal activity, independently of 
Nrf2 or astrocytes. 
Excitotoxicity and oxidative stress are implicated in various acute and chronic 
neurodegenerative diseases, as well as in brain injury (Parsons & Raymond 2014; Gan & 
Johnson 2014; Hardingham & Bading 2010). Unfortunately, NMDAR antagonists have failed 
in clinical trials for stroke and TBI, likely due to their inhibition of physiological NMDAR 
activity which is essential for cell survival (Ikonomidou & Turski 2002; Paoletti et al. 2013). 
Furthermore, small molecule antioxidants have also largely failed in human clinical trials for 
CNS diseases (Kamat et al. 2008), likely due to their inability to mimic the complex 
antioxidant and detoxification systems in neural cells. Thus, it is imperative to better 
understand the pro-survival and pro-death signalling cascades downstream of NMDAR 
activation, as well as the pathways controlling the brain’s endogenous antioxidant defences, 
to find new targets for developing alternative therapies to combat excitotoxicity and oxidative 
stress in these diseases. Inhibition of pro-death signals in concert with enhanced endogenous 
antioxidant responses both in neurons and astrocytes, could be used as a combined approach 
in alleviating neuronal death. Specific inhibition of extrasynaptic NMDARs or GluN2B 
containing NMDARs, which are known to preferentially couple to pro-death pathways, is 
another viable option. For instance, decoupling the C terminal domain of GluN2B containing 
NMDARs using small peptides has shown some promise (Aarts & Tymianski 2003).  
Mitochondrial dysfunction plays a large role in excitotoxicity and our group has found Mcu to 
be a key mediator of excitotoxic cell death (Qiu et al. 2013). Due to the importance of 
mitochondrial Ca2+ signalling in both physiological and pathological circumstances, the 
inhibition of Mcu is likely to lead to similar issues to those experienced with NMDAR 
antagonists. Thus, in Chapter 3 I investigated AMPK as a potential downstream effector of 
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Mcu during excitotoxicity, but found AMPK not to be activated downstream of Mcu-mediated 
Ca2+ uptake. Nevertheless, AMPK activation does promote excitotoxic death, although its 
route of activation and downstream effector(s) still need to be better established, especially 
due to the possible pro-survival effects mediated by AMPK (Anilkumar et al. 2013; Culmsee 
et al. 2001; Weisova et al. 2009). It is likely that AMPK is phosphorylated by CaMKKβ 
following Ca2+ influx independently of increases in AMP (Hawley et al. 2005; Mairet-Coello 
et al. 2013; Woods et al. 2005; Anderson et al. 2008). The search for Mcu’s downstream 
effector(s) following excitotoxicity also continues, with JNK, PARP-1 and mPTP opening 
being likely candidates (Brustovetsky et al. 2002; White & Reynolds 1996; Ichas & Mazat 
1998; Orrenius et al. 2003; Bernardi & Rasola 2007; Abramov & Duchen 2008; Duan et al. 
2007; Yu et al. 2002; Soriano et al. 2008b). Whether Mcu and AMPK mediate neuronal death 
through distinct pathways should be further examined, with the downstream effectors of Mcu 
and AMPK being potential therapeutic targets, which would likely cause less adverse effects 
compared to targeting molecules further up in the signalling cascades. 
The molecular identity of Mcu and other MCRGs has only come to light in recent years, with 
the function of many of the genes still debated. Since the cell specific expression of MCRGs 
in the brain was unknown, in Chapter 4 I investigated the expression of MCRGs and found 
them to be differentially expressed in neurons and astrocytes as well as neuronal subtypes, 
providing a clearer picture of which MCRGs may be more important in each cell type. 
Interestingly, certain neuronal subtypes are more susceptible to excitotoxicity and other insults 
(such as CA1 and CA3 neurons of the hippocampus (Strasser & Fischer 1995; Ikegaya & 
Matsuki 2002; Cronberg et al. 2005; Gee et al. 2006; Yang et al. 2000; Wilde et al. 1997)), 
and since mitochondria play such a key role in mediating excitotoxic cell death, it is tempting 
to speculate that the differential expression of these genes could be a coping mechanism, or 
perhaps the cause of their increased susceptibility to cell death. Thus, it is essential to 
investigate whether the results seen in Chapter 4 translate to the protein level and to study the 
function of these genes further, to help determine the functional outcome of the differences in 
MCRG expression for neuronal health. Understanding the function of these genes may aid in 
finding therapeutic targets, for instance although Mcu cannot be blocked due to its likely 
adverse effect on metabolism, inhibiting one of its regulators may reduce Mcu-mediated Ca2+ 
influx following a pathological insult. Since Mcu plays an important role in mediating 
excitotoxicity (Qiu et al. 2013), the correct functioning of mitochondrial Ca2+ efflux 
pathway(s) is likely to also be essential for neuronal survival during excitotoxicity. 
Surprisingly, I found Nclx expression levels to be very low in neurons, suggesting that Nclx 
may not be the predominant mitochondrial Ca2+ efflux pathway in neurons, even though it is 
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thought to be the main exchanger in excitable cells (Palty & Sekler 2012). The importance of 
Nclx for mitochondrial Ca2+ efflux in neurons shall be further addressed using cultures from 
an Nclx KO mouse, with further studies focusing on potential alternative mitochondrial Ca2+ 
efflux pathways in neurons, such as Letm1, Ncx1, Ncx2 and Ncx3 (Gobbi et al. 2007; 
Scorziello et al. 2013; Wood-Kaczmar et al. 2013; Jiang et al. 2009). Once the identity of the 
exchanger in neurons is established, its importance for neuronal health can be studied.  
Interestingly, a mild NMDAR antagonist, memantine, which is thought to preferentially inhibit 
excessive NMDAR activation whilst sparing physiological synaptic NMDAR activation, has 
been licensed for the treatment of moderate to severe AD (Xia et al. 2010; Léveillé et al. 2008; 
Zhou et al. 2015a). Memantine is also in clinical trials for HD (Kumar et al. 2015) and vascular 
dementia (Lipton 2006) with promising results. Moreover, memantine has shown some 
benefits in patients with PD (Varanese et al. 2010). Furthermore, rodent experiments suggest 
that memantine may be neuroprotective in mild TBI (Effgen & Morrison 2016) as well as 
following stroke (Chen et al. 1992; Chen et al. 1998). 
Interestingly, AMPK activation by CaMKKβ following NMDA treatment of neurons was 
abolished by memantine pre-treatment, as was AMPK activation after Aβ treatment which 
leads to tau phosphorylation and toxicity (Thornton et al. 2011; Mairet-Coello et al. 2013). 
This suggests that AMPK plays a pro-death role in AD and is not activated following 
physiological synaptic NMDAR activity, although this should be further examined. Moreover, 
this provides evidence that memantine blocks pro-death pathways, and its inhibition of other 
signalling cascades such as Mcu-mediated excitotoxic death is likely. In addition, memantine 
allows physiological neuronal activity to take place, including the upregulation of neuronal 
antioxidant defences such as Nrf2 target genes including genes involved in the GSH system, 
which is known to be dysregulated in several ND diseases (Johnson et al. 2012). Thus, 
memantine or similar drugs preferentially blocking extrasynaptic NMDARs are likely to have 
therapeutic benefit in a number of ND diseases. 
Another possibility in tackling these diseases is increasing endogenous antioxidant defences 
to reduce oxidative stress. The data presented in Chapter 5 demonstrates that whilst the Nrf2 
pathway is expressed at very low levels in neurons, some Nrf2 target genes are activated in 
neurons following neuronal activity independently of Nrf2 and astrocytes, contrary to previous 
reports (Habas et al. 2013). Thus, astrocytes can provide antioxidant support, such as 
supplying GSH to neurons during oxidative stress via Nrf2 (Shih et al. 2003), whilst neurons 
enhance their endogenous antioxidant capacity following physiological activity via 
transcription factors other than Nrf2, such as ATF4 and AP-1 (Papadia et al. 2008; Soriano et 
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al. 2009; Lewerenz et al. 2014), compensating for the epigenetic silencing of Nrf2 in neurons 
during early development (Bell et al. 2015) and increasing GSH production. Treating neurons 
with medium from human embryonic stem-cell (hESC) derived astrocytes treated with Nrf2 
activator CDDOTFEA provides GSH-dependent neuroprotection against H2O2-mediated cell 
death (Gupta et al. 2012).  Furthermore, our group demonstrated that preconditioning mixed 
mouse cultures with CDDOTFEA and Bic/4-AP has additive neuroprotective effects against 
H2O2-mediated cell death (Baxter et al. 2015). Since the two pathways are distinct and help to 
maintain redox homeostasis in neural cells, it is tempting to speculate that Nrf2 pathway 
activation in astrocytes in concert with increasing neuronal activity may have additive 
neuroprotective effects in diseases involving oxidative stress.  
Indeed, CDDOTFEA and CDDOEA have been shown to be neuroprotective in rodent models of 
ALS and HD (Stack et al. 2010; Neymotin et al. 2011). Additionally, Nrf2 activators SLF and 
tBHQ are neuroprotective in mouse models of stroke (Jiang et al. 2016; Shih et al. 2005). 
Furthermore, Nrf2-GFAP mice, which selectively overexpress Nrf2 in astrocytes, are 
neuroprotective in various ND diseases, such as ALS and PD (Vargas et al. 2008; Gan et al. 
2012; Chen et al. 2009). Interestingly, an Nrf2 activator, DMF (also known as BG-12), has 
been approved for treating relapsing remitting MS (Linker et al. 2011; Cada et al. 2013; 
Bomprezzi 2015). Thus, it is tempting to speculate that DMF or other Nrf2 activators could be 
used as a therapeutic approach in other ND diseases. Indeed, DMF has been tested in mouse 
models of HD and PD showing some promising results (Ellrichmann et al. 2011; Ahuja et al. 
2016). Since correct redox balance is crucial in neural cells, prolonged activation of the Nrf2 
pathway may lead to reductive stress. Thus, use of an Nrf2 pro-drug, which would only be 
converted to its active form upon oxidative stress, could exert its effect only when and where 
enhanced antioxidant defences were required, providing a more sophisticated treatment (Satoh 
et al. 2013). 
Environmental enrichment in rodents, activating glutamatergic signalling in vivo, is 
neuroprotective and has been shown to have beneficial effects in models of AD and HD 
(Young et al. 1999; Nichols et al. 2007; Spires & Hannan 2005; Herring et al. 2010). 
Additionally, a cognitively active lifestyle was reported to reduce the likelihood of developing 
AD in humans (Spires & Hannan 2005). Thus, promoting a more cognitively active lifestyle 
may have some benefits in ND diseases, likely at least partially due to enhanced neuronal 
antioxidant defences following increased neuronal activity. Alternatively, neuronal activity 
could be pharmacologically enhanced, although this may be problematic due to too much 
system disinhibition leading to seizures.   
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Therefore, the use of memantine or drugs targeting specific NMDAR-mediated pro-death 
pathways in conjunction with drugs increasing antioxidant defences in neurons and/or 
astrocytes, such as DMF, may provide additional neuroprotection for some ND diseases and 
the possible additive therapeutic benefits of these approaches should be investigated.  
The results presented in this thesis have been acquired using primary neuronal cultures, which 
although a great model system for deciphering molecular mechanisms in neural cells, do have 
their limitations. Thus, it is imperative that the findings in this thesis are studied and confirmed 
in vivo. Additionally, the experiments were performed in developing neurons, thus whether 
the results found persist in older cells/animals should also be examined, especially in light of 
the possible therapeutic manipulation of these pathways in ND diseases, which often present 
at a later age. Although rodents are a good model organism, results acquired do not always 
translate well to human clinical trials, likely due to species specific differences; thus the 
replication of the results in this thesis in human cells is desirable. For instance, neural cells 
generated from human embryonic stem cells (hESCs) or human pluripotent stem cells (hPSCs) 
from patients, which have been previously employed to study ND diseases as well as the 
neuroprotective capacity of astrocytes (Gupta et al. 2013b; Gupta et al. 2013a), could be used 
to investigate the findings presented in this thesis in humans in vitro. 
It can be hoped that the data presented in this thesis will enhance the understanding of pro-
survival and pro-death Ca2+-mediated signalling cascades and lead to the establishment of new 
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Supplemental figure 1. NMDA toxicity curves for (A) 1 hour or (B) 10 min stimulation of primary 
cortical neuronal cultures with different NMDA concentrations. Points represent the mean from 
multiple experiments (n=4 for (A) and n=3 for (B)). Error bars=SEM. *p<0.05 compared to the 
control, analysed with a one-way ANOVA with Dunnett’s post-hoc test. Note the difference in the 
scale of the y axis in (A) and (B). 
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Supplementary figure 2. Example raw traces of Ca2+ decay following ATP application to 
astrocytes. A-B. Example traces of mitochondrial Ca2+ decay in astrocytes stimulated with ATP with 
(B) or without (A) CGP-37157 pre-stimulation (10 min). C-D. Example traces of cytoplasmic Ca2+ 
decay in control astrocytes (C) or astrocytes pre-treated with CGP-37157 (D). The traces in each 
graph represent single astrocytes on the same coverslip. The x-axis shows time (s). Recordings 
were taken every second, and a rolled average calculated every 5 seconds.  
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Supplementary figure 3. The amount of mitochondrial Ca2+ influx following stimulation of neural 
cells influences mitochondrial Ca2+ decay kinetics. A. Whilst there is lower amount mitochondrial 
Ca2+ influx following ATP stimulation of CGP-37157 treated astrocytes than in control astrocytes, 
the top 50% of CGP-37157 treated astrocytes according to their total mitochondrial Ca2+ influx 
have similar levels of total mitochondrial Ca2+ influx to control astrocytes. Unpaired two-tailed t-
tests. *p≤0.05. p=0.0018 and p<0.0001, respectively. B. Although the top 50% of CGP-37157 pre-
treated astrocytes displays faster mitochondrial Ca2+ decay kinetics following ATP stimulation than 
the total average of CGP-37157 pre-treated astrocytes, there is still a significant delay in 
mitochondrial Ca2+ decay compared to control astrocytes. Two-way ANOVA with Bonferroni post-
hoc test. *p≤0.05. p=0.0106, then p<0.0001 for the rest. C. Same as (A), except neurons in 
astrocyte-free neuronal culture treated with high K+. *p≤0.05. p=0.0005 and p<0.0001, 
respectively. D. Same as B, except neurons in astrocyte-free neuronal culture treated with high K+. 








Supplementary figure 4. Example raw traces of Ca2+ decay following KCl application to neurons 
in a mixed culture. A-B. Example traces of mitochondrial Ca2+ decay in neurons stimulated with KCl 
with (B) or without (A) CGP-37157 present. C-D. Example traces of cytoplasmic Ca2+ decay following 
KCl-induced depolarisation of control neurons (C) or neurons pre-treated with CGP-37157 (D). The 
traces in each graph represent single neurons on the same coverslip. The x-axis shows time (s). 






Supplementary figure 5. Example raw traces of Ca2+ decay following KCl application to neurons 
in an astrocyte-free neuronal culture. A-B. Example traces of mitochondrial Ca2+ decay in neurons 
stimulated with KCl with (B) or without (A) CGP-37157 present. C-D. Example traces of cytoplasmic 
Ca2+ decay following KCl-induced depolarisation in control neurons (C) or neurons pre-treated with 
CGP-37157 (D). The traces represent single neurons in astrocyte-free neuronal culture on the same 
coverslip. The x-axis shows time (s). Recordings were taken every second, and a rolled average was 





Ensemble gene ID Gene name Fold-induction by tBHQ (Mix) padj-values 
ENSMUSG00000020620 Abca8b 1.647771992 0.0000421 
ENSMUSG00000032849 Abcc4 2.052724696 6.08E-16 
ENSMUSG00000076435 Acsf2 1.58236664 9.74E-08 
ENSMUSG00000039116 Adgrg6 1.535699232 0.008179017 
ENSMUSG00000045875 Adra1a 1.560437013 0.025671195 
ENSMUSG00000033715 Akr1c14 2.364852566 4.95E-13 
ENSMUSG00000015134 Aldh1a3 1.541880181 0.000130289 
ENSMUSG00000063558 Aox1 2.844437816 0.00000674 
ENSMUSG00000037683 Armc3 1.515747116 0.04826957 
ENSMUSG00000074892 B3galt5 1.811962751 0.0000127 
ENSMUSG00000027381 Bcl2l11 1.675577971 0.0000494 
ENSMUSG00000040466 Blvrb 2.49056564 1.09E-08 
ENSMUSG00000022947 Cbr3 2.171760717 0.000000103 
ENSMUSG00000070348 Ccnd1 1.529765761 0.000289206 
ENSMUSG00000073802 Cdkn2b 1.930454405 0.009158467 
ENSMUSG00000056501 Cebpb 2.181531906 0.005772088 
ENSMUSG00000046818 Ddit4l 1.800405691 0.00000635 
ENSMUSG00000038776 Ephx1 2.140991041 2.67E-37 
ENSMUSG00000078161 Erich3 1.568707623 0.000381001 
ENSMUSG00000022707 Gbe1 1.543835483 0.0000203 
ENSMUSG00000032350 Gclc 1.98550662 2.03E-26 
ENSMUSG00000028124 Gclm 2.272822126 6.44E-52 
ENSMUSG00000049092 Gpr137c 1.535332048 0.0000281 
ENSMUSG00000031584 Gsr 1.740832641 1.31E-17 
ENSMUSG00000032348 Gsta4 2.063372676 3.62E-32 
ENSMUSG00000058135 Gstm1 1.798422723 5.96E-36 
ENSMUSG00000004038 Gstm3 1.97128279 0.029885617 
ENSMUSG00000005413 Hmox1 9.367309395 7.45E-216 
ENSMUSG00000022323 Hrsp12 1.568839801 5.09E-08 
ENSMUSG00000041548 Hspb8 1.725879597 3.61E-10 
ENSMUSG00000027070 Lrp2 1.688167405 0.001205087 
ENSMUSG00000022324 Matn2 1.534955439 0.001462768 
ENSMUSG00000054619 Mettl7a1 1.500366287 0.002425834 
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ENSMUSG00000008540 Mgst1 1.823180458 7.48E-15 
ENSMUSG00000092274 Neat1 1.642970561 0.01840806 
ENSMUSG00000003849 Nqo1 2.652431297 5.11E-10 
ENSMUSG00000074063 Osgin1 13.78345543 5.51E-23 
ENSMUSG00000049112 Oxtr 1.993355818 0.000172173 
ENSMUSG00000031379 Pir 2.380511433 0.0000843 
ENSMUSG00000021822 Plau 1.660325943 0.0280684 
ENSMUSG00000028378 Ptgr1 1.727154326 0.009873294 
ENSMUSG00000005716 Pvalb 1.537239228 0.039673796 
ENSMUSG00000015846 Rxra 1.617530387 0.00000168 
ENSMUSG00000050195 Scd4 1.81112659 0.000332861 
ENSMUSG00000037762 Slc16a9 1.829158715 0.026845756 
ENSMUSG00000028645 Slc2a1 1.682345448 9.95E-21 
ENSMUSG00000025993 Slc40a1 2.432396268 0.000161414 
ENSMUSG00000027737 Slc7a11 (xCT) 3.971487223 3.28E-77 
ENSMUSG00000027227 Sord 1.536066166 0.00000319 
ENSMUSG00000026532 Spta1 3.315431621 5.91E-11 
ENSMUSG00000005803 Sqrdl 1.815976022 0.001275515 
ENSMUSG00000032802 Srxn1 3.726150886 4.36E-117 
ENSMUSG00000050315 Synpo2 1.513199417 0.00028744 
ENSMUSG00000020250 Txnrd1 1.994064131 9.28E-42 








Supplemental table 1. List of the 55 Nrf2 target genes significantly induced ≥1.5-fold by tBHQ 
(8h) in mixed culture, but not in neuronal culture.  The Ensembl ID, gene name, fold induction by 




Ensemble gene ID Gene name Fold-induction by 4h Bic/4-AP (Neu) padj-values 
ENSMUSG00000045875 Adra1a 7.743697176 8.27E-09 
ENSMUSG00000015134 Aldh1a3 2.445322021 2.23E-14 
ENSMUSG00000027381 Bcl2l11 4.246634069 7.55E-36 
ENSMUSG00000040466 Blvrb 5.256086205 2.94E-20 
ENSMUSG00000070348 Ccnd1 1.857560079 0.00047168 
ENSMUSG00000056501 Cebpb 4.452641531 2.1E-13 
ENSMUSG00000032350 Gclc 2.368963465 4.36E-18 
ENSMUSG00000049092 Gpr137c 2.702938458 1.17E-08 
ENSMUSG00000041548 Hspb8 33.06669871 3.74E-17 
ENSMUSG00000092274 Neat1 3.768743593 3.9E-32 
ENSMUSG00000021822 Plau 3.184361283 0.0043157 
ENSMUSG00000037762 Slc16a9 4.622607931 0.00676989 
ENSMUSG00000028645 Slc2a1 4.964378601 4.33E-27 
ENSMUSG00000025993 Slc40a1 3.406941281 1.05E-11 
ENSMUSG00000027737 Slc7a11 (xCT) 3.251151851 4.07E-32 











Supplementary table 2. Some, but not all of the 55 tBHQ-induced Nrf2 target genes are upregulated 
following 4h Bic/4-AP treatment of pure neuronal culture. The Ensembl ID, gene name, fold induction 
by 4h Bic/4-AP in neuronal culture, and the adjusted p value are shown for each gene. Padj was 




Ensemble gene ID Gene name Fold-induction by 24h Bic/4-AP (Neu) padj-values 
ENSMUSG00000045875 Adra1a 43.628391 0.00217577 
ENSMUSG00000027381 Bcl2l11 2.663623322 9.03E-07 
ENSMUSG00000040466 Blvrb 4.344412769 4.17E-08 
ENSMUSG00000070348 Ccnd1 2.477488506 0.00066831 
ENSMUSG00000056501 Cebpb 2.864556509 0.00126478 
ENSMUSG00000022707 Gbe1 2.005964912 0.00030995 
ENSMUSG00000005413 Hmox1 9.316813788 4.3E-20 
ENSMUSG00000041548 Hspb8 9.64344588 0.00051578 
ENSMUSG00000092274 Neat1 3.760673316 2.65E-09 
ENSMUSG00000021822 Plau 4.997294429 0.00039469 
ENSMUSG00000037762 Slc16a9 16.28481285 6.75E-08 
ENSMUSG00000028645 Slc2a1 3.361321276 4.77E-10 
ENSMUSG00000025993 Slc40a1 5.956486946 9.05E-15 
ENSMUSG00000027737 Slc7a11 (xCT) 3.533248065 3.19E-16 
ENSMUSG00000027227 Sord 4.320112238 7.49E-12 
ENSMUSG00000026532 Spta1 9.496404941 0.0000542 









Supplementary table 3. Some, but not all of the 55 tBHQ-induced Nrf2 target genes are 
upregulated following 24h Bic/4-AP treatment of pure neuronal culture. The Ensembl ID, gene 
name, fold induction by 24h Bic/4-AP in neuronal culture, and the adjusted p value are shown for 




Ensemble gene ID Gene name 
 





















































   
 
 
Supplementary table 4. List of the tBHQ-induced Nrf2 target genes not upregulated by Bic/4-AP 
treatment of pure neuronal culture. The Ensembl ID and gene name are shown for each gene. 
n=3. 
